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1. INTRODUCTION 
  
 Siddha system of medicine is one of the long-lived traditional system which is 
gradually evolved along with Dravidian’s culture and hence this system is known as 
Dravidian system of medicine. This system was contemporaneous with those of the 
submerged lands, Egyptian, Mesopotamian, Chinese and Greciam medicine. 
The unique nature of this medicine is the continuous service to humanity for more 
than 5000 years in combating diseases and in maintaining physical, mental, moral and 
spiritual components of human beings and to make the body perfect, imperishable, hence 
to promote longevity. 
This is the ancient synthetic chemico – philosophical system, which deals with 
1.Vada(Alchemy)  2.Vaidhya(Medicine)  3.Gnanam(Wisdom) and  4.Yoga 
1. Alchemy – chemistry which deals and treats of transforming in clear lucid fashion 
in all its branches of changing baser metals to higher by minerals, vegetables and 
animals. 
2. Vaidhya – is that of medicine by chemistry for the ailments of man. 
3. Gnana – is the study of nature, matter, soul and of man and human society and the 
scientific modulation of man and universal god. 
4. Yoga – is the practice of Brahma vidya or Raja yoga to attain the “Moksham” 
  Siddha system has unique art of healing founded by great spiritual scientist called 
“SIDDHARS”. The term SIDDHAR has derived from the word ‘SIDDHI’ which 
literally means accomplished, achieved or success and so it refers to one who had 
attained his end in spiritual goal by focusing Eight Supernatural Power “Ashtamaha 
Siddhi”.  
They belong to the class of EIGHTEEN SUPERNALS or DEMIGODS 
inhabiting the middle air and embracing several subdivisions, hence the following 
proverb is applicable only to them. 
                “THERE IS NO GREY HAIR NOR WRINKLE AND NO DEATH”  
            Siddhars, the followers of LORD SHIVA where AGASTHIAR being the first 
siddhar. Along with SRI LOBHA MATHA DEVI, he adorns the first and foremost 
peedam(seat) of the siddhas.  
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THIRUMOOLAR, the prince of mystics was one of the disciples of Nandhi 
Dever. The 3000 stanzas(Poems) delivered by him during the course of 300 years what is 
today known as “THIRUMANTRAM”.  
Thirumantram deals with body as well as soul. It is concerned with human 
anatomy as well as human mind. 
“IF THE BODY IS DESTROYED, LIFE IS DESTROYED; 
 NOR WILL LIFE COME BY TRUE WISDOM FIRM; 
               KNOWING MEANS, THE BODY TO FOSTER,   
               I FOSTER THE BODY AND THUS THE LIFE” 
Which means the body is as important as the soul. Divorced from the body the soul is 
naught. 
  According to the siddhar ‘YUGI MUNI’, the diseases are classified into 4448 
based on derangement of Vadha, Pitha and Kabha. 
 The disease “UTHIRAVADHA SURONITHAM” are brought under the types of 
vadha diseases. Here the clinical features of ‘RHEUMATOID ARTHRITIS’ are 
correlated with “UTHIRAVADHA SURONITHAM”. 
 Rheumatoid arthritis is a generalized chronic multisystem disease affecting the 
connective tissues of the whole body with focalized involvement of musculoskeletal 
system. It is considered to be an autoimmune response to an unknown antigen and 
antibody formed is rheumatoid factor which is identified as IgM. 
 About 1% of world population is affected by RA. In adult Indian population, 
prevalence rate is 0.75%. 80% womens were affected. Womens 2 to 3 times more 
common than males. Male Female ratio is 1:3. Most often occur in 25 - 50 years of age. 
 Since RA is a chronic disease, NSAID drugs are used in modern medicine to 
reduce the pain and inflammation but do not slow down the progression of joint damage. 
Recently approved DMARD Leflunomide, an Immunomodulator drug have high 
potential effect on managing the signs and symptoms of RA but it shows some side 
effects like alopecia, diarrhoea, elevated liver enzymes and allergic rashes. 
 In siddha system of medicine, thousands of raw drugs are used in the treatment of 
diseases. These drugs are catagorised into 3 groups namely Metals, Minerals, Herbals 
and Animal products. More than 80% of medicines are formulated by herbal products. 
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But in certain life threatening diseases and in many chronic diseases, the herbal 
medicines alone have not been much effective. In such conditions, siddhars enumerated 
some Herbo – metal and Herbo – mineral formulations. 
For this reason I chosen the siddha trail medicine Herbal – Mineral formulation 
drug “SAMUTHARA CHOORANAM” (Internal) which have 
IMMUNOMODULATOR ACTIVITY in its ingredients and “VADHA NOIKU 
VELIPRAYOGHA THAILAM” (External) along with “OTTRADAM” (Therapy) 
for the study of ‘UTHIRAVADHA SURONITHAM’ 
Hence my study goal is to evaluate whether the trial drug Samuthara 
Chooranam(Internal) along with External medicine and Ottradam(Therapy) is Efficacy 
and Safety for the disease Uthiravadha Suronitham(RA). 
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2. AIM AND OBJECTIVES  
 
AIM:   
        To Study the safety and the therapeutic efficacy of Siddha medicine “Samuthara 
chooranam” (Internal) and “Vadha noiku veliprayogha thailam” (External) and 
“Ottradam”(Therapy) in “Uthiravadha Suronitham”(Rheumatoid arthritis)  
 
OBJECTIVES:  
 
PRIMARY OBJECTIVE: 
To study the safety and therapeutic efficacy of siddha medicine in “Samuthara 
chooranam”(Internal) and “Vadha noiku veliprayogha thailam”(External) and 
“Ottradam”(Therapy) in “Uthiravadha suronitham”(Rheumatoid arthritis).  
 
SECONDARY OBJECTIVE:   
1.To collect the various siddha literature and modern literature regarding the disease 
Uthiravadha suronitham(Rheumatoid arthritis)  
2.To use modern parameters to confirm diagnosis, severity of the disease and 
progress of the disease.  
3.To explore the traditional preparations with scientific evaluation of trial drug. 
4.To evaluate the physico-chemical analysis of siddha trial drug “Samuthara chooranam”. 
5.To evaluate the pharmacological and safety standard of trial drug in animal models. 
6.To evaluate the efficacy of the trial drug in Rheumatoid patients in terms of pain 
assessment score before and after treatment.  
7.To evaluate the therapeutic efficacy of external therapy “Ottradam” in Rheumatoid 
patients.  
8.To evaluate the safety parameters of the siddha trial drug in Rheumatoid patients in 
terms of liver function and renal function test before and after treatment.  
 
  
 
     REVIEW OF                
        LITERATURES 
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                   3. REVIEW OF LITERATURE 
                                 3.1. SIDDHA ASPECT 
 
Man according to siddha system is production of divine mind and thought 
produced essence of the five elements, sole of the stars, and the spirit which is the stellar 
and temporal sides of magnum limbus from the matrix of nature formed of seven layers 
of tissues.  
These five elements together constitute the human body and origin of other 
material objects are explained as Pancheekaranam (Mutual Intra Inclusion). None of 
these elements could act independently by themselves. They could act only in 
coordination with other four elements. All the living creatures and the non-living things 
are made up of these five basic elements. The five basic elements form the connecting 
link between the Microcosm (Man) and Macrocosm (World). Any change in the 
universe due to natural or unnatural causes will create changes in human systems. 
               “நிலம் நீர் தீ வளி விசும்ப ோ டைந்தும் 
                கலந்த மயக்க முலகமோதலின்” 
       -   ததோல்கோ ்பியம் த ோருள் அகரோதி 
 Again it is said, like the universe man is composed of five elements such as 
earth, water, air, fire, ether. Therefore life force is the basis for man’s mental and 
spiritual activities on that nature may evolve him towards perfection.  
• The earth gives shape to the body and release Sits energy, Bones, muscles, and 
tissues represent if in the body.  
• Water makes the earth supple and helps in the transmission of energy, serum, 
lymph, saliva etc.. represent it in the body.  
• Fire makes the form of the body steady and gives vigour and stimulation. 
Digestion and circulation represent it in the body.        
• Air ignites the fire and works as a life carrier and is the support of all contact 
and exchange. Respiration and Nervous system represent it in the body.  
• Ether is the creator of life itself in the body. A harmonious combination and 
function of these elements in the body produce a healthy and beautiful life.  
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THE 96 BASIC PRINCIPLES (96 Thathuvam)   
 
According to Siddha system of medicine, ‘Thathuvam’ is considered as a 
science that deals with basic functions of the human body. Siddhars described 96 
principles as the basic constituents of human body that include physical, physiological, 
psychological and intellectual components of an individual. These 96Thathuvams are 
considered to be the cause and effect of our physical and mental well-being. The 
Thathuvam is the author of the conception of human embryo on which the theory of 
medicine is based.  
There are in our body several supports to the soul for the existence and 
sustenance of life and they are the five elements (Earth, Water, Fire, Air, Ether), the six 
plexus, the three humors (mukkuttram), 72,000 blood vessels and nerves etc.. 
Constituting in all 96 thathuvas.i.e constitute principles in nature. These three humours 
(vatham, pitham, kabham) plays a major role in the body and their function remain in 
the balanced state in a normal healthy person and disturbance in their equilibrium leads 
to the development of diseases in the body.  
If the siddha medicine is to accomplish its real mission it must start a double 
movement of revival and reform. It must to revive its tridoshic theory on which the 
whole ancient medicine is based. 
                           “மு ்பிணி மருவி முனிவுதகோள் குறி ்ட த் 
த ் ோதறியும் தன்டமயும் வோத 
பித்தடவயம் பிரிடவயும் அடவதோம் 
  ஏறியிறங்கி இடணந்துக் கலந்து 
  மோறிமோறி வரும் தெயற்டகயோர் பிணி 
பநரட்மயறிந்து நீை்டு மருந்பத 
சீரியதோதமனெ ்தெ ்புவர் சித்தபர” 
                     -  பநோய் நோைல் பநோய் முதல் நோைல் திரை்டு 
Man develops three distinct, personalities namely the mind and the vital or life 
force and the body. Through the mind he thinks and wills; through the vital or life force 
he executes his thought and will; through the physical body he expresses what he thinks 
and wills. The mind is vatha, vital or life force is Pitha, and the body is kabha.  
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• Vatha, pitha, kabha have multiple significances and symbolical in terms.  
• Vatha represents Vayu, mind, dryness, pain, flatulence, sensitiveness, lightness, 
and also air.  
• Pitha represents gastric juice, bile energy heat, inflammation, anger and 
irritation, etc...  
• kabha represents feeling of cold, heaviness, running of the nose, passing mucoid 
discharge and also the saliva.  
They are also formed by the combination of the five basic elements. Accordingly 
Vali is formed by the combination of Vali (Air) and Aagayam (Space). This is the 
Creative force. Azhal is formed by Thee (Fire). This is the Force of Preservation. Iyyam 
is formed by Mann (Earth) and Neer (Water). This is the Destructive Force. These three 
humours are in the ratio 4:2:1 in equilibrium which is a healthy normal Condition. They 
are called as the life forces or humours.  
  
THE FORMATION OF UYIR THATHUKKAL:  
       1.The Valinaadi is formed by the combination of Abanan and Idagalai.  
       2.The Azhalnaadi   is formed by the combination of Piranan and Pinkalai.   
       3.The Iyyanaadi is formed by the combination of Samanan and Suzhumunai.   
 Vaatham - Ten types   
 Pitham    - Five types   
 Kabam    - Five types  
 
(a) Five forms of vadha:  
       These are the five main centres of the subtle physical body and correspond to the 
nervous plexuses of the gross physical body.  
 Matedial of muladhar centre (அ ோனன்): This centre corresponds to the 
pelvic plexus and is the seat of kundalini or material energy and controls 
excretions  
 Navel centre (ெமோனன்): This corresponds to the solar plexus in the navel 
region and controls digestion.  
 Heart centre (பிரோணன்): This refers to the cardiac plexus in the Heart and 
circulation.  
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 Throat Centre (உதோனன்): This corresponds to the pharyngeal plexus in the 
throat region and control breathing and speech.  
 Forehead centre (வியோனன்): This corresponds to the Naso-ciliary plexus at 
the root-of the nose and base of the skull and control “will”. 
 
(b) Five forms of pitha:  
• Gastric juice ( ோெகம்): This give appetie and helps Digestion.  
• Bile (பிரோெகம்): which gives complexion to the skin.  
• Haemoglobin (இரஞ்ெகம்): which colours the blood.  
• Aqueous Humour (ஆபலோெகம்): Which brightens the eyes  
• Life energy (ெோதகம்): Which controls the whole body  
•  
(c) Five form of kapha:  
• Saliva (கிபலதகம்): Which helps mastication  
• Cerebrospiral fluid (தற் கம்): Which keeps the head cool  
• Lymph (ப ோதகம்): Which gives taste  
• Serum (அவலம் கம்): Which helps the Heart in pumping  
• Synovial fluid (ெந்திகம்): Which lubricate and aids free movement of the  
joints  
        The three humours of vatha, pitha and kapha which are absorbed and circulated 
in the blood have each certain definite qualities:  What are they actually,  
1. VADHA.  
 
(Own qualities-6)-                                                (Opposite qualities-6)-  
 
Vatha is dry - வறட்சி                                   Unctuous - பசுமை 
Vatha is cold - குளிரச்ச்ி                                       Hot -அக்கினி 
Vatha is subtle - அணூத்துவை்                           Solid - ககட்டி 
Vatha is rough - கடினை்                                           Soft - மிருது  
Vatha is unstable - அமசதல்                                      Stable - ஸ்திரை்  
Vatha is light - இலகு                                          Heavy - பளுவு  
      
       All this qualities are present in Air and hence air we inhale is Vadha  
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2. PITHA  
 
(Own qualities-6)-                                    (Opposite qualities-6)-  
 
Pitha is hot - அக்கினி                                        Cold - குளிரச்ச்ி  
Pitha is acid - புளிப்பு                                                 Sweet - இனிப்பு   
Pitha is mobile - பசுமை                                      Immobile - நிமலதிருத்தல் 
Pitha is liquid - சலரூபை்                                       Solid - ககட்டி  
Pitha is acute - குரூரை்                                         Mild or harmless - சாந்தை்  
Pitha is pungent - காரை்                                         Bitter - கசப்பு  
     
 All this qualities are present in the gastric juice and hence the gastric juice is Pitha 
  
3. KAPHA  
 
(Own qualities-6)-                                       (Opposite qualities-6)-  
 
Kapha is cold – குளிரச்ச்ி                                     Hot - உட்டிணை்  
Kapha is heavy - பளுவு                                          Lite - இலகு  
Kapha is immobile - அமசவின்மை                         Mobile - அமசதல்  
Kapha is sweet - இனிப்பு                                        Pungent - காரை்  
Kapha is soft - மிருது                                          Rough - கடினை்  
Kapha is unctuous - ஈரை்                                         Dry – வறட்சி 
Kapha is viscid - வழவழப்பு                                      Sandy - கரகரப்பு  
 
All this qualities are present in in Saliva so Saliva is Kapha  
 
VADHAM:  
The term Vadham denotes Vayu, pain, dryness and flatulence. Vadham is 
responsible for respiration and control of all movements.   
Location -Abanan, Faeces, Idakalai, Pelvic bone, spermatic cord, skin, nerves, 
joints, hairs and muscles.   
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Character -It governs the other two basic elements and responsible for all 
physical process in general. For this reason, disturbance in vadha tend to have more 
severe implication than the other two humours and other affect the mind as well as 
entire physical body and also responsible for respiration.  
         Functions -Pain in the whole body, twitching, pricking pain, inflammation, 
reddish complexion, and roughness of skin, hardness of limbs, astringent sense of taste 
in the mouth, constipation, and oliguria, blackish discoloration of skin, stool, urine and 
muddy conjunctiva.  
         So for 4448 diseases are classified by Agasthiyar rathina surukkam naadi and 
in this Vadha diseases are classified as 84 types 
“நோளைோ நோற் த்து நோலு நூறு 
  நயமுைபன நோற் த்து எை்டு பரோகம் 
  ோர ் ோ வோதமது எண் த்து நோலு”                                                                  
Vadham or vali is not mere wind, but also that causes motion, energy, and 
sensation of every cell in the body. Vali relates to the nerve force. It is responsible for 
all movements in the mind and the body.  
In human body the locomotors activity functions through voluntary muscles and 
its activities controlled by nerves system called Kanmendhriyam, likewise the sensation 
and its activities are known as Gnanendhriyam. These types of activities are governed 
by valikutram among the mukkutram.  
 
LOCATION OF VADHA HUMOUR:  
• Below the navel region (umbilicus)  
• Urinary bladder, motion, Spermatic cord, Umbilical cord, thigh, bone, skin, 
nerves, joints, muscles, hair follicles, pelvis, ear.  
• வாதத்தின் இருப்பிடை்: த ருங்குைல்.  
NATURAL PROPERTIES OF VADHAM:  
“ஒழுங்குடன் தாததழ் மூசத்சாங்கி இயங்க 
எழுசச்ிகபற எப்பணியு ைாற்ற எழுந்தரிய  
தவகை் புலன்களூக்கு தைவச ்சுறுசுறுப்பு  
வாகளிக்குை் ைாந்தரக்்கு வாயு”  
                        -ைருத்துவ தனி பாடல், சித்த ைருத்துவாங்க சுருக்கை் (பக்கை் 140) 
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• Functioning of mind throughout the body  
• Giving briskness  
• Making the uniform functioning of seven udalkattugal  
• Protection and strengthening of five sensory organs.  
• Regulation of fourteen physiological reflexes.  
 
QUALITIES OF VADHAM:  
“வோதங் கடுடம வறை்சியுைன் தநோய்டம 
 சீதமுஞ்ெ ்ெலனம் சிதறணுவு ஏதமுை 
 னிக்குணத்பதோடுற் பறயியக்கந்த ருமளவிற் 
 தக்க ரிகோரந்தோ” 
-  கண்ணுெோமியம் ( க்கம் 21) 
 
Own qualities-6    
Vadha is dry - வறட்சி 
Vadha is cold - குளிரச்ச்ி  
Vadha is subtle - அணூத்துவை்  
Vadha is rough - கடினை்  
Vadha is unstable -அமசதல்  
Vadha is light - இலகு.  
 
       “வோத குணமோறுக்கு மோறுகுணபம பனோக்கின்   
          ஒதமிரு தீரம் உயிர ்ோரம்  ப ரோதரபவோ  
          யுள்ள தீபயோடுறதி யியற்றுத் திரளோக  
          உள்ள குணத்டதபய ஊை்டு.  
- கண்ணுெோமியம்- க்கம்-22  
 (Opposite qualities-6) 
Unctuous - பசுமை  
Hot - அக்கினி  
Solid - ககட்டி  
Soft - மிருது 
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Stable - ஸ்திரை்  
Heavy - பளுவு  
 VARIETIES OF VADHAM:  
 
“முமறயாை் பிராணதனாட பானன் வியானன் 
மூரக்்கைா முததானகனாடு சைான னாகுை் 
திறமையாங் கூரை் தனாடுகிருகிர ன்தறான் 
ததவத ்ததனாடு தனஞ்கசயனு ைாகுை்.”  
                               - சித்த ைருத்துவாங்க சுருக்கை்  பக்கை்-142  
 
 
VAAYU – 10 (VITAL NERVE FORCE WHICH IS RESPONSIBLE FOR ALL  
KINDS OF MOVEMENTS)   
1.Uyirkaal (Piraanan)   
  
        This is responsible for the respiration of the tissues, controlling knowledge, mind 
and five sense organs and digestion of the food taken in.   
  
2.Keel nokkukaal (Abanan)   
  
        It lies below the umbilicus. It is responsible for the downward expulsion of stools 
and urine, ejaculation of semen and menstruation.   
  
3.Paravukaal (Viyanan)   
  
       This is responsible for the motor and sensory function of the entire body and the 
distribution of nutrients to various tissues.  
  
4.Maelnokkukaal (Uthanan)   
  
      It originates at Utharakini. It is responsible for digestion, absorption and distribution 
of food. It is responsible for all the upward movements.   
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5.Samaanan (Nadu kaal)   
     This is responsible for the neutralization of the other 4Valis i.e. Piranan, Abanan, 
Viyanan and Uthanan. Moreover it is responsible for the nutrients and water balance of 
the body.   
 
6.Naagan  
     It is a driving force of eye balls responsible for movements.  
  
7.Koorman  
     It is responsible for the opening and closing of the eyelids and also vision. It is 
responsible for yawning.   
  
8.Kirukaran  
    It is responsible for the salivation of the tongue and also nasal secretion.  
Responsible for cough and sneezing and induces hunger.   
        
9.Devathathan  
   This aggravates the emotional disturbances like anger, lust, frustration etc. As 
emotional disturbances influence to a great extent the physiological activities, it is 
responsible for the emotional upsets.   
  
10.Dhanancheyan  
     Expelled three days after the death by bursting out of the cranium. It is responsible 
for edema, plethora and abnormal swelling in the body in the pathological state.  
  
As per yugi  vaithiya  cindhamani  
“என்னபவ வோதமது எண் தோகும் 
            ஏற்றமோம் ப ருடைய தவழிடலக் பகளோய் 
…………………………………………. 
 ஊனுதிரவோதசுபரோணிந்தோ தோபனோடு 
    ……………பவதத்தினுண்டம தோபன” 
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AETIOLOGY OF VADHA DISEASES:  
According to yugi vaithya cindhamani 
“என்னபவ வோதம்தோ தணன் தோகும் 
  இகத்திபல மனிதரக்ளுக்கு தகய்யுமோறு 
 பின்னபவ த ண்தடனபய பெோடரஞ் தெய்து 
  த ரிபயோரக்ள் பிரோமணடர தூறணித்தும் 
  வன்னபவவெத்ெோத்திற் பெோரஞ் தெய்து 
  மோதோபிதோ குருடவம றந்தப ரக்்கும் 
  கன்னபவ பவதத்டத நிந்டத தெய்தோல் 
  கோயத்திற் கலந்திடுபம வோதந்தோபன” 
 
“தோதனன்ற கெ ்ப ோடுதுவர் ்பு டற ்பு  
  ெோதகமோய் மிஞ்சுகிலுந் ெடமத்த வண்ண 
  ஆதனன்ற வோறினது த ோசித்தோலும் 
  ஆகோயத் பதறலது குடித்தலோலும்  
  ோதனன்ற கலுறக்க மிரோவிழி ்பு 
  ை்டினிய மிகவுறுதல் ோரதமய்தல் 
  சீக்கிரமோய் வோதமது தெனிக்குந்தோபன”  
• Excessive sexual indulgence  
• Over consumption of bitters, astringents and rancid foods.  
• Drinking rain water  
• Day time sleep  
• Night time work  
• Starvation  
• Lifting over weight  
• Will initiate and aggravate vali  
  
As per Konganavar Vadha Kaviyam   
             “ஆெெ் ் ோ யிதன்கூடற நலதோய்ெத்ெோன்பனோம் 
  ஆகோகோ யிந்நூல்தோன் கோவியகோண்ைத்தில் 
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 வோெெ் ் ோ வோதத்தின் கூடறெத்ெோன்பனோம் 
 வோதமதின் வோயுனிடல மயங்கி ்ப ோகும் 
 கோெெ் ் ோ கலங்கியது தியங்கி ்ப ோகும் 
 கண்மணிபய வதுக்குமத்தி ந்தோன் பகளு 
 மோெெ் ் ோ மக்கினிதோன் மதுபவோதைோக்க 
 மோரக்்கமதோய் கூடிவிடள யோடும் ோபர”  
 
வோதம் பதோன்றுதல்: 
             “தவய்யிலில் நைக்டக யோலும் மிகதண்ணீர் குடிக்டக யோலும் 
 ட யபவ உண்டக யோலும் ோகற்கோய் தின்டக யோலும் 
 டதயபல வோத பரோகஞ் ெனிக்குதமன்றறிந்து தகோள்பள”  
• Excessive exposure to the sun  
• Excessive intake of water  
• Postponed of proper intake of food  
• Excessive intake of bitter gourd  
 
 According to Agathiyar Kanma Kaandam  
          “நூதலன்ற வோதம் வந்த வடக தோபனது 
 நுண்டமயோய்க் கன்மத்தின் வடகடய பகளு 
 கோலிபல பதோன்றியது கடு ்  பதது 
 டககோலிபல முைக்கியது வீக்கமது 
 பகோலிபல டுக்கின்றவிருை்ெமோன 
 குழந்டத மரந்தடன தவை்டி பமல்பதோ சீவல்  
 நோனிபல சீவதெந்து கோல் முறித்தல் நலித்தல் கோபண” 
• cutting trees and barks  
• Breaking the legs of living animals  
• cutting the leaves of living trees  
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According to Agathiyar Gunavagadam,  
           
             “அம்புவியில் வோதபனோய் வருகும் பநரட்ம 
 அ ் பன தெோல்லி கிபறன்றி வோய்க்பகளு 
 அறுகுமைோ மோமிெத்தின் வியோதி யோலும் 
 அ ் பன சூதகத்தின் த ருக்கோலும்  
 குடிதகடுத்த வோதமது உண்ைோ ம ் ோ” 
• Muscular diseases  
• Menorrhagia  
• Consumption of improper preparation of metallic compounds like mercury and 
lead will cause vadha diseases  
 
CHARACTERISTIC FEATURES OF VATHA DISEASE:   
 
1.As per Theraiyar Vaagadam:  
          “வோதவீறு அன்னமிறங்கோது கடு ்புண்ைோம் வண்ணமுண்ைோம் 
 பமோது கை்டுபரோகம் கரமுண்ைோ மிருமலுமோ முறங்கோ ததன்றும் 
 ஓது சூரிய வோதமனலோகு நடுக்கமுண்ைோம் த ோருள்களோய்த் 
 தீததனபவ நரம்பிசித்து ெந்துகள்பதோறும் கடுக்குந் தின்முந்தோபன” 
• Loss of appetite  
• Pain and redness  
• Fever and cough  
• Insomnia  
• Shivering  
• Hyperpyrexia  
 
      “ெந்திரவோத முைம்பு குளிரத்்ததழுந்பத நடுக்குங் சீதவோய்வோம்  
 முந்திய குத்திவோஞ் ெந்துகள் பதோறுங் குடைந்து தமோளிகள் வீங்கும்   
 வந்திய ததோந்தவோதம் நரம்புகதளல்லோ மிசித்துவலம் வீைோது 
 அந்து அவ்வோகு வோதம் வீக்கமுண்ைோ முைற்றிமி ருண்ைோபம”    
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• Chillness of the body   
• Rigor and spasm  
• Pain and tenderness of joints 
• Swelling of the joints.  
     
“அறியதிம் மூன்றின தோண்டம  தெோன்னோர் னநந்தி  
 றிதயன  தநோந்து  மற் ெட்ெ புண்ணோகும்”  
                                            -திருமூலர்  நோயனோர்  சிகிெெ்ோ ரத்ன தீ ம்  
• Pain in the upper and lower limbs, pain in the costochondral junctions will be 
seen in vadham diseases.  
 
“வோதம் வந்துற்றப ோது வயறது  த ோருமி  தகோள்ளும்  
............................வந்த  வோதத்தின்  குணமிதோ பம”  
                                        -யூகி முனிவர் த ருனூல் டவத்திய  கோவியம்(1000)  
• When vadham increases it produce abdominal discomfort, pain in the hip joint 
and all the joints of upper and lower limbs, constipation and painful voiding of 
urine and stools will be seen.  
• The diseases will be precipitated in months from aani to karthigai.. i.e.,from 
June to December,(muthuvenil, kaar and koothirkaalam)  
 
           “ கரபவ வோதமது பகோபித் த ்ப ோ  
  ண் ோக த ண் ப ோகமது தோமன் தெய்யில் 
 ……………………..கடனக் கோலும் கடு ்பு உண்ைோபம 
- யூகி டவத்திய சிந்தோமணி ோைல்-285  
• Indulging in sexual act during vitiation of vadham  
• Walking for long distance  
• Exposing to cold and dampness and harmful combinations like fruits vegetables 
and tubers with curd causes toxic factors which affects bones and joints  
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In Aaviyalikkum Amutha murai Surukkam  
 
             “தெோல்லபவ வோதமது மீறிற்றோனோல் 
தெோரவ்டைந்து வோயுவோல் பதகதமங்கும் 
 தமல்லபவ டககோல்களெதி யுண்ைோம் 
 தமய் முைங்கும் நிமிர தவண்ணோ திமிருண்ைோகும் 
 தவல்லபவ வுைல் த ோருமும் வயிருடளக்கும் 
 விரும்பி யன்னஞ்தெல்லோது விந்துநை்ைம் 
 தெோல்லபவ நோ ்புளிக்கும் கழிெெ்ல் உண்ைோகும் 
 கூறினோர் மடலயமுனி கூறினோபர” 
• Fatigue, tiredness  
• Nausea  
• Loss of appetite  
• Pricking sensation all over the body   
• Pain all over the joints.  
• Diarrhoea  
• Azoospermia  
• Incontinence of urine  
• Difficulty in flexion and extension  
• Constipation  
  
Agathiyar 2000  
             “வோதத்தின் குணபமதன்னில் மயக்குந்தியங்கும் மலர்சிவக்கும் 
 ோதங்குளிர்ந்து ெருவோங்கம் ற்றி நைக்குமுகங் கடுக்குஞ் 
 சீதத்துைபன வயிறு புண்ணோஞ் சிரி ்பித் தகுந்ததறி மூெெ்ோம் 
 ப ோதத் தண்ணீரத்ோன் வோங்கும்புகழும் ஞ்ெகுணபம” 
 Giddiness  
 Redness of eyes  
 Stabbing pain in the face  
 Abdominal distension  
 Joint pain in upper and lower limbs  
 Numbness in the limbs  
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 Oliguria  
 Drowsiness  
 Chillness of the body  
 
வோத மிகுதலின் இயல்பு 
             “தக்க வோயு பகோபித்தோல் ெந்து வுடளந்து தடலபநோவோ 
 மிக்க மூரி தகோை்ைோவி விை்ைங் தகரியு மலங்கை்டும்  
 ஒக்க நரம்பு தோன்முைங்கும் முலர்ந்துவோய்நீ ரூறிவரும் 
 மிக்க குளிரும் நடுக்கமுமோம் பமனி குன்றி வருங்கோபண” 
 
• Pain in the joints  
• Head ache  
• Excessive yawning  
• Constipation  
• Burning sensation of the body  
• Paralysis  
• Excessive salivation  
• Chillness and tremor 
 
In kaaviyanaadi 
 
“கோண ் ோ வோதமீறில் கோல்டககல் த ருத்து பநோகும்” 
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    UTHIRAVADHA SURONITHAM  
 
“UTHIRAVADHA SURONITHAM” is one among the eighty types of vadha 
diseases described by the great siddha pathologist yugi munivar in the textbook of  
“YUGI VAIDHYA CHINDHAMANI”.  
A form of arthritis of rheumatic origin  marked  by  severe  pain  and  the formation  
of  inflammatory  nodules  in  the  region  of  the  joints  and  especially  in the limbs of the 
body.  
 
According to kathirai velpillai tamil mozhi agarathi  
   சுபரோணிதம் - உதிரம்  
உதிரவோதம்  
According to sambasivam pillai dictionary 
சுபரோணிதம் – உதிரம் 
   மகளிர் சூதகம்  
  
சுபரோணித வோதம்:  
A disorder of menstruation in women marked by affection in the chest and 
limbs extreme sensibility to pain, dryness in the dendrites nervous shock, 
accompanied by intense body pain.  
  
Therayar vaagadam: 
 
             “சுபரோணிதவோத பிரவிடையோன் ப ோபத ததோடுக்குந் துைரந்்து 
பநோகுங்……………….  
     ( பிரிவிடை- த ண்ணின்மத்திய புருவம்)  
         The disease “suronithavatham” is occurs in the middle aged women. 
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    “உடரத று உதிரவோத சுபரோணித முடறக்குங் கோடல 
தடரத று வோதந்தூற்பற சுபரோணிதக் குணமுந்தக்க 
விரிவுறு லித்துவோத சுபரோணிதக் குணமுமிக்க 
சுடரத று உதிரவோத சுபரோணித குணமுமுண்ைோம்”    
     Vitiation of vatha aggravates the signs and symptoms of “vatha suronitham”.  
  
Jeeva raksha mirtham classifies this disease into two types,   
 Pitha sonitha vatha rogam, which is soft and cause emaciation.  
 Slethuma sonitha vatha rogam has polyarthralgia and spindle shaped swelling in 
the phalanges.  
  
Siddha pathology:  
“காணப்பா வாத மீறில் கால்மககள் கபாருத்து தநாகுை்..............  
 கசால்லதவ வாதைது மீறிற் றானால்  
தசாரவ்மடந்து வாயுவினால் ததகைங்குை்  
கைல்லதவ மககால் களசிக லுண்டாகுை்                      
…….……….   …………..   …………….திமிருண்டாகுை்” 
                                             - அகத்தியர ் 
“வளிவாக  நாலாயிரத்து  நானூற்று  நாற்பத்கதடட்ு                                                                                                                             
வந்தணுகில் ததகைதில் வலுவியாதி”    
                                                   -அகத்தியர ்
 
“எரியநல் வாத கைறிக்குங்வ குணங்தகளு 
குறிகயனக் மககால் குளசச்ு விலாச ்சந்து”  
                        --தநாய்   நாடல்  தநாய்  முதல்   நாடல்  திரடட்ு  
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Naadi pathology:  
 
“திருந்துமோம் வோதத்  பதோபை  தீங்தகோடு  பித்தஜ்பெரில்  
    த ோருத்துகள்  பதோறும்  தநோந்து”  
                                                     -குணவோகைம்  பநோயின்  ெோரம்  
  
AETIOLOGY OF SURONITHA VADHAM  
 
             “தகோண்டிடிற் ெரரீம் கலந்தும் தோரத்்தங்கள் தகோள்டகயோலு 
முண்டியிரத்தந் தன்டன யுறிஞ்சிடும் தோரத்த்தோலும் 
மிண்டிய ெோக்கிரத்தில் விருந்தத் திடரகளோலும் 
மண்டுடம துணங்களோலும் வோதள த்டதயோலும் 
ஆகிய தெல்வமிஞ்சி நைவோம லிருக்டகயோலும் 
 ோகமோங் குதிடரயோடன ல ் ை பவறலோலும் 
ப தமோம் வோயுண்ைோய் வி ரதீமோ யிரத்தஞ் 
பெோகமோய்வோங்கிெ ்பெோர்ந்து சுபரோணித வோதமுண்ைோம்” 
 Intake of spicy food stuff  
 Intake of astringents  
 Daytime sleep  
 Sedentary life  
 Food which decrease the absorption of iron  
 Foods which increases the body heat.  
 Riding over the elephant and horse  
       All these factors will affect vatha which along with blood produces Suronithavadham.  
  
According to para rasa sekaram: 
 
             “ததோழில் த றுடக ்புக் கோரத்்தல் துவரத்்தல் விஞ்சுகினுஞ் பெோறும் 
 டழயதோம் வரகு மற்டறய ்ட ந்திடன யருந்தினோலும் 
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எழில் த ற ் கலுறங்கி இரவினி லுறங்கோத தோலும் 
மடழநீர் குழலினோபல வோதங் பகோபிக்குங்கோபன”     
1.Over conception of bitters, astringents, savouries and rancid foods  
2.Intake of cold water  
3.Intake of varagu, thinai  
    
     “கோணபவ மிகவுண்ைோலுங் கருது ை்டினி விை்ைோலும் 
மோனடன யோரக்ண் பமோகமறக்கினு மிகுந்திை்ைோலும் 
ஏற்த று தனது தநஞ்சின் மிகத்துக்க மடைந்திருந்தோலும் 
 ோரிய கோற்றினோளும் ைரினும் வோதங்கோனும்” 
• Eating of excessive intake of food  
• Starvation  
• Excessive sexual indulgence  
• Sleeping in the day time & not sleeping in the night  
• Not taking food at proper time, Decreased intake of sour and ghee diet increase the 
vadham 
 
      “ ோரினிற் ய ் ை்ைோலும் லருைன் பகோபித்தோலும் 
கோதரனக் கருகிபயோடிக் கழுமரத்தினோலும் 
ஏற்த று தனது தநஞ்சின் மிகத்துக்க மடைந்திருந்தோலும் 
 ோரிய கோற்றினோளும் ைரினும் வோதங்கோணும்” 
• Fear  
• Anger  
• Worry  
 
In textbook of siddha medicine (sabaa pathy kaiyedu) 
          “வளிதரு கோய்கிழங்குவடரவிலோ தயிலல் பகோடழ 
முழுதயிர் ப ோன்மி குக்கு முடரயிலோ வுண்டி பகோைல் 
களித்தரு முயக்கம் த ற்பறோர் கடிதெயல் கருவியோமல்” 
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 Intake of vadham containing food stuffs  
 Intake of cold items  
 Exposure to extreme cold air, rain, and 
snow 
 Hereditary  
 Stay in mountain                                   
 
CLINICAL FEATURES OF UTHIRAVADHA SURONITHAM:  
  
In yugi vaithiya chindhamani  
            
             “டவகிதமோய்க் கடணகோலு முழங்கோல் தோனு 
மற்கைஞ் ெந்து புறவடியும் வீங்கிெ ்
தெய்கிதமோய் சிறுவிரல்கள் மிகவு தநோந்து 
சிந்டததடு மோறிபய ெலி ்புண்ைோகும் 
ட கிதமோம் யித்தியத்தில் வோத மிஞ்சி ் 
 ோரமோ யுற் வித் தழலுண் ைோகும் 
உய்கிதமோ மெனமது தோனும் பவண்ைோ”  
• Swelling of the ankle and knee joints  
• Swelling of the foot  
• Pain in the fingers and toes  
• Confusion  
• Fatigue  
• Loss of appetite  
  
In Dhanvandhiri vaithiyam  
 
             “கோணுபம எலி விஷம் ப ோல் கன ்புைன் தடி ்புமோக 
பூணுைம் புடளயங்குத்தும் தெோறி கன ்புந் 
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பதோணிருந் துடி ்புத் பதகங் கிள்ளினோற் பெோதியோது 
மோனில முடலயோய் சுபரோணித வோதமோபம 
டகயினிற் கறண்டை தண்ணீர் கை்டுஞ் ெடதப ோல் வீங்கு 
தமய்யிடன ்பிளக்கும் வோதம் வியோ ்பிக்கும் உைம் தோக்கு 
டமயலர் உைல் தம்புக்கும் வோதசுபரோணித மிததன்பன”  
• Pyrexia and swelling of the body as in rat poison intoxication  
• Pain and tenderness  
• Twitching of muscles   
• Loss of sensation  
• Swelling of the wrist and phalanges  
• Black and redness of swelling due to vascular failure  
• Hyperaemia  
 
சுபரோணிதவோதம்: 
              “ஓடிய சுபரோணித வோதமுைல்தடன தநஞ்சுலர்ந்து 
பதடிய கோல் டககள் திருபம பிளக்க தவோண்ணோ 
வோடிய பமனிதோனும் வறண்டிடும் நோவும் ல்லும் 
மூடிறக் கடுத்து தநோந்து அடளவுைன் குத்துமுண்பை”  
  
According to Vaithiya Cindhamani by kannusamy 
 
உதிரவோத சுபரோணிதம் என்ற பநோயில் கடனக்கோலும், முழங்கோலும், 
ெந்துபுறங்களும் வீங்கி வடிவதுைன் விரல்களில் அதிக பநோயுண்ைோகும். இன்னும் 
சிந்டத தடுமோறல், ெலி ்பு, ஆகோர தவறு ்பு இடவயும் த ற்றிருக்கும் 
  
• The disease name suronithavatham is also mentioned in Aaviyalikkum 
Amuthamurai Churukkam as painful and swollen joints.  
• Anubogavaithiya Deva Ragasiyam also deals with vatha diseases.  Instead of 
“Uthiravaatha suronitham” it is mentioned as “Sonithavatharogam”.  
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• Jeevarakshamirtham also deals it as sonithavaatharogam in Vaatharogapadalam 
and the symptoms are polyarthralgia, swelling, anaemia, spindle shaped swelling 
in the joints.  
   
In pararaasasekaram  
          “வீழித று சுபரோணி தந்தோன் மிகவுைன் தமலிவு மோகித் 
வோழ்வுறு டகயுங்கோலும்வெமின்றி யுழன்று பநோவோம் 
 ோழ்த று மணங்கி நோபள யனுற ் கர்ந்திை் பைோபம” 
• Decrease in the haemoglobin level  
• Pain in the upper and lower limbs  
• Swelling especially in the peripheral joint and deformities  
• Morning stiffness present more than 1 hr. 
 
    “ க்கமும் மோர்பும் கூை ் ற்றிபய இழுத்துக் தகோண்டு 
தநக்கிபய மோர்பிடளத்து பநோதோய் நரம்பிழுத்து 
ஒக்கபவ ெயித்தியங்கள் உயர்ந்துைன் பமலும் கோலும் 
மிக்குபம உதிரவோதம் என்றிதுவிளம் லோபம”  
 
             “தெோர்சீபத வுதிர சுபரோணித முழங்கோல் தோணும் 
த ோற்கடன கோலுங்ந் ெந்தும் புறவடி தோணும் வீங்கி 
…………………..முண்ைோ முறுநூலிற் தெோன்ன தோபம”    
• Swelling of the ankle and knee joint  
• Swelling of hind foot  
• Pain in the distal interphalangeal joint  
  
According to Agathiyar Ayulvedham– 1200  
           “டககோல் தநற்றித்தடல பிைறி கனத்துதநோந்து வுடளவுண்ைோம் 
தமய்யீன்ரூ ந்தோன்தகை்டு தவதும்பி விதனமிக வுண்ைோந் 
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ததோய்யெ ்சுருை்டி முைக்கிவிைஞ் சுபரோணிதவோதக் குணமதுதவன் 
டறயோ முனிவரத்ோளி தனோலறியஸ் தெோன்னோரரிவோபர”  
• Pain in the upper and lower limbs, forehead and cervical region.  
• Restricted joint movements.  
  
DIFFERENTIAL DIAGNOSIS:  
Among the 80 types of vatdha diseases mentioned in “yugi vaithiya cindhamani” 
the “Uthiravadhasuronitham” is differentiated from the following types of suronitham.  
 
1.வோத சுபரோணிதம்: 
             “அறிந்திை்ை அங்கதமலோ தமலிவுமோகி 
அடெவோன தவ்விைங்கள் வீக்கமோகி 
………………………………………………………….. 
வோதசுபரோணிதந் தோனும் வகுத்தவோபற”   
 Emaciation  
 Swelling of joints  
 Restriction of movements  
 Anorexia  
 Excessive salivation  
 Discomfort 
 
2.சிபலை்டுமவோத சுபரோணிதம்: 
 “ ண் ோக வுைல்குளிர்ந்து வயிறு வீங்கி ் 
   டத ் ோன விைந்ததோை்ைோற் ப ோல பநோவோந் 
                  ………………………………………………………………….. 
                  நற்சிபலை்ம சுபரோணிதமோம் நோடுங் கோபல”    
 Chillness with abdominal distension  
 Severe pain  
 Headache  
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 Bronchitis with dyspnoea  
 Giddiness  
 Dryness of mouth  
 Tachycardia  
 Syncope and Hallucination  
 Anorexia  
 
3.சித்துவோத சுபரோணிதம்:   
“வோறோன ெரரீதமலோ நுடழந்பத யூதும் 
                மோெற்ற பதோல்தோனுந் திடரந்து ப ோகும் 
                ……………………………………………………………….. 
                மிக்கசித்து வோதசுபரோ ணிதம தோபம” 
 Anasarca  
 Reduced haemoglobin level  
 Wrinkles  
 Neural pain  
 Bullous eruption as in palms   
 Glossy tongue  
 Sialorrhoea 
 Exfoliation 
 swelling   
 Warmness.  
 
4.டவகிதவோத சுபரோணிதம்: 
“ஆதமன்ற வீங்கினபதோர் இைத்தில் ரத்த 
                மழுத்தமோய்த் திரண்டுபம தயங்கும் ோய்ந்து 
                ……………………………………………………………………... 
                ோரமோய் டவகிதமோம் வோதந் தோபன” 
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 Swelling with hyperaemia  
 Soft on touch  
 Cough  
 Pyrexia  
 Irritability  
 
5.ட த்தியவோத சுபரோணிதம்: 
“உணரெ்ச்ியோய்ெ ்சுபரோணிதந்தோன் மிகதவ தும்பி 
                ஊக்கமோய்த் பதகதமங்கு மிகபவ தநோந்து 
                …………………………………………………………………….. 
                யித்தியவோத சுபரோணிதத்தின் ண்பு தோபன”  
 Hyperaemia  
 Tenderness in knee, elbow and smaller joints  
 Polyarthralgia  
 Pyrexia  
 Anaemia 
 
6.உதரவோத சுபரோணிதம்: 
“நோடுபம சுரம்வந்து நடுக்கலுண்ைோம் 
  நோவறண்டு கடல தநோந்து உைம்  ழுந்தி 
                ………………………………………………………………….. 
                தெயவுதர வோதசுபரோ ணிதந்தோ தனன்பன” 
 Fever with rigor  
 Dryness of mouth  
 Diarrhoea  
 Headache  
 giddiness  
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 Excessive thirst  
 Loss of appetite  
 Pain all over the body  
 
IN SIDDHA - MODE OF PATHOLOGY  
• Vadham is said to be phenomenon responsible for the movements of the parts 
involved in locomotor system, hence it is responsible for the articulation of the 
joints, tendons and muscles.  
• Bone and lower abdomen is considered to be the place for vadham.  
• Santhiga kabam is said to be the phenomenon which is responsible for the normal 
maintenance of synovial fluid.  
• Synovial fluid provides nutrition for the articular cartilages, disc, meniscus and 
thereby avoids friction of the bones and erosion of the bones, it helps the smooth 
articulation.  
• In Uthiravadha suronitham due to factors related to diet, habit, environment etc, 
adversely influence of vali and azhal mainly in mukkutram.  
• The involvement of viyanavayu and abanavayu plays a major role in the 
manifestations of signs & symptoms. Viyana is responsible for all the motor and 
sensory functions of the body and the nutrition of tissues.  
• Abananvayu is responsible for the assimilation of the nutritional factors from the 
gastro intestinal tract distribution between various thathus and expulsion of waste 
product through faeces, urination etc...  
AZHAL:  
• The azhal is responsible for the healthy maintenance of every tissue of the body 
and its variation results in inflammatory changes in the bone and other accessory 
structures like tendons, cartilage and synovial membrane which helps in perfect 
articulation of joints. 
IYAM :  
• The deterioration of iya humour leads to structural changes in the bones and the 
fluids in the joints which are mainly controlled by the factors of santhigam.  
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• Disturbance in humours it produces different clinical manifestations. They Include,  
o Swelling of the joints,  
o Pain  
o Stiffness  
o Restricted movements of the joints due to disturbed vali.  
o Inflammatory changes of the joints like redness hyperaemia, and warmness 
due to disturbed azhal and erosion of bone margin, increased synovial fluid 
due to disturbed iyam.  
o The tridosha phenomenon and the functioning of the joints. 
 
“வளிமிகு வபான வியான வாயுகளதிகரிக்குை் 
 இளமிகு ைலனீரக்் கடட்ுை் இயை்பிய வபானன் கசய்யுை் 
 வளிவிலா வியானன் கீலின்விளங்குறு புமழகதபாறுை் 
  ஒளியுறு குற்றகைல்லா கைான்றிகலன்று லவசக்சய்யுை்” 
- சபாபதி மகதயடு(சித்த ைருத்துவை், பக்கை் 603 
 
UYIRTHAATHUKKAL:  
These are the fundamentals and essential factors in the composition and 
constitution of the human body.  
 Vaatham(vali)  
 Pitham(azhal)  
 Kabam(iyyam)  
  
PINIYARI MURAIMAI (DIAGNOSIS):  
             The methodology of diagnosing in siddha science is very unique and solely based 
on the clinical acumen of the physician. It is based on the three main principles,  
 PORIYAL THERTHAL  
 PULANAL THERTHAL  
 VINATHAL  
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1. PORIYAL THERTHAL:  
   Pori means sense of perception. Poriyaltherthal understands by the five sense 
organs such as nose, tongue, eyes, skin, and ear.  
  
2. PULANAL THERTHAL:  
Pulan means objects of senses. Pulanaltherthal understands by the sense objects.  
1. Smell (Manam)  
2. Taste (suvai)  
3. Vision (oli)  
4. Somatic sense (ooru)  
5. Sound (oosai)  
In both of the above said methods, physician, pori and pulan are used as tools for 
examine the pori and pulan of the patients.   
 
3. VINATHAL:  
Vinathal is the process of obtaining the detailed history of the disease by 
interrogation the patient. By this gathering the history of disease, complaints, and duration, 
personal history, family history, clinical features, where an accurate history, is available, a 
disease can be easily diagnosed ever before clinical examinations carried out. It is the focal 
point of the “physician –patient” relationship and established the bonding necessary for 
patient cure. The classified method of clinical examinations is known as ENVAGAI 
THERVU, Siddhars have devolved a unique method of diagnosing the diseases by 
“ENVAGAI THERVU” eight basic diagnostic parameters namely,  
i. Sparism  
ii. Naa  
iii. Niram  
iv. Mozhi  
v. Vizhi  
vi. Malam  
vii. Moothiram  
viii. Naadi  
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NAADI NADAI IN UTHIRA VATHA SURONITHAM:  
Naadi diagnosis is the confirmatory diagnosis, Naadi is the inherent seat anchor of 
energy on which vibration the entire thathus of the body are functioning.  
1. Vathakapham  
2. Kaphavatham.  
  
      வோத க ம்: 
    “ ோங்கோன வோதத்தில் பெத்தும நோடி 
  ரிசித்தோற் திமிர்பமவு முடளெெ்லோகுந் 
     ……………………………………………………………………… 
            …………………….தவகு பநோய்க்கு முறுதி தோபன” 
       க  வோதம்: 
     “கண்ைோபயோ சிபலற் னத்தில் வோத நோடி 
 கலந்திடுகில் வயிறு த ோருமல் கனத்த வீக்கம் 
      …………………………………………………………………………… 
             ……………………… லவும் வந்து சிக்குந் தோபன” 
 
Derangements of vatham in uthiravadhasuronitham:  `   
 
Abhanan: Constipation, polyuria, menstrual  
Viyanan:  Pain and tenderness in the affected joints  
Samanan:  Affected due to the derangements  
Koormam: Extra articular features 
Kirukiran: Loss of appetite  
  
Derangements of pitham in uthiravadhasuronitham:  
  
Analagam:  Loss of appetite  
Ranjagam: Anaemia  
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Saadhagam: Disturbances in regular activities  
Aalosagam: Disturbances in vision  
Prasagam:   Redness  
  
Disturbances of kabham in uthiravadhasuronitham:  
 
Avalambagam: Dyspnoea (due to anaemia)  
Kiledham: Loss of appetite  
Sandhigam: Restriction of joint movements  
 
Udalthathukkal:  
In uthiravathasuronitham cases,  
 Saaram  
 Senneer  
 Oon  
 Kozhuppu  
 Enbu  
 Moolai  
               Are the most affected  
  
Gnanendhiriyam:  
      In uthiravathasuronitham cases,  
      Mei: Pain and tenderness in the joints  
      Kan: Disturbances of vision (scleritis)  
  
Kanmendhiriyam:  
       In uthiravathasuronitham cases,  
     Kai  : Difficulty to use the upper limbs   
                 Kaal: Difficulty to use the lower limb   
     Eruvai: Constipation in some cases  
     Karuvai: Irregular menstrual cycle in some cases   
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PININEEKAM:  
      Siddha system of medicine is a unique system of medicine in which treatment 
is given both for the body and mind. Thiruvalluvar in his thirukural under the heading  
“MARUNDHU” mentions about the diseases and its prevention.  
So in Siddha system, treatment is not only for the removal of diseases, but for 
prevention and improving the body condition-Rejuvenation.  
1. Prevention  
2. Treatment-curative  
3. Restoration-promotive  
1. PREVENTION:  
  It is very much, essential and stressed in all siddha literature. Body and mind 
should be very clean and free from evil thoughts and deeds.  
2. TREATMENT:  
     A Good physician should know about the derangements of humours and should 
treat the patients on the basis of altered humours.  
Treatment is based on,  
    To bring the tridosham to normal  
    To treat the disease according to its symptoms through medicines,  
    To increase the natural immunity  
    To normalize the tridosham,  
                                            
                                         “விபரெனத்தோல் வோதம் தோழும்” .  
        
Vadha disease can be brought down by vireasanam(purgation), by giving 
the laxatives and purgatives according to the patient conditions, Four requisites of 
successful treatment are explained by “THIRUVALLUVAR”  
    
“உற்றவன்  தீர் ் ோன்  மருந்துடழவெ ் தெல்வோதனன்  
                ற ் னோற் கூற்பற மருந்து”.  
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3.RESTORATION:  
• Reassurance is given to all the patients for fast recovery  
• Not to be anxious  
• Not to be depressive  
• Avoid exposure to cold  
• Avoid excessive workload  
• To advice the patients to do asanas regularly   
  
MANEGEMENT OF UTHIRAVADHA SURONITHAM:  
The treatment of siddha medicine is aimed at keeping the three humours in equilibrium 
and maintenance of seven elements. So proper diet, medicine and disciplined regimen of 
life are advised for the healthy living and to restore equilibrium of humours in diseased 
condition.  
  
 INTERNAL MEDICINE:  
‘SAMUTHARA CHOORANAM’ -  2 grams with Ghee, twice daily, after 
food for the period of 48 days 
 
 EXTERNAL MEDICINE: 
‘VADHA NOIKU VELIPRAYOGHA THAILAM’ 
 
 OTTRADAM (THERAPY) 
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     3.2. REVIEW OF LITERATURE – MODERN ASPECT 
 
BONE: 
   Bone is a specialized connective tissue in the human body that serves  
(1) locomotion by providing the insertion site of the muscles,  
(2) protection of the internal organs and the bone marrow as well, and  
(3) metabolic function such as storage and provision of calcium to the body 
   Two major types of bones exist:  
1.Flat bones, which are built by intramembranous ossification, and  
2.Long bones, which emerge from endochondral ossification.  
    Intramembranous bone formation is based on the condensation of mesenchymal stem 
cells, which directly differentiate into bone-forming osteoblasts.  
    In contrast, during endochondral ossification of the long bones, the mesenchymal stem 
cells first differentiate into chondrocytes that will further be replaced by osteoblasts. Long 
bones consist of the 
 (1) epiphyses, which are protrusions at the ends of the long bones; 
 (2) the diaphysis constituting its shaft; and  
 (3) the metaphysis, which are located between the epiphysis and the diaphysis. The 
metaphysis is separated from the epiphysis by the growth plate, a proliferative cartilage 
layer, which is essential for the longitudinal growth of bones. 
 
JOINT: 
  A joint, also called an articulation, is any place where adjacent bones or bone and 
cartilage come together (articulate with each other) to form a connection. 
    Human joints provide the structures by which bones join with one another and may 
be classified according to histologic features of the union and range of joint motion. 
Joints are classified both structurally and functionally. 
A. STRUCTURAL CLASSIFICATION OF JOINTS: 
The structural classification of joints is based on whether the articulating 
surfaces of the adjacent bones are directly connected by fibrous connective tissue 
    REVIEW OF LITERATURE/2018 
38 
 
or cartilage, or whether the articulating surfaces contact each other within a fluid 
– filled joint cavity. 
1. FIBROUS JOINT – is where the adjacent bones are united by fibrous connective 
tissue. 
2. CARTILAGINOUS JOINT – the bones joined by hyaline cartilage or fibro 
cartilage. 
3. SYNOVIAL JOINT – the articulating surfaces of the bones are not directly 
connected, but instead come into contact with each other within a joint cavity that 
is filled with a lubricating fluid. This joint allow for free movement between the 
bones and are the most common joints of the body. 
 
A. FUNCTIONAL CLASSIFICATION OF JOINTS: 
The functional classification of joints is determined by the amount of mobility 
found between the adjacent bones. 
1. Synovial or Diarthrodial joints which articulate with free movement, 
have a synovial membrane lining the joint cavity, and contain synovial 
fluid; 
2. Amphiarthroses, in which adjacent bones are separated by articular 
cartilage or a fibrocartilage disk and are bound by firm ligaments permitting 
limited motion (e.g., pubic symphysis, intervertebral disks of vertebral 
bodies, distal tibiofibular articulation, sacroiliac joint articulation with 
pelvic bones); and 
3. Synarthroses or Immovable joint, which are found only in the skull 
(suture lines), where thin, fibrous tissue separates adjoining cranial plates 
that interlock to prevent detectable motion before the end of normal growth, 
yet permit growth in childhood and adolescence. 
 
Joints also can be classified according to the connective tissues present.  
1. Symphyses -  have a fibrocartilaginous disk separating bone ends that are joined 
by firm ligaments (e.g., symphysis pubis and intervertebral joints). 
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2. Synchondroses - the bone ends are covered with articular cartilage, but no 
synovium or significant joint cavity is present (e.g., sternomanubrial joint). 
3. Syndesmoses -  the bones are joined directly by fibrous ligaments without a 
cartilaginous interface (the distal tibiofibular articulation is the only joint of this 
type outside the cranial vault).  
4. Synostoses -  bone bridges are formed between bones, producing ankylosis. 
 
SYNOVIAL JOINT 
General Structure 
 Synovial(diarthrodial) joints account for most of the body's articulations and are  
characterized by wide ranges of almost frictionless movement.  
 The synovium is a membranous structure that extends from the margins of articular 
cartilage and lines the capsule of diarthrodial joints, including the 
temporomandibular joint and the facet joints of vertebral bodies. 
 The healthy synovium covers intra-articular tendons and ligaments, as well as fat 
pads, but not articular cartilage or meniscal tissue.  
 Synovium also ensheathes tendons where they pass beneath ligamentous bands and 
bursas that cover areas of stress such as the patella and the olecranon.  
 
COMPONENTS AND ITS FUNCTION OF SYNOVIAL JOINT: 
                       
                                 
               
               Structure of synovial joint 
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1.ARTICULAR CARTILAGE: 
The articulating bony surfaces of synovial joints are usually bulbous, sometimes 
flattened excrescences of cancellous bone, capped by a thin plate of dense cortical bone 
(the subchondral plate), which is covered by articular cartilage. 
 Articular cartilage is a specialized tissue characterized macroscopically by its 
milky, shelled-almond (hyaline) appearance. It is an avascular tissue nourished by 
diffusion from the vasculature of the subchondral bone and from the synovial fluid.  
 Articular cartilage is more than 70% water, and it is hypocellular compared with 
other tissues; chondrocytes constitute only 1% to 2% of its total volume. 
 Most of the dry weight of cartilage consists of two components: 
1.Type II collagen and  
2. the large aggregating proteoglycan, aggrecan. 
 
2.CALCIFIED CARTILAGE: 
A layer of calcified cartilage exists in the interface between the articular cartilage and 
its underlying (subchondral) bone.  
 The articular cartilage and its calcified cartilage bed are separated from the bone 
by a wavy, irregular bluish line (on hematoxylin and eosin staining) called the 
tidemark. The tidemark is similar in appearance and composition to the cement 
lines in bone and may act as a limit to calcification. 
 The collagen in calcified cartilage is type II and it is heavily encrusted with 
hydroxyapatite. This 
 tissue contains cells that are metabolically active.  
 The deep surface of the calcified cartilage merges with the endplate of the 
underlying bone in an undulating interface. 
 This permits a significant increase in resistance to shearing forces and helps to 
keep the cartilage on its bony bed. 
 The fibers in the lowermost region are perpendicular to the surface and firmly fixed 
to the underlying calcified subchondral structures, also positioned to resist shear 
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3.SUBCHONDRAL BONE: 
At the tissue level, the bone located in the subchondral plate and the cancellous bone 
that supports it are indistinguishable from bone in other sites, the organization of the 
subchondral bone is specific.  
 The subchondral plate on which the calcified cartilage lies is thinner than cortical 
bone in most sites and contains variable numbers of mature haversian systems.  
 These systems run parallel to the joint rather than parallel to the long axis of the 
sheets and interconnecting struts of cancellous bone, which support the plate and 
fill the epiphyseal end of the bone, differ considerably from joint to joint, but are 
highly ordered and characteristic for any one joint.  
 The major plates are arranged at right angles to the predominating stresses and, 
together with the subchondral bony plate, are approximately 10 times more 
deformable than is the cortical bony shaft. 
 An increase in this bony structure, so-called subchondral sclerosis, is associated 
with thickening of the subchondral plate and thinning of the overlying articular 
cartilage. These changes are pathognomonic of osteoarthrosis and are deleterious 
to the function of the joint and the health of the overlying articular cartilage 
 
4.SYNOVIAL MEMBRANE: 
The synovial membrane serves two functions in the adult joint 
1. the provision of nutrients to cells of the articular cartilage and  
2. the production of lubricating fluid to ensure the low friction characteristic of joint 
articulation.  
The membrane consists of two distinct layers: 
1. the thin intimal lining or synovial surface layer, the synovial lining produces 
synovial fluid and represents the direct interface to the intraarticular cavity. 
2. the subintimal layer of connective tissue that supports both the lining and the 
blood vessels that supply the membrane.  
In the normal condition, synovial membrane is an irregular membrane merely two to 
three cells thick.  
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In inflammatory disease, this appearance can change dramatically, with both 
hypertrophy and hyperplasia rapidly developing, resulting in an inflammatory, fibrous 
membrane.  
The main cells of the synovial surface layer and its vascular sublining have been 
historically divided into two distinctive populations, historically termed  
 synovial type A cells – have macrophage morphology  
 synovial type B cells – appears fibroblastic 
There is no basement membrane beneath the synovial intima, although both 
laminin and type IV collagen may be found underlying the synovial intima. Subintimal 
tissue is sparsely populated with cells compared with the intima, and fat cells and blood 
vessels are integrated within this matrix, which is rich in type I and type III collagen, 
proteoglycans, and fibronectin 
 
5.SYNOVIAL FLUID AND JOINT LUBRICATION: 
Synovial fluid serves multiple roles in the function of the normal joint. It provides 
nutrients to cells embedded within the cartilage matrix and lubrication to the 
articulating surfaces of the joint. These functions require a surprisingly low amount of 
fluid, with an average normal volume of 1.1 mL of fluid and a range of 0.13 to 3.5 mL 
The composition of synovial fluid is similar to that of plasma, but with additional 
HA, which provides the high viscosity that is characteristic of synovial fluid. HA, a linear, 
non-branching polysaccharide, is secreted into the fluid by the fibroblastic cells of the 
synovial lining and achieves a concentration between 2 and 4 mg/Ml. 
In the adult, there is little or no traverse of water through the subchondral plate and 
only modest flow through the substance of the cartilage, the water displaced by cartilage 
compression is expressed onto the surface of the cartilage, preferentially peripheral to the 
zone of impending contact. 
The lubrication of synovium on cartilage or synovium upon itself is the result of 
the affinity of HA for synovial surfaces. Thus, HA acts as a boundary lubricant for 
synovium. This is an important component in the ease of motion of joints, because the 
periarticular soft tissues contribute much more resistance to joint motion than do 
cartilaginous surfaces. 
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In addition, HA appears to exert a major influence in maintaining the volume of 
synovial fluid in the joint. HA acts to reduce the volumetric loss that would be expected 
to occur as fluid pressure increases during joint flexion. As pressure increases, fluid loss is 
retarded, due to polarized HA accumulation at the interstitial spaces of membrane surface, 
resulting in elevated osmotic pressure, which retains water molecules within the synovial 
fluid. 
 
6.CAPSULE: 
The joint capsule is vital to the function of synovial joints. It seals the joint space, 
provides passive stability by limiting movements, provide active stability via its 
proprioceptive nerve endings and may form articular surfaces for the joint.  
It is a dense fibrous connective tissue that is attached to the bones via specialized 
attachment zones and forms a sleeve around the joint. 
 Outer fibrous layer – made up of white fibrous tissue, called capsular ligament. 
This holds together articulating bones and supports the synovium. 
 Inner synovial layer – a highly vascularized layer of connective tissue. It absorbs 
and secretes synovial fluid, and is responsible for the mediation of nutrient 
exchange between blood and joint.  
 
7.LIGAMENTS AND TENDONS: 
Stability for the joint is provided by the joint capsule, tendons, and ligaments. These 
structures govern the motion of a joint and distribute the forces that impinge on the joint. 
 Ligaments and tendons are classified as dense connective tissue structures and are 
generally alike in both structure and function. Ligaments form connections 
between bones, whereas tendons provide the attachment of muscle to bone. 
 Ligaments consist of collagen fibrils embedded in a proteoglycan matrix sparsely 
populated with fibroblastic cells. The microfibril may be considered the basic 
building block of the ligament derived from the properties of the type I collagen 
molecule.  
 The insertion of ligaments into bone can be classified as direct or indirect. Indirect 
insertions are more common and are characterized by Sharply fibers, which are 
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oblique anchor points for the deep fibers within bone. Superficial fibers form a 
contiguous merger directly with the periosteum in indirect attachment.  
 Ligaments may be viewed as resistant to force, whereas tendons actively 
transfer force, but they exhibit the same basic structure.  
 Tendons contain a higher ratio of collagen to proteoglycan matrix than ligaments, 
and the longitudinal alignment of the collagen fibrils is more polarized in tendons. 
This reflects the variations in directional loading that impinge on ligaments, as 
opposed to the unidirectional forces that typically are carried by tendons. 
 
8.BURSAE: 
A bursa is a small sac lined by synovial membrane filled with synovial fluid. They 
are placed at key points of friction in a joint, providing the joint with free movement.  
They can become inflamed following infection or irritation by over use of the 
joint(bursitis). Examples of this friction points are where tendons run over the joints, as 
they do in the knee, a common location for bursitis.  
 
9.MUSCLES: 
The muscles surrounding synovial joints are responsible for moving the body in 
space. These muscle actions are often paired, like flexion and extension or abduction and 
adduction or pronation and supination or elevation and depression. 
 
10.MENISCI: 
The menisci, like articular cartilages, are for the most part, avascular, but at the 
site of bony attachment, they usually display a surprisingly rich vascular arcade. No nerves 
or lymphatics have been identified in meniscal tissues. They presumably derive some of 
their nutrition from synovial fluid, but also by diffusion from vascular plexuses, which are 
present adjacent to their attachment to bone or fibrous capsule 
The fibrocartilage of the meniscus has a biochemical composition considerably 
different from that of articular cartilage. The water content ranges between 70% and 78%. 
Inorganic ash accounts for approximately 3% of the wet weight. The remainder of the 
material, the organic solids, are principally collagen, with type I. Collagen accounts for 
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60% to 90% of the organic solids. Elastin is present in low concentration (<1%). 
Proteoglycans constitute less than 10% of the dry weight, and the constituent 
glycosaminoglycans are principally chondroitin sulfates and dermatan sulfate, with 
keratin sulfate representing only a minor component. 
Meniscal collagen fibers are arranged circumferentially, presumably to withstand 
the tensile hoop stresses generated during load bearing. 
 
TYPES OF SYNOVIAL JOINTS: 
 
 
 
 PIVOT JOINT – found in the first few cervical vertebrae, which must twist and 
turn to allow for rotation of the head and neck. 
 HINGE JOINT – seen in elbow and knee which are only allowed to bend in one 
direction. 
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 SADDLE JOINT – which exist between the bones of the fingers and palm, allow 
the fingers and bones in the hand to rotate in a variety of directions. 
 PLANE JOINT – allow bones to slide past one another. 
 CONDYLOID JOINT – are found in the wrist, and allow for a complex range of 
movement that also holds many bones together. 
 BALL AND SOCKET JOINT – are synovial joints which are found in several 
places in the body, including shoulders and hips. It can rotate almost freely around 
the connection it makes with another bone.  
                                        
 
SUBINTIMAL VASCULATURE: 
 The vascular supply to the synovium is provided by many small vessels and is 
shared in part by the joint capsule, epiphyseal bone, and other perisynovial 
structures. Arteriovenous anastomoses communicate freely with the vascular 
supply to the periosteum and to periarticular bone.  
 As large synovial arteries enter the deep layers of the synovium near the capsule, 
they branch to form microvascular units in the more superficial subsynovial layers.  
 Precapillary arterioles probably play a major role in controlling circulation to the 
lining layer.  
 The surface area of the synovial capillary bed is large, and because it runs only a 
few cell layers deep to the surface, it has a role in trans-synovial exchange of 
molecules.  
 The intimal lining, however, is devoid of blood vessels. 
 
SUBINTIMAL LYMPHATICS: 
 Lymphatics are present in the superficial, intermediate, and deeper layers of 
synovial membrane in synovium from normal individuals or patients with 
osteoarthritis and rheumatoid arthritis joints, although the number in the superficial 
subintimal layer is low in normal synovium. 
 Little difference in the distribution and number is noted between normal and 
osteoarthritis synovium, which is characterized by lack of villous hypertrophy. 
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 Lymphatic channels are plentiful, however, in the subintimal layer in the presence 
of villous edema hypertrophy and chronic inflammation. 
 
SUBINTIMAL NERVE SUPPLY:  
 The synovium has a rich network of sympathetic and sensory nerves. The former, 
which are myelinated and detected with the antibody against S-100 protein, 
terminate close to blood vessels, where they regulate vascular tone.  
 Sensory nerves respond to proprioception and pain via large myelinated nerve 
fibers and via small (<5μm) unmyelinated or myelinated fibers with unmyelinated 
free nerve ends (nociceptors).  
 The latter are immune-reactive in the synovium for neuropeptides, including 
substance P, calcitonin gene–related peptide, and vasoactive intestinal peptides. 
 
DISEASES OF JOINTS AND THEIR CLASSIFICATIONS: 
A.Infective arthritis: 
Bacterial, viral and parasite 
    1.Acute infection: 
 Acute pyogenic arthritis 
 Acute gonococcal arthritis 
 Acute rheumatic arthritis 
 Small pox arthritis 
    2.Chronic infection: 
 Non-specific: Pyogenic arthritis                                                                             
 Specific: Tuberculous arthritis, syphilitic arthritis, gonococcal arthritis 
 Parasitic: Guinea worm arthritis 
B.Autoimmune arthrosis 
 Rheumatoid arthritis 
 Juvenile rheumatoid arthritis 
 Seronegative spondyloarthropathy 
 Ankylosing spondylitis 
 Reiter’s disease 
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 Psoriatic arthritis 
 Enteropathic arthritis 
C.Degenerative arthrosis(orteoarthritis) 
 Osteoarthritis 
 Cervical spondylosis 
 Lumbar spondylosis 
D.Neuropathic arthrosis 
 Charcot’s arthropathy 
 Syringomyelia 
 Leprosy 
 Diabetes mellitus 
E.Metabolic arthritis 
 Gout 
 Pseudo-gout 
 Alkaptonuric arthritis 
F.Arthritis in system disorders 
 Haemophilic arthritis 
 Reactive arthritis 
G.Miscellaneous conditions 
 Villonodular synovitis 
 Synovial chondromatosis 
 
IMMUNE SYSTEM: 
The human immune system has evolved over millions of years from both 
invertebrate and vertebrate organisms to develop sophisticated defense mechanisms to 
protect the host from microbes and their virulence factors.  
The normal immune system has three key properties  
 a highly diverse repertoire of antigen receptors that enables recognition of a nearly 
infinite range of pathogens; 
 immune memory, to mount rapid recall immune responses and  
 immunologic tolerance, to avoid immune damage to normal self-tissues. 
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A.INNATE IMMUNE SYSTEM: 
 From invertebrates, humans have inherited the innate immune system, an ancient 
defense system that uses germ line-encoded proteins to recognize pathogens. 
 Cells of the innate immune system, such as macrophages, dendritic cells, and 
natural killer (NK) lymphocytes, recognize pathogen-associated molecular 
patterns (PAMPs) that are highly conserved among many microbes and use a 
diverse set of pattern recognition receptor molecules (PRRs).  
 Important components of the recognition of microbes by the innate immune system 
include  
            (1) recognition by germ line–encoded host molecules,  
(2) recognition of key microbe virulence factors but not recognition of    
self-molecules,  
(3) non-recognition of benign foreign molecules or microbes.  
 Upon contact with pathogens, macrophages and NK cells may kill pathogens 
directly or, in concert with dendritic cells, may activate a series of events that both 
slow the infection and recruit the more recently evolved arm of the human immune 
system, the adaptive immune system. 
 
B.ADAPTIVE IMMUNE SYSTEM:  
 Adaptive immunity is found only in vertebrates and is based on the generation of 
antigen receptors on T and B lymphocytes by gene rearrangements, such that 
individual T or B cells express unique antigen receptors on their surface capable of 
specifically recognizing diverse antigens of the myriad infectious agents in the 
environment.  
 Coupled with finely tuned specific recognition mechanisms that maintain tolerance 
(non-reactivity) to self-antigens, T and B lymphocytes bring both specificity and 
immune memory to vertebrate host defenses. 
 
THE MAJOR HISTOCOMPATIBILITY COMPLEX: 
 The human major histocompatibility complex (MHC), commonly called the 
human leukocyte antigen (HLA) complex, is a 4-megabase (Mb) region on 
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chromosome 6 (6p21.3) that is densely packed with expressed genes. The best 
known of these genes are the HLA class I and class II genes, whose products are 
critical for immunologic specificity and transplantation histocompatibility, and 
they play a major role in susceptibility to a number of autoimmune diseases.  
 Many other genes in the HLA region are also essential to the innate and antigen-
specific functioning of the immune system. The HLA region shows extensive 
conservation with the MHC of other mammals in terms of genomic organization, 
gene sequence, and protein structure and function. 
 
A.Class I Structure: 
 MHC class I molecules provide a cell-surface display of peptides derived from 
intracellular proteins, and they also provide the signal for self-recognition by NK 
cells. 
 Surface-expressed class I molecules consist of an MHC-encoded 44-kD 
glycoprotein heavy chain, a non-MHC-encoded 12-kD light chain β2-
microglobulin, and an antigenic peptide, typically 8–11 amino acids in length 
and derived from intracellularly produced protein.  
 The heavy chain displays a prominent peptide-binding groove.  
 In HLA-A and –B molecules, the groove is ∼3 nm in length by 1.2 nm in maximum 
width (30 Å × 12 Å), whereas it is apparently somewhat wider in HLA-C.  
 Antigenic peptides are non-covalently bound in an extended conformation within 
the peptide-binding groove, with both N- and C-terminal ends anchored in pockets 
within the groove (A and F pockets, respectively) and, in many cases, with a 
prominent kink, or arch, approximately one-third of the way from the N-terminus 
that elevates the peptide main chain off the floor of the groove. 
 
B.Class II Structure: 
 A specialized functional architecture similar to that of the class I molecules can be 
seen in the example of a class II molecule depicted in with an antigen-binding cleft 
arrayed above a supporting scaffold that extends the cleft toward the external 
cellular environment.  
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 However, in contrast to the HLA class I molecular structure, β2-microglobulin is 
not associated with class II molecules. Rather, the class II molecule is a 
heterodimer, composed of a 29-kD α chain and a 34-kD β chain.  
 The amino-terminal domains of each chain form the antigen-binding elements that, 
like the class I molecule, cradle a bound peptide in a groove bounded by extended 
α-helical loops, one encoded by the A (α chain) gene and one by the B (β chain) 
gene.  
 Like the class I groove, the class II antigen-binding groove is punctuated by pockets 
that contact the side chains of amino acid residues of the bound peptide, but unlike 
the class I groove, it is open at both ends. Therefore, peptides bound by class II 
molecules vary greatly in length, since both the N- and C-terminal ends of the 
peptides can extend through the open ends of this groove. 
 
FUNCTIONS OF CLASS I AND CLASS II MOLECULES: 
 Class I and class II molecules display a distinctive structural architecture, which 
contains specialized functional domains responsible for the unique genetic and 
immunologic properties of the HLA complex. The principal known function of 
both class I and class II HLA molecules is to bind antigenic peptides in order to 
present antigen to an appropriate T cell.  
 The ability of a particular peptide to satisfactorily bind to an individual HLA 
molecule is a direct function of the molecular fit between the amino acid residues 
on the peptide with respect to the amino acid residues of the HLA molecule.  
 The bound peptide forms a tertiary structure called the MHC-peptide complex, 
which communicates with T lymphocytes through binding to the TCR molecule.  
 The first site of TCR-MHC-peptide interaction in the life of a T cell occurs in the 
thymus, where self-peptides are presented to developing thymocytes by MHC 
molecules expressed on thymic epithelium 51 and hematopoietically derived 
antigen-presenting cells, which are primarily responsible for positive and negative 
selection, respectively. Thus, the population of MHC–T cell complexes expressed 
in the thymus shapes the TCR repertoire.  
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 Mature T cells encounter MHC molecules in the periphery both in the 
maintenance of tolerance and in the initiation of immune responses.  
 The MHC-peptide-TCR interaction is the central event in the initiation of most 
antigen-specific immune responses, since it is the structural determinant of the 
specificity.  
 For potentially immunogenetic peptides, the ability of a given peptide to be 
generated and bound by an HLA molecule is a primary feature of whether or not 
an immune response to that peptide can be generated, and the repertoire of peptides 
that a particular individual’s HLA molecules can bind exerts a major influence over 
the specificity of that individual’s immune response. 
 
AUTOIMMUNITY: 
 The immune system is the capacity to mount an inflammatory response to non-self 
while avoiding harm to self tissues. The essential feature of an autoimmune disease 
is that tissue injury is caused by the immunologic reaction of the organism against 
its own tissues. Autoimmunity, on the other hand, refers merely to the presence of 
antibodies or T lymphocytes that react with self-antigens and does not necessarily 
imply that the self-reactivity has pathogenic consequences. 
 Autoimmunity is present in all individuals; however, autoimmune disease 
represents the end result of the breakdown of one or more of the basic mechanisms 
regulating immune tolerance. 
 Currently, three general processes are thought to be involved in the maintenance of 
selective unresponsiveness to autoantigens.  
(1) sequestration of self-antigens, rendering them inaccessible to the immune  
system;  
(2) specific unresponsiveness (tolerance or anergy) of relevant T or B cells; and 
(3) limitation of potential reactivity by regulatory mechanisms. 
           Derangements of these normal processes may predispose to the development 
of autoimmunity. 
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MECHANISM OF AUTOIMMUNITY: 
I. Exogenous 
A. Molecular mimicry 
B. Superantigenic stimulation 
C. Microbial adjuvanticity 
II. Endogenous 
A. Altered antigen presentation 
1. Loss of immunologic privilege 
2. Presentation of novel or cryptic epitopes (epitope spreading) 
3. Alteration of self-antigen 
4. Enhanced function of antigen-presenting cells 
a. Co-stimulatory molecule expression 
b. Cytokine production 
B. Increased T cell help 
1. Cytokine production 
2. Co-stimulatory molecules 
C. Increased B cell function 
D. Apoptotic defects 
E. Cytokine imbalance 
F. Altered immunoregulation 
 
AUTOIMMUNE DISEASES: 
Organ Specific 
1.Graves’ disease    12.Vitiligo 
2.Hashimoto’s thyroiditis  13.Autoimmune hemolytic anemia 
3.Autoimmune polyglandular  14.Autoimmune thrombocytopenic 
Syndrome     purpura 
4.Type 1 diabetes mellitus   15.Pernicious anemia 
5.Insulin-resistant diabetes   16.Myasthenia gravis 
mellitus 
6.Immune-mediated infertility 17.Multiple sclerosis 
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7.Addison’s disease   18.Guillain-Barré syndrome 
8.Pemphigus vulgaris   19.Stiff-person syndrome 
9.Pemphigus foliaceus   20.Acute rheumatic fever 
10.Dermatitis herpetiformis   21.Sympathetic ophthalmia 
11.Autoimmune alopecia   22.Goodpasture’s syndrome 
Organ Nonspecific (Systemic) 
1.Systemic lupus erythematosus  4.Granulomatosis with 
        polyangiitis (Wegener’s) 
2.Rheumatoid arthritis              5.Antiphospholipid syndrome 
3.Systemic necrotizing   6.Sjögren’s syndrome 
vasculitis 
 
RHEUMATOID ARTHRITIS: 
Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology 
marked by a symmetric, peripheral polyarthritis. It is the most common form of chronic 
inflammatory arthritis and often results in joint damage and physical disability.  
Because it is a systemic disease, RA may result in a variety of extra-articular 
manifestations, including fatigue, subcutaneous nodules, lung involvement, pericarditis, 
peripheral neuropathy, vasculitis, and hematologic abnormalities.  
The identification and characterization of RF as an autoantibody that binds to the 
Fc portion of IgG was the first direct evidence that autoimmunity might play a role in RA. 
Although IgG and IgM RFs are the most abundant in RA, IgE RF has also been 
demonstrated, especially in patients with extra-articular manifestations. 
 
EPIDEMIOLOGY: 
 RA affects approximately 0.5–1% of the adult population worldwide. There is 
evidence that the overall incidence of RA has been decreasing in recent decades, 
whereas the prevalence has remained the same because individuals with RA are 
living longer.  
 The incidence and prevalence of RA varies based on geographic location, both 
globally and among certain ethnic groups within a country. For example, the Native 
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American Yakima, Pima, and Chippewa tribes of North America have reported 
prevalence rates in some studies of nearly 7%.  
 In contrast, many population studies from Africa and Asia show lower prevalence 
rates for RA in the range of 0.2–0.4%. 
 Like many other autoimmune diseases, RA occurs more commonly in females 
than in males, with a 2–3:1 ratio.  
 Interestingly, studies of RA from some of the Latin American and African countries 
show an even greater predominance of disease in females compared to males, with 
ratios of 6–8:1. Given this preponderance of females, various theories have been 
proposed to explain the possible role of estrogen in disease pathogenesis.  
 Most of the theories center on the role of estrogens in enhancing the immune 
response. For example, some experimental studies have shown that estrogen can 
stimulate production of tumor necrosis factor α (TNF-α), a major cytokine in the 
pathogenesis of RA. 
 
ETIOLOGY: 
Although the etiology of RA remains unknown, a variety of studies suggest that 
the interaction of environmental and genetic factors is responsible; either one is 
necessary but not sufficient for full expression of the disease.  
 
A.ROLE OF HLA-DR: 
     I. HLA-DRB1: 
The alleles known to confer the greatest risk of RA are located within the major 
histocompatibility complex (MHC). It has been estimated that one-third of the genetic risk 
for RA resides within this locus. 
This risk is associated with allelic variation in the HLA-DRB1 gene, which 
encodes the MHC II β-chain molecule. The disease-associated HLA-DRB1 alleles share 
an amino acid sequence at positions 70–74 in the third hypervariable regions of the HLA-
DR β-chain, termed the shared epitope (SE).  
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Carriership of the SE alleles is associated with production of anti-CCP antibodies 
and worse disease outcomes. Some of these HLA-DRB1 alleles bestow a high risk of 
disease, whereas others confer a more moderate risk. 
 
     II. HLA-DR4: 
The structure of class II MHC molecules on antigen presenting cells is associated 
with increased susceptibility and severity of RA and accounts for about 40% of the genetic 
influence.  
HLA-DR4 occurred in 70% of RA patients, compared with about 30% of 
controls, giving a relative risk of having RA to those with HLA-DR4 of approximately 4 
to 5.  
The shared epitope might not be an independent risk factor for RA but instead the 
presence of the shared epitope and ACPAs together is associated with even greater 
disease severity. 
 
B.ADDITIONAL POLYMORPHISMS: 
     I.CYTOKINES: 
The importance of cytokines in RA is not surprising that many studies have focused 
on these genes. The most intriguing evidence relates to tumor necrosis factor (TNF). This 
proinflammatory factor is a major cytokine in the pathogenesis of RA, and the TNF genes 
are located in the MHC locus on chromosome 6 in humans. 
 
     II.CITRULLINATING ENZYME (PADI): 
Among the many non-cytokine and non-MHC genetic linkages described for RA, 
the ones associated with peptidyl arginase deiminase (PADI) and PTPN22 have the 
strongest effect on susceptibility.  
The PADI genes are responsible for the post-translational modification of arginine 
to citrulline. Four isoforms have been identified, known as PADI1 through PADI4.  
An extended haplotype in the PADI4 gene that can lead to increased levels of 
PADI4 protein due to enhanced messenger RNA (mRNA) stability. So, a twofold increase 
in risk of RA was observed with PADI4 SNPs 
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     III.PTPN22: 
Protein tyrosine phosphatase-22 (PTPN22) associations have been discovered in 
large-scale screening efforts to identify SNP associations in RA. 
 
C.ENVIRONMENTAL FACTORS: 
          I.Infectious Agent                                      Potential Pathogenic Mechanisms 
Mycoplasma          Direct synovial infection; superantigens 
Parvovirus B19         Direct synovial infection 
Retroviruses          Direct synovial infection 
Enteric bacteria         Molecular mimicry (QKRAA, e.g., in                
                                                                             bacterial heat shock proteins) 
Mycobacterium         Molecular mimicry (proteoglycans,  
                                                                                                       QKRAA), 
Immunostimulatory DNA (Toll-like   
                   receptor 9 activation) 
Epstein-Barr virus         Molecular mimicry (QKRAA in gp110) 
Bacterial cell walls         Toll-like receptor 2 activation 
     II.Smoking 
     III.Gender 
 Female predominance – a. Role of oestrogen 
      b. During pregnancy 
      
PATHOGENIC MECHANISMS IN RA: 
 
A.AUTOIMMUNITY: 
     1.Rheumatoid Factor 
 The identification and characterization of RF as an autoantibody that binds to the 
Fc portion of IgG was the first direct evidence that autoimmunity might play a role 
in RA. For many years, immune complexes comprising RF and other 
immunoglobulins were thought to play a primary role in the pathogenesis of 
synovitis 
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TCR- T cell receptor, TH-T helper cell, IFN-Interferon, TNF-Tumour Necrosis 
Factor,  IL-Interleukin, TGF-Transforming Growth Factor, FGF-Fibroblast Growth 
Factor, SF-Synovial Fibroblast, OC-Osteoclast, OB-Osteoblast, RANK-Receptor 
Activator Of Nuclear Factor, OPG-Osteoprotegerin, TLR-Toll like receptor 
 
2.Anti-citrullinated Protein Antibodies (ACPAs): 
 One of the most striking recent observations related to autoantibodies is the 
observation that immunoglobulins that bind to citrullinated proteins are produced 
by patients with RA.  
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 The discovery of antibodies directed against keratin were detected in rheumatoid 
serum and that the primary target antigen was filament-aggregating protein, 
filaggrin. These antibodies actually bind to epitopes on filaggrin that contain 
citrulline, which is derived from posttranslational modification of arginine by 
PADI. Humans have four isoforms of PADI.  
 PADI2 and PADI4 are especially abundant in synovium. The function of PADIs 
in normal immune responses is not certain; citrullination of some chemokines can 
decrease activity, and modification of histones can regulate gene expression in 
stressed cells.  
 Induction of PADI expression and citrullination of peptides are not specific to RA 
and can occur in many inflammatory settings. Not only are other inflammatory 
arthropathies marked by citrullinated proteins, but other organs such as the lungs 
in smokers have significant PADI activity.  
 The presence of CPs in the lungs of smokers could provide the systemic antigen 
exposure that can contribute to anti-CP antibody production and begin the long 
road to developing RA. 
 
B.INFECTIOUS AGENTS: Direct Infection and Innate Immune Responses 
1.Toll-like Receptors and the Inflammasome in the Joint 
 Some arthrotropic microorganisms could potentially infect the synovium and cause 
a local inflammatory response. There is increasing awareness that the innate 
immune system could also directly affect the onset and course of synovitis. 
Pathogen-associated molecular pattern receptors, especially the Toll-like receptors 
(TLRs), are expressed by sentinel cells in the host that provide a first line of 
defense.  
 These receptors recognize preserved structures in bacteria and other infectious 
agents and permit rapid release of inflammatory mediators, activation of antigen-
presenting cells, and enhancement of adaptive immune responses 
2.Bacteria, Mycobacteria, Mycoplasma and Their Components: 
 Active infection of synovial tissue by pyogenic bacteria is an unlikely cause of RA, 
and extensive searches for a unique or specific organism in synovial tissue or joint 
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effusions have been negative. Antibodies to certain organisms such as Proteus are 
reportedly elevated in the blood of patients with RA, but this could represent an 
epiphenomenon or a nonspecific B cell activation.  
 Most RA and reactive arthritis patients contain bacterial DNA sequences in their 
synovium.The bacteria identified are not unique and generally represent a cross-
section of skin and mucosal bacteria including Acinetobacter and Bacillus spp.  
 It is possible that the synovium functions as an adjunct to the reticuloendothelial 
system in arthritis, allowing local macrophages to accumulate circulating bacterial 
products. 
     3.Epstein-Barr Virus, dnaJ Proteins and Molecular Mimicry 
 Epstein-Barr virus (EBV) is a polyclonal B lymphocyte activator that increases the 
production of RF, and rheumatoid macrophages and T cells have defective 
suppression of EBV-induced proliferation of human B cells.  
 Rheumatoid patients have higher levels of EBV shedding in throat washings, an 
increased number of virus-infected B cells in the circulating blood, higher levels of 
antibodies to normal and citrullinated EBV antigens, and abnormal EBV-specific 
cytotoxic T cell responsiveness. 
     4.Mycoplasma: 
 Mycoplasma-derived superantigens such as from Mycoplasma arthritis can directly 
induce T cell–independent cytokine production by macrophages and can 
exacerbate or trigger arthritis. 
 There is also a higher prevalence of antimycoplasma pneumoniae IgG antibodies 
in RA patients. 
 
C.SMOKING: 
 A number of environmental factors clearly contribute to RA susceptibility, 
although no specific exposure has been identified as the pivotal agent. Smoking is 
the best defined environmental risk factor for seropositive RA. 
 The reason for its influence on the development of synovitis is not fully defined but 
could involve the activation of innate immunity and PADI in the airway.  
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 Increase in protein citrullination in smokers(tobacco) and increased ability of 
SE-containing HLA-DR molecules to bind some citrullinated proteins which 
results in synovitis(auto-reactivity). 
 
D.GENDER 
 RA is one of many chronic autoimmune diseases that predominates in women. The 
ratio of female-to-male patients is 2 : 1 to 3 : 1, 
 Estrogens hormones modulate immune function, an auto-antibody producing B 
cells exposed to estradiol are more resistant to apoptosis, suggesting that 
autoreactive B cell clones might escape tolerance. 
 Estrogen receptors are expressed on fibroblast-like synoviocytes (FLS) and 
increase 
 production of metalloproteinases. In macrophage cell lines, estrogen can enhance 
production of TNF. 
 Pregnancy is often associated with remission of the disease in the last trimester. 
More than three quarters of pregnant patients with RA improve in the first or second 
trimester, but 90% of these experience a flare of disease associated with a rise in 
RF titers in the weeks or months after delivery. 
 
PATHOLOGY: 
      RA affects the synovial tissue and underlying cartilage and bone.  
Synovial membrane: 
 The synovial membrane, which covers most articular surfaces, tendon sheaths, and 
bursae, normally is a thin layer of connective tissue.  
 It consists primarily of two cell types. 
1.type A synoviocytes (macrophage-derived) and  
2.type B synoviocytes (fibroblast-derived).  
 The synovial fibroblasts are the most abundant and produce the structural 
components of joints, including collagen, fibronectin, and laminin, as well as 
other extracellular constituents of the synovial matrix.  
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 The sublining layer consists of blood vessels and a sparse population of 
mononuclear cells within a loose network of connective tissue.  
 Synovial fluid, an ultrafiltrate of blood, diffuses through the subsynovial lining 
tissue across the synovial membrane and into the joint cavity. Its main constituents 
are hyaluronan and lubricin.  
 
Stages and Its Mechanism in Pathology of RA: 
The above etiological factors like gene variations, chronic exposure to infective 
agents, and certain environmental factors will lead to  
1.Synovial inflammation and proliferation,  
2.Focal bone erosions and  
3.Thinning of articular cartilage  
 1.Synovial inflammation and proliferation: 
      A.Synovitis:: 
 Chronic inflammation leads to synovial lining hyperplasia and the formation of 
pannus, a thickened cellular membrane of granulation–reactive fibrovascular tissue 
that invades the underlying cartilage and bone.  
  B.Proliferation and Pannus formation: 
                
    
a. Normal joint             b. Pannus formation in joint 
 
    REVIEW OF LITERATURE/2018 
63 
 
 Cadherin-11, the chief organizing molecule of the synovial membrane, confers the 
invasive nature of the fibroblast-like synoviocytes, the prevailing cell type of the 
pannus.  
 The inflammatory infiltrate is made up of no less than 6 cell types: T cells, B cells, 
plasma cells, dendritic cells, mast cells, and a few granulocytes.  
 The T cells comprise 30–50% of the infiltrate, with the other cells accounting for 
the remainder. The topographical organization of these cells is complex and may 
vary among individuals with RA.  
 The B cells, T cells, and dendritic cells may form higher levels of organization, 
such as lymphoid follicles and germinal center–like structures. 
      C.New Vascularisation: 
 Growth factors secreted by synovial fibroblasts and macrophages promote the 
formation of new blood vessels in the synovial sublining that supply the increasing 
demands for oxygenation and nutrition required by the infiltrating leukocytes and 
expanding synovial tissue. 
 
2.Focal bone erosions: 
      a.1st Stage 
 The structural damage to the mineralized cartilage and subchondral bone is 
mediated by the osteoclast.  
 Osteoclasts are multinucleated giant cells that can be identified by their expression 
of CD68, tartrate-resistant acid phosphatase, cathepsin K, and the calcitonin 
receptor. They appear at the pannus-bone interface where they eventually form 
resorption lacunae.  
      Common site: 
 These lesions typically localize where the synovial membrane inserts into the 
periosteal surface at the edges of bones close to the rim of articular cartilage and at 
the attachment sites of ligaments and tendon sheaths.  
 This process most likely explains why bone erosions usually develop at the radial 
sites of the MCP joints juxtaposed to the insertion sites of the tendons, collateral 
ligaments, and synovial membrane. 
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b.2nd Stage: 
 Another form of bone loss is periarticular osteopenia that occurs in joints with 
active inflammation. It is associated with substantial thinning of the bony 
trabeculae along the metaphysis of bones, and likely results from inflammation of 
the bone marrow cavity. These bone marrow lesions are often the forerunner of 
bone erosions.  
 The cortical bone layer that separates the bone marrow from the invading pannus 
is relatively thin and susceptible to penetration by the inflamed synovium. 
c.3rd Stage: 
 Finally, a third form of bone loss is generalized osteoporosis, which results in the 
thinning of trabecular bone throughout the body. 
 
     3.Thinning of articular cartilage: 
 Articular cartilage is an avascular tissue and was considered to be an inert tissue, 
but it is now known to be a highly responsive tissue that reacts to inflammatory 
mediators and mechanical factors, which in turn, alter the balance between cartilage 
anabolism and catabolism. 
 In RA, the initial areas of cartilage degradation are juxtaposed to the synovial 
pannus. The cartilage matrix is characterized by a generalized loss of 
proteoglycan, most evident in the superficial zones adjacent to the synovial fluid.  
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 Degradation of cartilage may also take place in the perichondrocytic zone and in 
regions adjacent to the subchondral bone. 
At last the extending granular pannus gets organized into fibrous tissue, which bridges 
the articulating bone ends, leading to two types of deformity i.e.,  
 Fibrous ankylosis 
 Later to Bony ankylosis   
 
CLINICAL FEATURES:  
 Edema fluid within inflamed tissues during sleep 
 Fatigue, malaise, swollen hands, and diffuse musculoskeletal pain 
 Symmetrical Inflammation in Wrists, Metacarpophalangeal (MCP), and Proximal 
interphalangeal (PIP) joints -most frequently involved joints 
 Morning stiffness > 1 hour - cardinal sign of inflammatory arthritis that can appear 
even before pain and may be related to the accumulation of  
 Muscle weakness  
 A low-grade fever without chills 
 Anorexia. 
 Weight loss  
 Anaemia 
 Depression and anxiety 
 
Distribution of Joints Involved in RA: 
       Joint Involvement         Percentage (%) 
MCP, PIP       91  
Wrists        78  
Knees        64  
Shoulders       65  
Ankles       50  
Feet        43  
Elbows       38  
Hips        17  
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Temporomandibular       8  
Spine         4  
Sternoclavicular       2  
Peri-articular sites      27 
 
DEFORMITIES OF RA: 
 
               
Polyarticular arthritis with fusiform swelling   Complete subluxation with ulnar deviation  
of PIP joint                                                         at MCP joint 
 
           
              Swan-neck deformity                  Boutonniere deformity 
 
              
           Rupture of Baker’s cyst posteriorly at left knee 
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  Rheumatoid nodules in olecranon bursa              Livedo reticularis & Digital gangrene                                                                                                              
  
 
EXTRA ARTICULAR COMPLICATIONS OF RA: 
 
1.RHEUMATOID NODULES: 
 The mature rheumatoid nodule has a central area of necrosis rimmed by a corona 
of palisading fibroblasts that is surrounded in turn by a collagenous capsule with 
perivascular collections of chronic inflammatory cells. 
 They occur most often on extensor surfaces or pressure points, such as the 
olecranon process and the proximal ulna, as well as on tendons. 
 They are subcutaneous and vary in consistency from a soft, amorphous, entirely 
mobile mass to a hard, rubbery mass attached firmly to the periosteum. 
2.BONE DENSITY: 
 Osteopenia 
 Osteoporosis  
Which results in Hip fracture, Stress fracture, Vertebral compression fracture 
3.MUSCLE: 
 Muscle weakness and tenderness 
 Muscle atrophy 
 Nodular myositis 
 Peripheral neuromyopathy 
 Steroid myopathy 
 4.SKIN: 
 Rheumatoid nodules 
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 Senile purpura 
 Palmar erythema 
 Pyoderma gangrenosum 
 
                         
                                   Extra articular complications of RA 
5.EYE: 
 Keratoconjuctivitis 
 Scleritis 
 Episcleritis 
 Scleromalacia perforans 
 Chronic blepharitis 
6.HAEMOTOLOGIC ABNORMALITIES: 
 Mild normocytic normochromic anaemia 
 Elevated ESR 
 Thrombocytosis 
 Folate or vitamin B12 deficiency 
 Eosinophilia 
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 Neutropenia 
7.VASCULITIS: 
 Distal arteritis 
 Cutaneous ulceration 
 Palpable purpura 
 Arteritis of viscera including heart, lungs, bowel, kidney, liver, spleen, pancreas, 
lymph nodes, or testis 
8.RENAL DISEASE: 
 AA Amyloidosis 
 Renal papillary necrosis 
 Membranous nephropathy 
 Focal necrotizing glomerulitis 
9.PULMONARY DISEASE: 
 Pleuritis 
 Interstitial pneumonitis  
 Pulmonary fibrosis 
 Pulmonary nodules 
 Caplan’s syndrome – pneumoconiosis and RA are synergistic 
 Bronchiolitis 
 Pulmonary hypertension 
 Small airway diseases 
10.CARDIOVASCULAR DISEASE: 
 Atherosclerosis 
 Pericarditis 
 Myocarditis 
 Endocarditis 
 Conduction defects 
 Granulomatous aortitis 
11.NERVOUS DISORDERS: 
 Carpal tunnel syndrome 
 Tarsal tunnel syndrome 
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 Mononeuritis multiplex 
 Subluxation of c1 and c2 etc… 
 
DIAGNOSIS: 
 The clinical diagnosis of RA is largely based on signs and symptoms of a chronic 
inflammatory arthritis, with laboratory and radiographic results providing 
important supplemental information.  
 In 2010, a collaborative effort between the American College of Rheumatology 
(ACR) and the European League Against Rheumatism (EULAR) revised the 
1987 ACR classification criteria for RA in an effort to improve early diagnosis 
with the goal of identifying patients who would benefit from early introduction of 
disease-modifying therapy. 
     2010 ACR/EULAR Classification 
     Diagnostic Criteria for Rheumatoid Arthritis  
      [Cutpoint for RA: ≥6/10]) 
            Joint Involvement              (0-5) 
1 medium to large joint       0 
2-10 medium to large joints       1 
1-3 small joints (with or without involvement of large 
joints)      2 
4-10 small joints (with or without involvement of large 
joints)      3 
>10 joints (at least one small joint)      5 
                     Serology               (0-3) 
Negative RF AND negative ACPA      0 
Low-positive RF OR low-positive ACPA     2 
High-positive RF OR high-positive ACPA     3 
            Acute Phase Reactants                  1 
Normal CRP AND normal ESR      0 
Abnormal CRP OR abnormal ESR      1 
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     Duration of Symptoms                (0-1) 
            <6 weeks        0 
            ≥6 weeks        1 
 
DIFFERENTIAL DIAGNOSIS: 
       Discriminating Features in Patients Presenting with Polyarthritis and Fever 
              Symptom or Sign               Possible Diagnoses 
Temperature >40° C      Still’s disease 
Bacterial arthritis 
SLE 
Fever preceding arthritis     Viral arthritis 
Lyme disease 
Reactive arthritis 
Still’s disease 
Bacterial endocarditis 
Migratory arthritis      Rheumatic fever 
Gonococcemia 
Meningococcemia 
Viral arthritis 
SLE 
Acute leukemia 
Whipple’s disease 
Effusion disproportionately    Tuberculous arthritis 
       greater than pain      Bacterial endocarditis 
Inflammatory bowel disease 
Giant cell arteritis 
Lyme disease 
Pain disproportionately     Rheumatic fever 
       greater than effusion     Familial Mediterranean fever 
Acute leukemia 
AIDS 
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Positive test for Rheumatoid     Rheumatoid arthritis 
             Factor      Viral arthritis 
Tuberculous arthritis 
Bacterial endocarditis 
SLE 
Sarcoidosis 
Systemic vasculitis 
Morning stiffness      Rheumatoid arthritis 
Polymyalgia rheumatica 
Still’s disease 
Some viral and reactive    
                arthritides 
Symmetric small joint     Rheumatoid arthritis 
        synovitis       SLE 
Viral arthritis 
Leukocytosis (>15,000/mm3)    Bacterial arthritis 
Bacterial endocarditis 
Still’s disease 
Systemic vasculitis 
Acute leukemia 
Leukopenia       SLE 
Viral arthritis 
Episodic recurrences      Lyme disease 
Crystal-induced arthritis 
Inflammatory bowel disease 
Whipple’s disease 
Mediterranean fever 
Still’s disease 
SLE 
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LABORATORY INVESTIGATIONS: 
1.Complete blood count: 
 Normocytic hypochromic anaemia 
 Eosinophilia 
 Thrombocytosis 
 Increased ESR 
 Neutropenia 
2.Increased CRP 
3.Increased plasma viscosity 
4.Serum proteins 
 Decreased albumin 
 Increased gammaglobulins 
 Increased IgG, IgM, IgA 
5. Serological tests: 
A. IgM (Rheumatoid factor) is detected by the following methods: 
I.Rose Waaler test: It is more specific and is said to be positive when more 
                                             than 1:32 
II.Latex test: It is sensitive and less specific and said to be positive when more 
                                   than 1:20. 
B. Anti-CCP(cyclic citrullinated polypeptide) – Positive test for 95% of RA. 
 I.ELISA  
 II.Serum/CMIA 
6.Synovial fluid analysis: 
 Yellow, watery 
 Turbidity due to increased WBC from 5000 – 50,000 WBC/ µ3 
 Reduced viscosity 
 Increased proteins 
 Low sugar content 
7.Synovial biopsy and histological examination 
8.Arthroscopic examinations to evaluate damage to articular cartilage. 
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9.Radiological features of RA 
Early: 
 Soft tissue swelling 
 Periarticular osteopenia 
 Periosteoitis 
 Erosions-periarticular and articular 
Later: 
 Narrowed joint spaces is caused by loss of cartilage 
 Juxta –articular erosion 
 Articular surface irregularity 
 Subluxation 
 Large cystic erosions of bone 
 Ankylosis 
10.Ultrasound and MRI imaging has improved the sensitivity of detecting joint damage 
earlier in diseases. 
 Ultrasound may detect synovitis, effusions, and erosions, in addition to Doppler 
providing estimates of ongoing inflammation. 
 MRI may show inflammatory synovitis that enhances with Gadolinium and 
shows 
early erosions 
11.Arthroscopy- Synovium oedematous, diffusely erythematous, and friable and later 
the synovium becomes thickened. 
12.Computerised tomography 
13.Scintigraphy. 
 
TREATMENT AND MANAGEMENT: 
1. DRUGS: 
The amount of clinical disease activity in patients with RA reflects the overall 
burden of inflammation and is the variable most influencing treatment decisions. 
Several developments during the past two decades have changed the therapeutic 
landscape in RA. They include:  
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(1) the emergence of methotrexate as the disease- modifying antirheumatic drug 
(DMARD) of first choice for the treatment of early RA;  
(2) the development of novel highly efficacious biologicals that can be used alone or in 
combination with methotrexate; and 
(3) the proven superiority of combination DMARD regimens over methotrexate alone.  
The medications used for the treatment of RA may be divided into broad categories: 
a. nonsteroidal anti-inflammatory drugs (NSAIDs) 
b. glucocorticoids, such as prednisone and methylprednisolone 
c. conventional disease-modifying anti-rheumatic drugs (DMARDs) such as 
hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide 
d. biologic DMARDs such as The TNF-inhibitors, Anakinra an IL-1 receptor 
antagonist, Abatacept, rituximab, and tocilizumab 
 
2. SURGERY:  
 Surgical procedures may improve pain and disability in RA—most notably the 
hands, wrists, and feet, typically after the failure of medical therapy with varying 
degrees of   reported long-term success.  
 Total joint arthroplasty is an option for advanced joint diseases in larger joints 
such as the knee, hip, shoulder, or elbow. 
 Silicone implants are the most common prosthetic for MCP arthroplasty, and are 
generally implanted in patients with severe decreased arc of motion, marked flexion 
contractures, MCP joint pain with radiographic abnormalities and severe ulnar 
drift.  
 Synovectomy and limited fusion are offered for the early rheumatoid wrist, but 
they are used much less frequently now compared to the past because of the 
availability of improved DMARD therapies.  
 Arthrodesis and total wrist arthroplasty are reserved for patients with severe 
disease that have substantial pain and functional impairment.  
 
3. PHYSICAL THERAPHY AND ASSISSTIVE DEVICES: 
 All patients should receive a prescription for exercise and physical activity.  
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 Dynamic strength training, community-based comprehensive physical therapy, and 
physical-activity coaching (emphasizing 30 minutes of moderately intensive 
activity most days a week) have all been shown to improve muscle strength and 
perceived health status.  
 Foot orthotics for painful valgus deformity decreases foot pain and resulting 
disability and functional limitations.  
 Judicious use of wrist splints can also decrease pain; however, their benefits may 
be offset by decreased dexterity and a variable effect on grip strength. 
 
4. FOODS: 
 Good diet rich in proteins and minerals 
 Grains, Olive oil, Fatty fish, Walnuts, Almonds, Flax and Chia seeds which contain 
rich Omega-3s. 
 Berries, Green tea, Grapes, Broccoli, Soy and dietary antioxidants with vitamin 
A,C,E and Selenium. 
 Turmeric, Ginger, Capsaicin have anti-inflammatory properties which can reduce 
inflammation in the body. 
 
5.SELF-HELP TECHNIQUES: 
 Positive mental attitude 
 Regular medications 
 Regular exercises and Massage 
 Adequate sleep 
 Modification of daily activities like  
 Using western toilets. 
 Bath aids and railings. 
 Long handle broomstick and mop to clean the floors. 
 Use of walking stick while walking, climbing etc. Avoid walking on hard, 
rough surfaces. 
 Avoid squatting on the ground for food. Use high chairs and dining table. 
 Avoid squeezing cloths after washing. 
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             REVIEW OF LITERATURE 
                                    3.3.DRUG REVIEW – INTERNAL 
 
1 . கடுக்காய் 
வேறுபெயர்: 
         அபெயன், அமுதம், அம்ருதா, அரிதகி, ேரிக்காய், சாமுதம் 
 
GENERAL PROPERTIES OF KADUKKAI 
KINGDOM: Plantae 
DIVISION: Angiosperms  
CLASS: Eudicots 
SUBCLASS: Rosids 
ORDER: Myrtales 
FAMILY: Combretaceae 
GENUS: Terminalia 
SPECIES: T.chebula 
BOTANICAL NAME: Terminalia chebula 
ENGLISH NAME: Chebulic Myrobalan, Ink nut 
 
PART USED:  
Unriped fruit and Galls 
 
CHEMICAL CONSTITUENTS:  
 Gallic acid, Chebupentol, Chebulagic acid, Terminoic acid, p-coumaric acid,   
Tannin(30-32%), Arjunolic acid 
 
ACTIONS:  
Astringent, Alterative, Carminative, Anti septic 
 Anti – inflammatory, Anti – arthritic, Anti – oxidant 
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பொதுகுணம்: 
“தாபை கழுத்தக்கி தாலு குறியிவிைெ் 
 பீபை சிலிெதமுற் வெதமுை – மாபைபயை்ைாத் 
 தூலமிடி புண்ோத வசாணிகா மாபலயிரண் 
 ைாலமிடி வொம்ேரிக்கா யால்” 
    -ெதாரத்்த குண விளக்கம்- ெக்கம் 157 
கடுக்காயின் சிறெ்பு 
“கடுக்காயுந் தாயுங் கருதிபலான்பறன் றாலும் 
 கடுக்காய்த் தாய்க்கதிகங் காண்நீ – கடுக்காய்வநாய் 
 ஓை்டி யுைற்வறற்றும் உற்றேன்பன வயாசுபேகள் 
 ஊை்டியுைற் வறற்று முேந்து” 
    -அகத்தியர் குணோகைம் 
சுபே : கார்ெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: இனிெ்பு 
ேபககள்: 
 கருங்கடுக்காய் 
பசங்கடுக்காய் 
ேரிக்கடுக்காய் 
ொல்கடுக்காய் 
 
MEDICINAL USES: 
 Fruit kernel paste with water is externally applied for Anti-inflammatory, 
Analgesic and having purifying and healing capacity of wounds. 
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 The powdered fruit act as an astringent and is used in haemorrhoids, dentrifice in 
loose gums, bleeding and ulceration in gums. 
 Fruit decoction used in curing diarrhoea and dysentery. 
 Fruit powder has Anti-ageing activity. 
 
2. ஓமம் 
வேறுபெயர்: 
 அசவமாதம், தீெ்பியம் 
 
GENERAL PROPERTIES OF OMAM 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Eudicots 
SUBCLASS: Asterids 
ORDER: Apiales 
FAMILY: Apiaceae 
GENUS: Trachyspermum 
SPECIES: T.ammi 
BOTANICAL NAME: Trachyspermum ammi  
ENGLISH NAME: Bishops weed 
 
PART USED:  
Seeds 
 
CHEMICAL CONSTITUENTS: 
             Essential oil, Thymol, Carvacrol, α and β – pinene, Camphene, Threonine 
 
ACTIONS: 
Diuretic, Carminative, Anti – vomiting, Anti – hypertensive, Anti – spasmodic 
Anti – oxidant, Anti - inflammatory 
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பொதுகுணம்: 
“சீதசுரங் காசஞ் பசரியாமந் தம்பொருமல் 
 வெதியிபரச ்சல்கடுெ்பு வெராமம் – ஓதிருமல் 
 ெல்பலாடுெல் மூலம் ெகமிபேவநா பயன்பசயுவமா? 
 பசால்பலாடுவொம் ஓமபமனச ்பசால்” 
-அகத்தியர் குணோகைம் 
சுபே: கார்ெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: கார்ெ்பு 
 
MEDICINAL USES: 
 The seed decoction used in the cases of asthma, anti – dyspnoeic effect, cutaneous 
disorders, neural and UTI disorders.  
 The seed decoction used to enhance the body’s resistance. 
 The watery extract used to relieve diarrhoea.  
 
3. இஞ்சி 
வேறுபெயர்: 
 அல்லம், ஆரத்்தரகம், ஆத்திரகம், இலாக்பகாை்பை, நறுமருெ்பு மதில் 
 
GENERAL PROPERTIES OF INJI 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Monocots 
SUBCLASS: Commilinids 
ORDER: Zingiberales 
FAMILY: Zingiberaceae 
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GENUS: Zingiber 
SPECIES: Z. officinale 
BOTANICAL NAME: Zingiber officinale 
ENGLISH NAME: Green ginger fresh 
 
PART USED:  
Rhizome 
 
CHEMICAL CONSTITUENTS: 
Zingiberene, Sesquiterpenes, Curcumene, Gingerols, Gingerdione 
 
ACTIONS: 
 Carminative, Aphrodisiac, Stimulant 
 Anti – inflammatory, Immunomodulator, Anti - oxidant 
 
பொதுகுணம்: 
“இஞ்சிக் கிழங்குக் கிருமல்ஐயம் ஓக்காளம் 
 ேஞ்சிக்குஞ் சன்னிசுரம் ேன்வெதி – விஞ்சுகின்ற 
சூபலயறும் ோதம்வொந் தூண்ைாத தீெனமாம் 
 வேபலயுறுங் கண்ணாய் – விளம்பு” 
- ெதாரத்்த குண விளக்கம் , ெக்கம் 70 
சுபே: கார்ெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: கார்ெ்பு 
MEDICINAL USES: 
 Rhizome soaked with honey daily taken at the morning for age preventing and 
brightness of vision, preventing of skin wrinkling and in albinism and considered 
as rejuvenating herb. 
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 It is used in imbalance of vadha and kabha dosha as in rheumatoid and 
osteoarthritis. 
 It helps to relieve weakness of heart, sharp pain due to cardiac condition. 
 It is used in congestion of chest, breathing difficulty, severe cough, cold and post-
delivery weakness. 
4. திெ்பிலி 
வேறுபெயர்: 
 வகாலகம், வகாபழயறுக்கி, பசௌண்டி, பேவதகி, அம்பு  ஆதி மருந்து 
 
GENERAL PROPERTIES OF THIPPILI 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Magnolids 
ORDER: Piperales 
FAMILY: Piperaceae 
GENUS: Piper  
SPECIES: P.longum 
BOTANICAL NAME: Piper longum 
ENGLISH NAME: Long pepper 
 
PART USED: 
 Fruits and roots 
 
CHEMICAL CONSTITUENTS: 
Guineensine, Pipernonaline, Pellitorine, Piperine, Pipermonaline, Brachyamide A 
and B from fruits and Piperlongumine and Sesamine from roots. 
 
ACTIONS: 
  Analgesic, Carminative, Stimulant  
 Immunomodulator, Anti – oxidant, Anti - inflammatory 
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பொதுகுணம்: 
“இருமல் குன்மம் இபரெ்பு கயெ்பிணி 
 ஈபள ொண்டு சந்யாசம் அவராசகம் 
 பொருமல் ஊபத சிரெ்பிணி மூரச்ப்சவநாய் 
 பூரிக் குஞ்சல வதாைம் பீலிகமும் 
 ேரும லெ்பெருக் வகாடு மவகாதரம் 
 ோதம் ஆதிமுத் வதாைஞ் சுரங்குளிர் 
 பெருமாபலெ்புரி வமகெ் பிைகமும் 
 வெருந் திெ்பிலிெ் வெரங்குபரக்கவே” 
- ெதாரத்்த குண விளக்கம் , ெக்கம் 412 
 “ஈபள யிரும லிபரெ்புெ் ெசெ்பிணிகள் 
 மாள போழியாமல் ோை்டுவம – யாளுமுபற 
 ொங்கா யறிந்துபசய்வீர் ெண்டிதத்பதெ் ெண்டிதவர 
 வேங்பகோய்ெ் ொங்கபண பமய்” 
- வதரன் பேண்ொ 
சுபே: இனிெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: இனிெ்பு 
 
MEDICINAL USES: 
 It is used to mitigate the diseases due to kabha dosha. 
 The fruit powder is used to cure cough, bronchitis, asthma, malarial fever, diarrhoea 
and jaundice. 
 Root and fruit decoction used for treating gonorrhoea, menstrual pain, RTI, TB. 
 Root decoction used in sciatica, hemiplegia, arthritis. 
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5. பெருங்காயம் 
வேறுபெயர்: 
அத்தியாகிரகம் , இங்கு , காயம் , சந்துநாசம் , பூதநாசம் 
 
GENERAL PROPERTIES OF PERUNGAYAM 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Eudicots 
SUBCLASS: Asterids 
ORDER: Apiales 
FAMILY: Apiaceae 
GENUS: Ferula 
SPECIES: F.asafoetida 
BOTANICAL NAME: Ferula asafoetida 
ENGLISH NAME: Asafoetida 
 
PART USED: 
 Oleo – gum resin 
 
CHEMICAL CONSTITUENTS: 
 Disulfides, Tri – and Tetrasulfides, Glucuronic acid, Galactose, Arabinose, 
Umbelliferone, Foetidin, Coumarin 
 
ACTIONS: 
Sedative, Anti – spasmodic,  Anthelmintic,  Emmenogogue, Expectorant, 
Carminative 
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பொதுகுணம்: 
“தந்தவே தந்த மூலத்பதழும்பிணி 
  சருேகாளம் விருசச்ிகங்கீைம்மா 
 மந்தம்ோதம் உதாேரத்்தம் அல்குல்வநாய் 
  மார்ெணங்கை்ை குன்மம்மவகாதரம் 
 உந்துபகர்ெ்ெத்தின் வித்திரஞ்சூபலசச்ூர் 
  உதிரெ்பூசச்ி சிவலத்துமத்துறும்ேலி 
 ேந்தபமய்க்கடுெ் வொடிபேமுற்றுவம 
  மாயுநாறுநற் காயங்கிபைக்கிவன” 
     -வதபரயர் குணோகைம்  
சுபே: பகெ்பு, கரகரெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: கார்ெ்பு 
 
MEDICINAL USES: 
 It has been used as the remedy for abdominal pain and constipation. 
 Resin used in the treatment for nervous disorders and spasmodic disorders. 
 In respiratory disorders like whooping cough, bronchitis, asthma – 30 to 60 mg of 
resin combine with 2 teaspoons of honey, a quarter teaspoon of white onion juice 
and 1 teaspoon of betel leaf juice- thrice daily would keep the disorders away. 
 Asafoetida used in sterility, unwanted abortion, premature labour, excessive 
menstruation, leucorrhoea. 
 
6. ோய்விைங்கம் 
வேறுபெயர்: 
ோயுவிளங்கம் , வகரளம் , ோய்விலங்கம் , ேரன்பன , ோய்விைங்கம் 
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GENERAL PROPERTIES OF VAIVIDANGAM 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Eudicots 
SUBCLASS: Asterids 
ORDER: Ericales 
FAMILY: Primulaceae 
GENUS: Embelia 
SPECIES: E.ribes 
BOTANICAL NAME: Embelia ribes 
ENGLISH NAME: False black pepper, White flowered embelia 
 
PART USED:  
Fruit, Seeds 
 
CHEMICAL CONSTITUENTS: 
 Embelin, Quercitol, Tannin, Christembine, Embelic acid and Vilangin 
 
ACTIONS: 
Anthelmintic, Carminative, Stomachic, Stimulant 
 Anti – oxidant, Anti – inflammatory, Analgesic 
 
பொதுகுணம்: 
“ொண்டுகுை்ைம்  குன்மம்  ெருந்தூல  வநாய்ோதத் 
 தீண்டு திரிவிைஞ் சிரந்துண்ைம் – பூண்ைமடி 
 வநாய்விளங்கக் காை்ைாத  நுண்கிருமி யாசனெ்புண் 
 ோய்விளங்கங்காை்ைா விருமார்” 
- அகத்தியர் குணோகைம் 
              
   REVIEW OF LITERATURE/2018 
87 
 
            “ோதகுரு ோயுைம்பு ோதமறுத் தெ்ெடிவய 
 வேபதயுவலா கங்களிவல வேண்டினாற் – ொத 
 விரதமுதற் பகயாை பலன்றா லிபசயும் 
 ேரன்பன நீமனத்தில் பே” 
- வதரன் பேண்ொ 
சுபே : பகெ்பு  
தன்பம : பேெ்ெம்  
பிரிவு : கார்ெ்பு 
 
MEDICINAL USES: 
 To prevent the flatulence, the fruit powder is mixed with milk and given twice a 
day. 
 To prevent worm infestation, the seed powder mixed with honey is given thrice a 
day. Then next day ask the patient to take 15 ml castor oil. The worms are died and 
expelled out. 
 It is used in the imbalance of vadha dosha and maintains the vadha. 
 Externally the seed powder paste is used in the scorpion and snake bite. 
 
7. இந்துெ்பு: 
வேறுபெயர்: 
பசந்தேம் , சிந்தூரம் , சந்திரனுெ்பு , மதிகூரப்ம , மதியுெ்பு , 
மிந்தாசப்சால் 
GENERAL PROPERTIES OF ROCK SALT 
CATEGORY: Hallide mineral 
FORMULA: Nacl 
CRYSTAL SYSTEM: Cubic 
CRYSTAL CLASS: Hexoctahedral 
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IDENIFICATION: 
FORMULA MASS: 58.433 g/mol 
COLOR: Colorless or White 
CRYSTAL HABIT: Predominantly cubes but also Granular, Fibrous and Compact 
FRACTURE: Conchoidal 
TENACITY: Brittle 
LUSTER: Vitreous 
STREAK: White 
SPECIFIC GRAVITY: 2.17 
OPTICAL PROPERTIES: Isotropic 
REFRACTIVE INDEX: n=1.544 
SOLUBILITY: Water soluble 
 
ACTIONS: 
Carminative, Diuretic, Stimulant, Laxative 
 
பொதுகுணம்: 
“அை்ைகுன்ம மந்தம் அசிரக்்கரஞ்சூர் சீதபித்தந் 
 துை்ைபேயம் நாடிெ்புண் வதாைங்கள் – பகை்ைமலக் 
 கை்டுவிை விந்பதயக் காமியவநாய் ேன்கரெ்ொன் 
 விை்டுவிை விந்துெ்பெ விள்” 
 
“பசன்னிக்கண்ணா ெற்றூர் பசவிகவுள்கண் ைம்ெகவநாய் 
 சந்நியா சங்காசந் தாகமிபரெ் – புன்னிரத்த 
 மூலஞ் சிலந்திநளி மூடிகநஞ் சூபத ேலி  
 சூலஞ் சிபதயுமிந்தாற் பசால் “  
 - குணொைம் தாது சீே ேகுெ்பு 
 
   REVIEW OF LITERATURE/2018 
89 
 
MEDICINAL USES: 
 It is used in the treatment for gastritis, indigestion, dental and genital disorders, 
venous ulcers.  
 
8. கல்லுெ்பு 
வேறுபெயர்: 
  கைற்குருவி 
 
GENERAL PROPERTIES OF KALLUPU: 
IUPAC NAME: Sodium chloride 
CHEMICAL FORMULA: Nacl 
CRYSTAL STRUCTURE: Face – centered, cubic 
MOLAR MASS: 58.44 g/mol 
APPEARANCE: Colorless crystals  
ODOR: Odorless 
DENSITY: 2.165 g/cm3 
MELTING POINT: 801֗C 
SPECIFIC HEAT CAPACITY: 36.79 J/k.mol 
GEOMETRY: Octahedral 
 
பொதுகுணம்: 
“ஐயமறுஞ் சூபல யவராசிபித்தஞ் சத்திவயாடு 
 பேய்யபிணி யை்ைகுன்மம் விை்வைகும் – பெய்ேபளவய 
 ோதமதி தாகம் மலக்கை்டும் வொமுலகிற் 
 வகாதறுகல் லுெ்பெக் பகாடு” 
- குணொைம் தாது சீே ேகுெ்பு 
ACTIONS: 
  Anti vadha, Anti pitham 
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MEDICINAL USES: 
 It is used to cure vadha dosha, Thirst, Constipation, Vomiting.  
 
9. எேை்சாரம் : 
வேறுபெயர் : 
 மர உெ்பு 
 
GENERAL PROPERTIES OF YAVACHARAM: 
IUPAC NAME: Potassium carbonate 
OTHER NAMES: Carbonate of potash, Pearl ash, Salt of tartar, Salt of wormwood 
CHEMICAL FORMULA: CK2O3 
MOLAR MASS: 138.20 g/mol 
APPEARANCE: White, hygroscopic solid 
DENSITY: 2.43 g/cm3 
MELTING POINT: 891֗C 
BOILING POINT: Decomposes 
SOLUBILITY: Water soluble 
 
பொதுகுணம் : 
 “குய்யம் களம்நா பகாடிறுோ யிே்விைவதா 
  பயய மிபரெ்பிரும லாசனெ்புண் – பெய்யவுறு 
  கீைவிைஞ் வசாபெ கிராணிபயயும் ெம்ெரம்வொ 
  லாைவிடு பமய்யேை்சா ரம்” 
 
 “அை்ைகுன்மஞ் சூபல யதிதூல முை்டினத்தா 
பலாை்டிேரு ோத முதரவநாய் – துை்ைமந்தம் 
  
   REVIEW OF LITERATURE/2018 
91 
 
 நீடுகெம் நீரபைெ்பு நீங்காெ் பீலிகமிபே 
  பயாடுபமேை் சாரத்தா லுன்” 
- குணொைம் தாது சீே ேகுெ்பு 
 
ACTIONS: 
       Deobstruent, Stimulant, Alterative, Diuretic 
  
MEDICINAL USES: 
 It is a mineral supplement used to treat or prevent low amounts of potassium in the 
blood. 
 Potassium helps our cells, kidneys, heart, muscles, nerves work properly.  
 It is used in the treatment of ascites, diarrhoea, indigestion, ulcers. 
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                  DRUG REVIEW – EXTERNAL MEDICINE 
1.ஊமத்பத 
வேறுபெயர்:  
 உம்மத்பத 
 
GENERAL PROPERTIES OF OOMATHAI 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Eudicots 
SUBCLASS: Asterids 
ORDER: Solanales 
FAMILY: Solanaceae 
GENUS: Datura 
SPECIES: D.metal 
BOTANICAL NAME: Datura metal  
ENGLISH NAME: Devils’s trumpet, Thorn apple 
 
PART USED: 
 Leaves, Flower, Fruit, Seeds 
 
CHEMICAL CONSTITUENTS: 
 Hyoscyamine, Scopolamine, Tricyclic diterpene, Daturabietariene 
 
ACTIONS: 
 Anodyne, Anti - spasmodic 
 
பொதுகுணம் : 
“நாய்க்கடியால் ேந்து நலிபசய் விரணமும்வொம் 
 ோய்குழிெ்புண் கை்டிகளு மாறுங்காண் – தீக்குணத்பதச ்
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 வசமத்தில் பேத்திலிைந் தீருமுத்வதா ைங்களறும் 
 ஊமத்பத யிங்குணத்பத யுன்னு” 
- அகத்தியர் குணோகைம்  
சுபே: பகெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: கார்ெ்பு 
 
MEDICINAL USES: 
 The leaves have been proved to relieve asthma and externally used to relieve 
swelling and pain in arthritis. 
 Powdered seeds mixed with butter are administered internally for impotence.   
 
2. சைாமாஞ்சில் 
வேறுபெயர்: 
  சைமாசி , ஜைமாஞ்சி , பெசாசி , சடிபல , மாமிசி பூதவசசிநி 
 
GENERAL PROPERTIES OF SADAMAANJIL 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Eudicots 
SUBCLASS: Asterids 
ORDER: Dipsacales 
FAMILY: Caprifoliaceae 
GENUS: Nardostachys 
SPECIES: N.grandiflora  
BOTANICAL NAME: Nardostachys grandiflora 
ENGLISH NAME: Spikenard, Muskroot, Valerina root 
 
   REVIEW OF LITERATURE/2018 
94 
 
PART USED:  
Root (Rhizome) 
 
CHEMICAL CONSTITUENTS: 
 Acaciin, Ursolie acid, Kanshone A, Nardosinonediol, Oleonolic acid, β sitosterol 
 
ACTIONS: 
 Analgesic, Stimulant, Anti - spasmodic 
 
பொதுகுணம் : 
“குை்ைஞ் சிலந்திவிைம் வகார புராண சுரம் 
 உை்டினங்கால் வெதிகண்வணாய் ஒை்டிருமல் - பசாை்டிரத்த 
 பித்தமிபரெ் வெகும் பெருங்வகாபர என்றுபரக்குஞ் 
 சுத்தசைா மாஞ்சிபல பசால்” 
- அகத்தியர் குணோகைம் 
சுபே: கார்ெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: கார்ெ்பு 
 
MEDICINAL USES: 
 The analgesic activity of Sadamanjil oil used to relieve pain and swelling of 
arthritis and spondylosis. 
 It has hepatoprotective characteristics thus useful in hepatitis, prevent 
enlargement of liver and jaundice. 
 It is beneficial for hyperactive children and helpful to reduce hyperactivity, 
restlessness and aggressiveness. 
 It is used to impact black colour to hair and prevents greying of hair.  
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3.ஓமம் 
வேறுபெயர்: 
 அசவமாதம் , தீெ்பியம் 
 
GENERAL PROPERTIES OF OMAM 
KINGDOM: Plantae  
DIVISION: Angiosperms 
CLASS: Eudicots 
SUBCLASS: Asterids 
ORDER: Apiales 
FAMILY: Apiaceae 
GENUS: Trachyspermum 
SPECIES: T.ammi 
BOTANICAL NAME: Trachyspermum ammi  
ENGLISH NAME: Bishops weed 
 
PART USED:  
Seeds 
 
CHEMICAL CONSTITUENTS: 
     Essential oil, Thymol, Carvacrol, α and β – pinene, Camphene, Threonine 
 
ACTIONS: 
Diuretic, Carminative, Anti – vomiting, Anti – hypertensive, Anti – spasmodic 
Anti – oxidant, Anti - inflammatory 
 
பொதுகுணம்: 
“சீதசுரங் காசஞ் பசரியாமந் தம்பொருமல் 
 வெதியிபரச ்சல்கடுெ்பு வெராமம் – ஓதிருமல் 
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 ெல்பலாடுெல் மூலம் ெகமிபேவநா பயன்பசயுவமா? 
 பசால்பலாடுவொம் ஓமபமனச ்பசால்” 
-அகத்தியர் குணோகைம் 
சுபே: கார்ெ்பு 
தன்பம: பேெ்ெம் 
பிரிவு: கார்ெ்பு 
 
MEDICINAL USES: 
 The seed decoction used in the cases of asthma, anti – dyspnoeic effect, cutaneous 
disorders, neural and UTI disorders.  
 The seed decoction used to enhance the body’s resistance. 
 The watery extract used to relieve diarrhoea.  
 
4.சூைம்  
வேறுபெயர்: 
   கருெ்பூரம் , சுைரப்காடிவயான் , பூரம் , தீெம் 
 
GENERAL PROPERTIES OF CAMPHOR: 
 It is waxy, flammable, white or transparent solid with strong aroma. 
 It is found in wood of the Camphor laurel (Cinnamomum camphora). 
IUPAC NAME: 1,7,7 – Trimethylbicyclo heptan- 2- one 
OTHER NAME: 2- Bornanone, Bornan – 2 - one 
CHEMICAL FORMULA: C10H16O 
MOLAR MASS: 152.24 g.mol-1 
APPEARANCE: White, translucent crystals 
ODOR: Fragrant and penetrating  
DENSITY: 0.992 g.cm-3 
MELTING POINT: 175-177֗C 
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BOILING POINT: 209֗C 
VAPOR PRESSURE: 4 mmHg 
 
ACTIONS: 
 Anodyne, Stimulant 
 
பொதுகுணம்: 
  “கிருமிசல வதாைங் கிபளேலிெ்பு சந்நி 
 பொருமுமந்தம் அங்கிெை்ை புண்வணா – பைரிசுரங்கள் 
 ோந்திபித்தஞ் சீதமுறு ோதஞ் பசவிமுகவநாய் 
 காந்திகருெ் பூரபமான்றாற் சாற்று” 
- குணொைம் தாது சீே ேகுெ்பு 
சுபே: விறுவிறுெ்புைன் கூடிய பகெ்பும் கார்ெ்பும் 
தன்பம: பேெ்ெம் 
பிரிவு: கார்ெ்பு 
 
MEDICINAL USES: 
 It is readily absorbed through skin, where it selectively stimulates nerve endings 
sensitive to cold, producing a warm sensation when applied externally. 
 It also induces a slight local anesthesia, and has an antimicrobial secondary effect. 
 It is used to treat sprains, swelling and inflammation 
 
5.நோசச்ாரம் : 
வேறுபெயர்: 
 இஷ்டிபக , சல்லிபக , சூளிபக , ெடு 
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GENERAL PROPERTIES OF NAVACHARAM: 
IUPAC NAME: Ammonium chloride 
OTHER NAME: Sal ammoniac, Salmiac, Sal armagnac  
CHEMICAL FORMULA: CIH4N 
MOLAR MASS: 53.49 g.mol-1 
APPEARANCE: White Solid, hygroscopic 
ODOR: Odorless 
DENSITY: 1.5274 g/cm-3 
MELTING POINT: 338֗C 
BOILING POINT: 520֗C 
VAPOR PRESSURE: 133.3Pa 
SOLUBILITY: Soluble in liquid ammonia, alcohol, slightly soluble in acetone 
ACIDITY: 9.24 
FLASH POINT: Non – flammable 
 
ACTION: 
 Diaphoretic, Diuretic, Expectorant 
 
பொதுகுணம்: 
“குன்மம் குைற்சூபல பகால்லும் மவகாதரத்பத 
 ேன்பமயுறு கல்லபைெ்பெ மாற்றுங்காண் – சன்மக் 
 கவிசச்ுமுத் வதாைங் கனோத நீக்கும் 
 நோசச்ார மாவத நவில்” 
- குணொைம் தாது சீே ேகுெ்பு 
MEDICINAL USES: 
 Navacharam mixed with Hemidesmus indicus root decoction and given twice daily 
for the treatment of rheumatoid arthritis and dental disorders. 
 On external application, it reduces joint pain and swelling. 
 It is used in used in the treatment hepato and spleenomegaly, chronic fever. 
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6. நல்பலண்பணய்: 
வேறுபெயர்: 
       திலம் 
 
GENERAL PROPERTIES OF GINGELLY OIL: 
KINGDOM: Plantae 
DIVISION: Angiosperms 
CLASS: Eudicots 
SUBCLASS: Asterids 
ORDER: Lamiales 
FAMILY: Pedaliaceae 
GENUS: Sesamum 
SPECIES: S.indicum 
BOTANICAL NAME: Sesamum indicum  
ENGLISH NAME: Gingeli oil  
 
PART USED: 
 Seed oil 
 
CHEMICAL CONSTITUENTS:  
 Lignans sesamolin, Sesamin, Pinoresinol, Lariciresinol  
 
ACTIONS: 
 Demulcent, Emollient, Laxative, Nutritive 
  
பொதுகுணம்: 
“புத்திநயனக்குளிரச்ச்ி பூரிெ்பு பமய்ெ்புளகஞ் 
 சத்துேங் கந்தி தனியிளபம – பமத்தவுண்ைாங் 
 கண்வணாய் பசவிவநாய் கொலேழல் காசவநாய் 
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 புண்வணாய்வொ பமண்பணய்யாற் வொற்று” 
- அகத்தியர் குணோகைம் 
சுபே : இனிெ்பு 
தன்பம : பேெ்ெம் 
பிரிவு : இனிெ்பு 
 
MEDICINAL USES: 
 Calcium, zinc, copper minerals in oil plays an important role in growth of bone, 
healing, regrowth of bone and prevent osteoporosis. 
 Externally it can increase skin elasticity, smoothness and reduce the appearance 
of age spots. 
 It can help to reduce the inflammation and discomfort of various conditions such 
as gout and arthritis by reducing the swelling of joints.   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 
  MATERIALS AND  
              METHODS 
                                                                         MATERIALS AND METHODS/2018 
101 
 
                                4. MATERIALS AND METHODS  
 
SELECTION OF DRUGS:  
I had chosen the Siddha Herbal – Mineral formulation drug “SAMUTHARA 
CHOORANAM”(Internal) for this study from classical siddha literature 
‘Pranarashamirtha Sindhu’ and “VADHA NOIKU VELIPRAYOGHA 
THAILAM”(External) from ‘The Pharmacopoeia of siddha research medicines’. 
The raw drugs were purchased from the raw drug shop R.N.RAJAN & CO, 
Paris. After getting proper authentication from the Head of the Department of 
Medicinal Botany and Pharmacology(Gunapadam), GSMC, Chennai-106 the 
medicines were prepared. 
 
           4.1.INTERNAL MEDICINE 
 
SAMUTHARA CHOORANAM 
INGREDIENTS: 
Purified Induppu(Rock salt)                                   - 5 gms  
Purified Yavacharam (Potassium carbonate)       - 5 gms  
Purified Kaluppu (Sodium chloride impura)         - 5 gms  
Omam(Trachyspermum ammi)                              - 20 gms  
 Kadukkai(Terminalia chebula)                - 20 gms  
 Thippili(Piper longum)                              - 20 gms  
 Inji(zingiber officinale)                          - 20 gms  
 Perungayam(Ferula asafoetida)             - 20 gms  
 Vaividangam(Embelia ribes)                  - 20 gms 
 
METHOD OF PURIFICATION: 
 
HERBAL DRUGS: 
 Purified and dried under classical text 
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MINERAL DRUGS: 
INDUPPU: 
 Soaked in rice vinegar for 3 days, dried in sunlight till all water content gets 
evaporated and then salt was powdered in stone mortar. 
YAVACHARAM: 
 Dissolved in Goat’s urine, filtered, dried in sunlight and then salt was powdered in 
stone mortar. 
KALUPPU: 
 Soaked in rice vinegar for few seconds. Remove the humidity of kaluppu by placing 
it in dry cotton cloth and dried in sunlight. At last, salt was powdered in stone mortar 
 
 
 
MATERIALS REQUIRED: 
 
4.1.1TERMINALIA CHEBULA  
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 4.1.2. ZINGIBER OFFICINALE  
      
 
4.1.3. PIPER LONGUM  
          
 
4.1.4. TRACHYSPERMUM AMMI 
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4.1.5. EMBELIA RIBES 
                                               
 
4.1.6. FERULA ASAFOETIDA 
        
 
4.1.7.INDUPPU (ROCK SALT) 
          Before purification           After purification 
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4.1.8.KALUPPU (SODIUM CHLORIDE IMPURA)  
                     Before purification               After purification 
      
 
4.1.9.YAVACHARAM (POTASSIUM CARBONATE) 
         Before purification    After purification 
      
 
                                 4.1.10.SAMUTHARA CHOORANAM 
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METHOD OF PREPARATION:  
             Above purified drugs were grinded separately and mixed well together. Then filter 
them as a fine powder and weighed. Atlast  the powder was stored in the air tight container. 
DOSAGE         :   Two gram(twice  daily) for 48 days 
ADJUVENT    :   Ghee 
INDICATION :   Vadham(80), Paandu(5), Moolam(8),  
                              Kiragani(11), Kunmam(8), Magotharam(8) , 
     Vayirru valli, Vaayu. 
REFERENCE :    Pranarashamirtha  sindu . Pg.no:166 
 
4.2.EXTERNAL MEDICINE 
 
VADHA NOIKU VELIPRAYOGHA THAILAM  
INGREDIENTS: 
 Oomathai ilai chaaru(Datura metal)                -  2.2 L 
 Omam(Trachyspermum ammi)           -  47 gm 
 Sadamanjil(Nardostachys grandiflora)            -  47 gm 
  Soodam(Camphor)                             -  23 gm 
  Purified Navacharam(Ammoni chloridum)      – 12 gm 
  Gingelly oil                        -  400 ml 
 
METHOD OF PURIFICATION: 
 
HERBAL DRUGS: 
 Purified and dried under classical text. 
 
MINERAL DRUG: 
NAVACHARAM – Dissolved in cow’s urine and filtered. Boiled till all the water content 
gets evaporated and dried it in sunlight. Then salt was powdered in stone mortar. 
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MATERIALS REQUIRED: 
4.2.1.DATURA METAL 
      
 
 
 
4.2.2.NARDOSTACHYS GRANDIFLORA 
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4.2.3.TRACHYSPERMUM AMMI 
     
 
4.2.4.NAVACHARAM (AMMONIUM CHLORIDE) 
                      Before purification    After purification 
      
 
                    4.2.5.CAMPHOR            4.2.6.GINGELLY OIL                                
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4.2.7.Omam and Sadamanjil were made into decoction and then filtered 
             
 
     4.2.8.Gingelly oil and the filtered decoction were mixed in the vessel and heated 
      
 
      4.2.9.oomathai leaf juice had been mixed with the above oil content and heated 
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   4.2.10.Prepared oil was filtered in the receiver containing purified Navacharam      
and Camphor 
       
                                      
 
  4.2.11. VADHA NOIKU VELIPRAYOGHA THAILAM 
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METHOD OF PREPARATION(EXTERNAL): 
           Omam and sadamanjil were added in water and boiled it, made into decoction and 
then filtered. Oomathai ilai charu, gingelly oil and the prepared decoction were mixed well 
and heated. Heat it well until needed consistency is attained. Navacharam and camphor 
powders was placed in the vadikalam. After this camphor and navacharam was well 
dissolved in the vadikalam (receiver) containing thailam. After the thailam was cooled 
under room temperature, it was bottled up in the air tight container. 
INDICATIONS: All kinds of pain in the joints, muscles, nerves    
                                 and burses are relieved.  
 REFERENCE: The pharmacopoeia of siddha research   
                                 medicines. Pg.no:122 
 
          4.3.THERAPY: OTTRADAM 
DEFINITION: 
The required plant parts, grains and others are put in a container, fried or boiled or heated 
and then tied in a cloth bag. The bag is put on the affected areas and then gently compressed 
and released in a rhythemic manner for few minutes or till the heat subsides. It is also called 
as Otral. Cold paste can also be used as otral. 
 Bronze, Iron, Rod, Sand, Cloth, Mud vessel are also heated and used for 
fomentation to give relief from pain.  
PROCEDURE: 
              The turmeric powder and salt was placed in half of the lemon and tied up in a 
bundle(kizhi). The kizhi was dipped in the heated vadha noiku veliprayogha thailam. 
Then the heated kizhi was used to give ottradam on the affected areas. Repeat the process 
for seven times. 
MEDICINAL USES: 
 Control the Inflammation of joints, Swelling, Redness, Pain and Improves the 
Circulation in the affected part. 
REFERENCE:  Aruvai maruthuvam pg.no:44 
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       4.4. STANDARDIZATION PARAMETERS 
 
4.4.1.ORGANOLEPTIC CHARACTERS: 
State: 
 Solid 
 Appearance: 
 Greenish brown in color 
Nature: 
 Mild coarse in nature 
Taste: 
 Astringent with mild Pungent 
Odor: 
 Strong characteristic 
 
4.4.2.PHYSICOCHEMICAL EVALUATION: 
Percentage Loss on Drying 
10gm of test drug was accurately weighed in evaporating dish. The sample was 
dried at 105oC for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/Wt of the sample X 100 
 
Determination of Total Ash 
3 g of test drug was accurately weighed in silica dish and incinerated at the furnace 
a temperature 400 ºC until it turns white in color which indicates absence of carbon. 
Percentage of total ash will be calculated with reference to the weight of air-dried drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Acid Insoluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of dilute hydrochloric 
acid for 6mins. Then the insoluble matter is collected in crucible and will be washed with 
hot water and ignited to constant weight. Percentage of acid insoluble ash will be calculated 
with reference to the weight of air-dried ash. 
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Acid insoluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Water Soluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of water for 5 mins. 
The insoluble matter is collected in crucible and will be washed with hot water, and ignite 
for 15mins at a temperature not exceeding 450ºC. Weight of the insoluble matter will be 
subtracted from the weight of the ash; the difference in weight represents the water soluble 
ash. Calculate the percentage of water-soluble ash with reference to the air-dried drug. 
Water Soluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Alcohol Soluble Extractive 
About 5 g of test sample will be macerated with 100 ml of Alcohol in a closed flask 
for twenty-four hours, shaking frequently during six hours and allowing to stand for 
eighteen hours. Filter rapidly, taking precautions against loss of solvent, evaporate 25 ml 
of the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 105ºC, to constant 
weight and weigh. Calculate the percentage of alcohol-soluble extractive with reference to 
the air-dried drug. 
Alcohol sol extract = Weight of Extract/ Wt of the Sample taken X 100 
 
Determination of Water Soluble Extractive 
About 5 g of the test sample will be macerated with 100 ml of chloroform water in 
a closed flask for twenty-four hours, shaking frequently during six hours and allowing to 
stand and for eighteen hours. Filter rapidly, taking precautions against loss of solvent, 
evaporate 25 ml of the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 
105ºC, to constant weight and weigh. Calculate the percentage of water-soluble extractive 
with reference to the air-dried drug. 
Water soluble extract = Weight of Extract/ Wt of the Sample taken X 100 
 
Determination of pH 
About 5 g of test sample will be dissolved in 25ml of distilled water and filtered 
the resultant solution is allowed to stand for 30 mins and the subjected to pH evaluation  
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4.4.3.HEAVY METAL ANALYSIS BY AAS 
Standard: Hg, As, Pb and Cd – Sigma 
 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique for 
detecting metals and metalloids in environmental samples. The total heavy metal content 
of the sample KN was performed by Atomic Absorption Spectrometry (AAS) Model AA 
240 Series. In order to determination the heavy metals such as mercury, arsenic, lead and 
cadmium concentrations in the test sample. 
 
Sample Digestion 
Test sample digested with 1mol/L HCl for determination of arsenic and mercury. Similarly 
for the determination of lead and cadmium the sample were digested with 1mol/L of 
HNO3. 
 
Standard reparation 
 As & Hg- 100 ppm sample in 1mol/L HCl 
 Cd & Pb- 100 ppm sample in 1mol/L HNO3 
 
4.4.4.TLC AND HPTLC ANALYSIS: 
                  
                   TLC Analysis 
Test sample was subjected to thin layer chromatography (TLC) as per conventional 
one dimensional ascending method using silica gel 60F254, 7X6 cm (Merck) were cut with 
ordinary household scissors. Plate markings were made with soft pencil. Micro pipette 
were used to spot the sample for TLC applied sample volume 10-micro liter by using 
pipette at distance of 1 cm at 5 tracks. In the twin trough chamber with different solvent 
system Toulene: Ethyl Acetate: Acetic Acid (1.5:1:0.5) After the run plates are dried and 
was observed using visible light Short-wave UV light 254nm and light long-wave UV light 
365 nm 
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            High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to achieve 
precision, sensitive, significant separation both qualitatively and quantitatively. High 
performance thin layer chromatography (HPTLC) is a valuable quality assessment tool for 
the evaluation of botanical materials efficiently and cost effectively. HPTLC method offers 
high degree of selectivity, sensitivity and rapidity combined with single-step sample 
preparation. In addition it is a reliable method for the quantitation of nano grams level of 
samples. Thus this method can be conveniently adopted for routine quality control analysis. 
It provides chromatographic fingerprint of phytochemicals which is suitable for confirming 
the identity and purity of medicinal plant raw materials.  
 
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was carried out 
according to the adsorption capability of the component to be analysed. After elution, 
plates were taken out of the chamber and dried. 
 
Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were brought 
into integration through CAMAG software. Chromatographic finger print was developed 
for the detection of phytoconstituents present in each extract and Rf values were tabulated. 
 
4.4.5.PHYTOCHEMICAL ANALYSIS 
 
Extraction 
Sample Extraction were carried out with water and the resulting extract was utilized for 
the phytochemical analysis 
 
Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
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Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
Test for saponins:  
       To the test sample, 5 ml of water was added and the tube was shaken vigorously. 
Copious lather formation indicates the presence of Saponins. 
Test for tannins:  
       To the test sample, ferric chloride was added, formation of a dark blue or greenish 
black color showed the presence of tannins. 
Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a water 
bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of filtered 
hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is separated and 
10% ammomia solution is added to it. Pink colour indicates presence of glycosides. 
Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added followed 
by addition of few drops of conc. Sulfuric acid. Appearance of yellow color indicates the 
presence of Flavonoids. 
Test for phenols: 
          Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was added.  
A bulky white precipitate indicated the presence of phenolic compounds. 
Test for steroids: 
       To the test sample, 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into red 
and sulphuric acid layer showed yellow with green fluorescence. It showed the presence 
of steroids. 
Triterpenoids  
Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added from 
the sides of the test tube, appearance of red ring indicates the presence of triterpenoids. 
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Test for Cyanins 
A. Aanthocyanin: 
       To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 min at 
100ᵒC. Formation of bluish green colour indicates the presence of anthocyanin. 
Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedict’s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate indicates 
the presence of sugar. 
Proteins (Biuret Test) 
 To extracts 1% solution of copper sulphate was added followed by 5% solution of 
sodium hydroxide, formation of violet purple colour indicates the presence of proteins. 
 
 
4.4.6. STERILITY TEST BY POUR PLATE METHOD: 
 
Objective  
The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition 
rich medium it promotes the growth of the organism and after stipulated period of 
incubation the growth of the organism was identified by characteristic pattern of colonies. 
The colonies are referred to as Colony Forming Units (CFUs).   
 
Methodology 
About 1ml of the test sample was inoculated in sterile petri dish to which about 15 
mL of molten agar 45oC were added. Agar and sample were mixed thoroughly by tilting 
and swirling the dish. Agar was allowed to completely gel without disturbing it. (about 10 
minutes). Plates were then inverted and incubated at 37o C for 24-48 hours. Grown 
colonies of organism was then counted and calculated for CFU.  
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       c    
Observation 
No growth was observed after incubation period. Reveals the absence of specific 
pathogen 
 
4.5. TOXICOLOGICAL STUDY 
 
        4.5.1. ACUTE ORAL TOXICITY STUDY OF SAMUTHARA CHOORANAM 
                                            (OECD GUIDELINE – 423)     
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals of 
a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on average 
2-4 steps may be necessary to allow judgement on the acute toxicity of the test 
substance.  
 This procedure is reproducible, uses very few animals and is able to rank substances 
in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification purposes 
and hazard assessment.  
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 In principle, the method is not intended to allow the calculation of a precise LD50, 
but does allow for the determination of defined exposure ranges where lethality is 
expected since death of a proportion of the animals is still the major endpoint of 
this test.  
 The method allows for the determination of an LD50 value only when at least two 
doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency and 
repeatability.  
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of a 
minimum number of animals per step, sufficient information is obtained on the acute 
toxicity of the test substance to enable its classification. The substance is administered 
orally to a group of experimental animals at one of the defined doses. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex. Absence 
or presence of compound-related mortality of the animals dosed at one step will determine 
the next step, i.e. 
− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose level. 
The method will enable a judgment with respect to classifying the test substance to one of 
a series of toxicity classes. 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent species 
may be used. Healthy young adult animals are commonly used laboratory strains should 
be employed. Females should be nulliparous and non-pregnant. Each animal, at the 
commencement of its dosing, should be between 6 to 8 weeks old and the weight (150-
200gm) should fall in an interval within±20 % of the mean weight of any previously dosed 
animals.  
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Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  Although 
the relative humidity should be at least 30% and preferably not exceed 70% other than 
during room cleaning the aim should be 50-60%. Lighting should be artificial, the sequence 
being 12 hours light, 12 hours dark. For feeding, conventional laboratory diets may be used 
with an unlimited supply of drinking water. Animals may be group-caged by dose, but the 
number of animals per cage must not interfere with clear observations of each animal. 
 
Preparation of animals: 
 The animals are randomly selected, marked to permit individual identification, and 
kept in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions. 
 
Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS,Madhavaram, Chennai. All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and standard 
pellet diet (Sai meera foods, Bangalore). 
 
Preparation for Acute Toxicity Studies 
Rats were deprived of food overnight (but not water 16-18 h) prior to 
administration of the, Samuthara chooranam.  
The principles of laboratory animal care were followed and the Institutional Animal 
Ethical Committee approved the use of the animals and the study design 
IAEC approved  Number: 1248/AC/09/CPCSEA-9/DEC-2013/12  
Test Substance  : SAMUTHARA CHOORANAM 
Animal Source  :TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
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Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual   
      marking by using Picric acid.  
Number of animals               : 3 Female/group,  
 Route of administration      :  Oral  
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd, Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
      provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days  
 
Administration of Doses:  
 Samuthara chooranam was suspended in water and administered to the groups of 
wistar albino rats in a single oral dose by gavage using a feeding needle. The control group 
received an equal volume of the vehicle. Animals were fasted 12 hours prior to dosing. 
Following the period of fasting, the animals were weighed and then the test substance was 
administered. Three Female animals are used for each group. The dose level of 5, 50, 300 
and 2000 mg/kg body weight was administered stepwise. After the substance has been 
administered, food was withheld for a further 3-4 hours. The principle of laboratory animal 
care was followed. Observations were made and recorded systematically and continuously 
as per the guideline after substance administration. The visual observations included skin 
changes, mobility, aggressively, sensitivity to sound and pain, as well as respiratory 
movements. Finally, the number of survivors was noted after 24 hrs and these animals were 
then monitered for a further 14 days and observations made daily. The toxicological effect 
was assessed on the basis of mortality. 
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Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the first 
4 hours, and daily thereafter, for a total of 14 days, except where they need to be removed 
from the study and humanely killed for animal welfare reasons or are found dead. It should 
be determined by the toxic reactions, time of onset and length of recovery period, and may 
thus be extended when considered necessary. The times at which signs of toxicity appear 
and disappear are important, especially if there is a tendency for toxic signs to be delayed. 
All observations are systematically recorded with individual records being maintained for 
each animal. 
Observations include changes in skin and fur, eyes and mucous membranes, and 
also respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Attention was directed to observations of tremors, 
convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles and criteria 
summarized in the Humane Endpoints Guidance Document taken into consideration. 
Animals found in a moribund condition and animals showing severe pain or enduring signs 
of severe distress was humanly killed. When animals are killed for human reasons or found 
dead, the time of death was recorded. 
 
              4.5.2. REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF 
                                          SAMUTHARA CHOORANAM 
Test Substance  : Samuthara chooranam 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals      : By cage number, animal number and individual  
                                                  marking by using Picric acid 
Diet    : Pellet feed supplied by Sai meera foods Pvt Ltd,        
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      Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
                 provided with bedding of husk. 
Housing temperature :  between 22ºC + 3ºC.    
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
 
Table 4.5.1  
 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. Each 
group consist of 12 animals (Male -6, and Female-6). First group treated as a control and 
other three group were treated with test drug (low, mid, high) for 28 days. Animals were 
allowed acclimatization period of 7 days to laboratory conditions prior to the initiation of 
treatment. Each animal was marked with picric acid. The females were nulliparous and 
non-pregnant. 
 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are low 
dose (X), mid dose (5X), high dose (10X). X is calculated from the dose (2000 mg) and 
Groups No of Rats 
Group I  Vehicle control (Water) 12(6male,6 female) 
Group II  low dose X (20mg) 12 (6male,6 female) 
Group III STR- Mid dose  5X (100mg) 12 (6male,6female) 
Group IV STR- High dose 10X(200mg) 12(6male,6female) 
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the X dose is 20mg/animal, 5X dose is 100mg/animal,10X dose is 200mg/animal. 
 
Preparation and Administration of Dose: 
        Samuthara chooranam suspended in with water, it was administered to animals at 
the dose levels of X, 3X, 6X. The test substance suspensions were freshly prepared every 
two days once for 28 days. The control animals were administered vehicle only. The drug 
was administered orally by using oral gavage once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of study 
for the following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course of 
study.  
 
Food and water Consumption: 
  Food and water consumed per animal was calculated for control and the treated 
dose groups.  
 
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity and 
duration of these symptoms, if any, were recorded. 
 
Mortality: 
All animals were observed twice daily for mortality during entire course of study. 
 
Necropsy: 
All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy of 
all animals was carried out. 
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Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted 
over-night. Blood samples were collected from orbital sinus using sodium heparin 
(200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as 
anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes. 
 
Haematological Investigations: 
Haematological parameters were determined using Haematology analyzer.  
 
Biochemical Investigations:  
Biochemical parameters were determined using auto-analyzer. 
 
Histopathology:  
              Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group than 
the low, then the mid dose group will also be examined. Organs will be collected from all 
animals and preserved in 10% buffered neutral formalin for 24 h and washed in running 
water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in an auto 
technicon and then cleared in benzene to remove absolute alcohol. Embedding was done 
by passing the cleared samples through three cups containing molten paraffin at 50°C and 
then in a cubical block of paraffin made by the “L” moulds. It was followed by microtome 
and the slides were stained with Haematoxylin-eosin red. 
 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, hematology 
and blood chemistry were subjected to One-way ANOVA followed by dunnet t test using 
a computer software programme – Graph pad version 7. All data were summarized in 
tabular form, (Table-6 to 12). 
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4.6. PHARMACOLOGICAL STUDY: 
 
IMMUNOMODULATOR ACTIVITY - CELL LINE STUDY 
 The evaluation of the immunomodulatory activity of Samuthara chooranam was 
carried out in cultured raw cell line in Biogenix Research Center. 
 
DETERMINATION OF INVITRO IMMUNOMODULATORY EFFECT OF 
EXTRACTS ON CULTURED RAW CELL LINES  
RAW 264.7 cells will be grown to 60% confluence followed by activation with 1 
µL lipopolysaccharide (LPS) (1µg/mL). LPS stimulated RAW cells were exposed with 
different concentration (25, 50, 100 µg/mL) of sample and incubated for 24 hours.  After 
24 hours of incubation the cells were digested and centrifugation was done at 6000 rpm for 
10 minutes. Supernatant was discarded and cells were then resuspented in 200µl of cell 
lysis buffer (0.1M Tris HCl, 0.25M EDTA, 2M Nacl, 0.5 % Triton x-100).  The samples 
were then kept at 40C for 20 minutes. After incubation, the immunomodulatory response 
was performed by estimating nitrite levels in the cell lysate. 
 
Estimation of Cellular Nitrite Levels  
The level of nitrite level was estimated by the method of Lepoivre et al. (Lepoivre 
et. al. 1990) To 0.5 mL of cell lysate, 0.1 mL of sulphosalicylic acid was added and 
vortexed well for 30 minutes. The samples were then centrifuged at 5,000 rpm for 15 
minutes. The protein-free supernatant was used for the estimation of nitrite levels. To 200 
μL of the supernatant, 30 μL of 10% NaOH was added, followed by 300 μL of Tris-HCl 
buffer and mixed well. To this, 530 μL of Griess reagent was added and incubated in the 
dark for 10–15 minutes, and the absorbance was read at 540 nm against a Griess reagent 
blank. Sodium nitrite solution was used as the standard. The amount of nitrite present in 
the samples was estimated from the standard curves obtained.  
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4.7. CLINICAL STUDY: 
This study was conducted after getting approval from IEC (Institutional Ethical 
Committee, GSMC Chennai. IEC No: GSMC-CH-ME-5/011/2016. This study was 
also registered in Clinical Trail Registry of India CTRI No: CTRI/2018/05/013780, this 
was done in Post graduate department Sirappu Maruthuvam, Government Siddha 
Medical College and Hospital, Arignar Anna Hospital Campus, Arumbakkam, Chennai 
-106 under the observation and guidance of Head of the department. 
In this clinical study totally 60 cases were enrolled out of which 20 cases were 
treated with Internal medicine alone, 20 cases were treated with Internal and External 
medicines, and 20 cases were treated with Internal, External medicines & Ottradam 
therapy. 
 
STUDY CENTER: 
OPD of Arignar anna Government Hospital of Indian Medicine and Homeopathy, 
Arumbakkam 
Chennai-106. 
 
TRAIL DRUG: 
Internal: Samuthara chooranam 
External: Vadha noiku veliprayoga thailam 
External therapy: Ottradam 
Study period: 48 days 
Sample Size: 60 cases 
20 cases treated with Internal drug alone 
20 cases treated with External drug and Ottradam(Therapy) 
20 cases treated with Internal, External drug and Ottradam(Therapy) 
 
SUBJECT SELECTION:  
         There is considerable number of patients reporting of Room no.04, PG Sirappu 
Maruthuvaum OPD, Aringar anna govt. hospital, GSMC, with the symptom of inclusion 
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criteria will be subjected to screening test and documented using screening proforma. 60 
patients who fulfilled the inclusion criteria were included for the study. 
 Patients criteria, clinical assessment, siddha assessment, laboratory investigations, 
diagnosis and treatment aspect in patients after the degree of palliationis achieved theywere 
advised to visit OPD for further follow up selection were strictly subjected to protocol 
comprising selection.  
 
INCLUSION CRITERIA: 
 Age: 18-60 Years  
 Sex: Both male & female (Female dominant disease) 
 Low grade fever 
 Pain and swelling in interphalangeal joints (mostly in PIP & MCP joints) 
 Redness of joint 
 Morning stiffness > 1 hr 
 Arthritis of 3 or more joints 
 Anti CCP +ve  
 CRP +ve 
 RA factor +ve /-ve 
 Patient willing to sign the consent form. 
 
EXCLUSION CRITERIA: 
KNOWN CASES OF 
 Rheumatic fever 
 Psoriatic arthropathica  
 Gouty arthritis 
 Systemic lupus erythematosus(SLE) 
 Progressive systemic sclerosis(PSS) 
 History of long term intake of steroids 
 DM, SHT, Renal failure 
 Carries spine 
 Ankylosing spondylitis  
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 Tumours  
 Osteomyelitis  
 HIV 
 Haemophilia 
 Pregnancy and lactation 
 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of any serious adverse effect during the 
period of drug trial.  
 Patient turned unwilling to continue in the course of Clinical trial with any other 
systemic illness.  
 
ADR REPORTING: 
      If ADR is reported, patients will be referred to SCRI (Peripheral 
Pharmacovigilance   centre) 
 
CLINICAL ASSESSMENT: 
BLOOD:  
Hb 
TC 
DC 
ESR - ½ hr, 1 hr 
          Blood Sugar-Fasting, PP  
         Serum Cholesterol 
SPECIAL INVESTIGATION: 
    BT, CT, S.Uric acid 
 Anti ccp, CRP 
URINE:  
   Albumin   
 Sugar  
 Deposits 
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KIDNEY FUNCTION TEST: 
          Blood Urea  
          Serum Creatinine 
LIVER FUNCTION TEST: 
     T. Bilirubin 
Serum Alkaline Phosphatase 
SGOT 
SGPT   
 
STUDY ENROLMENT: 
            Patient reporting at the OPD with symptoms of Low grade fever, Arthritis of more 
than 3 joints, Redness, Pain and swelling in PIP & MCP joints, Morning stiffness > 1hr, 
Subcutaneous nodules, Anti CCP +ve, CRP +ve, RA factor +ve/-ve, are chosen for 
enrolment based on the inclusion criteria. The patient who are enrolled are informed about 
the trial drug, possible outcomes and objective of the study in the language and terms 
understandable to them and the informed consent would be obtained in the consent form. 
 
CONDUCT OF THE STUDY: 
           Patients satisfying the inclusion and exclusion criteria will be included in the trial. 
Modern investigations will be carried out before treatment and at the end of the treatment. 
At the end of the study the trial patients are advised to report when there is recurrence. 
 
DATA COLLECTION FORMS: 
Required information will be collected from each patient by using following forms. 
Form I   : Screening and selection proforma 
Form II             : History taking proforma 
Form III  : Clinical assessment on enrollment and on visits proforma 
Form IV    : Laboratory investigation proforma 
Form V  : Informed consent form 
Form VI  : Withdrawal form 
Form VII    : Patients information sheet 
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Form VIII  : Dietary Advice form 
Form IX                      : Adverse Reaction form 
 
DATA ANALYSIS: 
           After enrolling the patients in the study, a separate file for each patient will be 
maintained and all forms will be kept in the file. Whenever the patients visit OPD during 
the study period necessary entries will be made in the assessment forms. The data entries 
and adverse events if any will be monitored by the head of the department. 
 
OUTCOME OF TREATMENT: 
PRIMARY OUTCOME:  
 Primary outcome is mainly assessed by reduction in pain and inflammation of any 
two joints. 
 Reduction of low grade fever and Morning stiffness.  
 Pain is assessed by universal pain assessment scale. 
 By comparing the any two parameters before and after treatment ESR, Hb, Anti-
CCP, CRP. 
SECONDARY OUTCOME: 
 Secondary outcome is assessed by comparing the safety parameters before and after 
treatment.  
 
ETHICAL ISSUES: 
 Informed consent will be obtained from the patients after explaining about the 
clinical trial in regional tongue. 
 After the consent of the patient (through consent form) if they are in the inclusion 
criteria they will be enrolled in the study. 
 Treatment will be provided free of cost. 
 Concomitant medications will be given when required. 
 Rescue medications will be given when needed. 
 The patients who are excluded (as per exclusion criteria) are given proper treatment 
with full care at OPD. 
  
 
   RESULTS AND          
     OBSERVATIONS 
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           5. RESULTS AND OBSERVATIONS 
ORGANOLEPTIC CHARACTERS 
  Table –5.1: Organoleptic character of SC 
S.NO CHARACTERS RESULTS 
1. State Solid 
2. Appearance Greenish Brown 
3. Nature Mild Coarse powder  
4. Taste 
Astringent with mild 
Pungent 
5. Odor Strong Characteristic  
 
PHYSICOCHEMICAL EVALUATION 
    Table – 5.2: Physicochemical evaluation of SC 
S.No Parameter Mean (n=3) SD 
1.  Loss on Drying at 105 °C (%) 24.67  ±  1.06 
2.  Total Ash (%)  1.544  ±  0.31 
3.  Acid insoluble Ash (%) 0.33  ±  0.04 
4.  Water Soluble Ash (%) 4.46  ±  1.10 
5.  Alcohol Soluble Extractive (%) 21.22  ±  0.53 
6.  Water soluble Extractive (%) 9.98  ±  1.15 
       7. PH  4.5 
 
HEAVY METAL ANALYSIS 
         Table –5.3: Heavy Metal Analysis of SC 
S.NO 
Name of the 
Heavy Metal 
Absorption Max 
Λ max Result Analysis 
Maximum 
Limit 
1. Mercury 253.7 nm BDL 1 ppm 
2. Arsenic 193.7 nm 0.268 ppm 3 ppm 
     BDL- Below Detection Limit 
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Report and Inference 
 Results of the present investigation has clearly shows that the sample SC has no 
traces of Mercury and further shows the presence of Arsenic at 0.268 ppm level 
and hence it was considered that the heavy metals mercury was absent in the 
sample SC. 
 The reported heavy metal arsenic seems very low (0.268 ppm) when compare to 
the allowed recommended limit of 3ppm. 
 
TLC AND HPTLC ANALYSIS 
                        
        TLC Analysis at 254 nm                    TLC Analysis at 366 nm                                                        
                                                                                 
                                
                                    HPTLC finger printing of sample SC   
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                                          Table – 5.4: HPTLC Analysis of SC 
Peak 
 
Start  
  Rf 
Start 
Height 
 Max  
  Rf 
Max 
Height 
Max 
  %      
 End  
  Rf 
End 
Height Area 
Area  
  % 
1 0.04 39.0 0.07 78.7 48.29 0.08 0.4 1461.7 33.99 
2 0.41 11.3 0.46 33.0 20.28 0.48 10.2 1089.4 25.33 
3 0.74 2.4 0.80 51.2 31.43 0.84 5.0 1749.9 40.69 
 
Report and Inference  
HPTLC finger printing analysis of the sample SC reveals the presence of three 
prominent peaks corresponds to presence of three versatile phytocomponents present with 
in it. Rf value of the peaks ranges from 0.04 to 0.74. Further the peak 1 occupies the major 
percentage of area of 48.29 % which denotes the abundant existence of such compound. 
Followed by this peak 3 and 2 occupies the percentage area of 31.43 and 20.28 %. 
 
PHYTOCHEMICAL ANALYSIS: 
 
                                    Table – 5.5: Phytochemical analysis of SC 
S.NO       TEST OBSERVATION 
1. Alkaloids             - 
2. Flavanoids             + 
3. Glycosides             + 
4. Steroids             + 
5. Triterpenoids             - 
6. Coumarin             - 
7. Phenol             + 
8. Tanin             + 
9. Protein             - 
10. Saponins             + 
11. Sugar             + 
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12. Anthocyanin             - 
13. Betacyanin             - 
 
                     +   indicates Presence and  - indicates Absence of the Phytocomponents 
 
TESTS DONE FOR 
 
 
               ALKALOIDS          FLAVANOIDS        GLYCOSIDES       STEROIDS 
                                              
 
 
 
            TRITERPENOIDS   COUMARINS             PHENOL                  TANIN 
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                 PROTEIN             SAPONIN            SUGAR         ANTHOCYANIN 
                                             
 
 
 
STERILITY TEST BY POUR PLATE METHOD 
 
Observation 
    No growth was observed after incubation period. Reveals the absence of specific 
pathogen 
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 Table – 5.6: Sterility test by Pour Plate Method for SC 
Test Result Specification 
As per 
AYUSH/WHO 
Total Bacterial Count Absent NMT 105CFU/g As per AYUSH 
specification Total Fungal Count Absent NMT 103CFU/g 
 
Result 
    No growth / colonies was observed in any of the plates inoculates with the test sample. 
 
TOXICOLOGICAL STUDY 
 
Acute oral toxicity study of Samuthara chooranam 
Observation done: 
 Table – 5.7: Dose finding experiment and its behavioral Signs of acute oral Toxicity   
SL              Group 
          CONTROL 
Observation SL TEST GROUP Observation 
1 Body weight Normal 1 Body weight Normally 
increased 
 
2 Assessments of 
posture 
Normal 2 Assessments of 
posture 
Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of Convulsion 
Limb paralysis 
Absence of sign 
(-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No significant 
color change 
7 Change in skin color No significant 
color change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 10 Sensitivity response Normal 10 Sensitivity response Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle gripness Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
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Behaviour: 
 The animals will be observed closely for behaviour in the first four hours which 
includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, catalepsy, 
convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, loss of traction, 
piloerection reactivity of touch, salivation, scratching, sedation, chewing, head 
movements, sniffing, straub, tremor and writhes, diarrhea, leathery, sleep and coma.  
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight changes 
were calculated and recorded. At the end of the test, surviving animals were weighed and 
humanly killed. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated 
dose groups.  
Mortality: 
           Animals were observed for mortality throughout the entire period.                                         
 
  Table – 5.8: Observational study Results 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
1
9 
2
0 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
 
2000mg 
 
+ - - + - + - - - - - - - - - - - - - - 
  1.Alertness 2. Aggressiveness 3. Pile erection  4.Grooming  5.Gripping  6.Touch      
  Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions  10. Muscle Spasm       
  11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia  15.Lacrimation 
  16. Exophthalmos 17. Diarrhea 18. Writhing 19. Respiration 20. Mortality. 
     (+  Present,   -  Absent) 
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                                         Table – 5.9: Body weight Observation 
          
        Table – 5.10: Water intake (ml/day) of Wistar albino rats group exposed to SC 
    DOSE 
 
                            DAYS 
        1          6        14 
CONTROL 58.5 ± 6.74 60 ± 9.13 60.4 ± 4.13 
HIGH DOSE 60.4 ± 2.33 60.6. ± 1.11 60.9 ± 6.19 
P value (p)* NS NS NS 
 N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
                     (One way ANOVA followed by Dunnett’s test) 
  
       Table -5.11: Food intake (gm/day) of Wistar albino rats group exposed to SC 
       DOSE 
 
                                   DAYS 
           1            7            14 
CONTROL 40.56 ± 9.36 42.6 ± 4.42 41.6 ± 7.46 
LOW DOSE 39.4 ± 1.64 39.3 ± 1.22 39.2 ± 6.24 
 
Results: 
 All data were summarized in tabular form, (Table 6 - 10) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, the 
number of animals found dead during the test, description of toxic symptoms, weight 
changes, food and water intake. 
       
 
DOSE 
 
                                   DAYS 
          1                  7          14 
CONTROL 220.6±31.474  221.4 ± 34.324 224.2 ± 27.623 
HIGH DOSE 210.5± 27.75 211.7 ± 31.67 213.4 ± 32.67 
P value (p)* NS NS NS 
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SUB ACUTE TOXICITY 
                  Repeated Dose 28- day oral toxic study of Samuthara chooranam                   
     Table – 5.12: Body weight of wistar albino rats group exposed to SC 
            NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D  
                                (One way ANOVA followed by Dunnett’s test) 
 
       Table – 5.13: Water intake (ml/day) of Wistar albino rats group exposed to SC 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 61.5 ± 8.95 61 ± 6.23 58.5 ± 6.23 59 ± 8.196 61.5 ± 3.96 
LOW DOSE 56.5 ± 3.31 56.4 ± 3.62 56.7 ± 3.26 56.2 ± 3.29 56.9 ± 3.13 
MID DOSE 55.7 ± 4.33 56.3 ± 2.11 57.1 ± 2.43 58.4 ± 2.11 58.4 ± 2.34 
HIGH 
DOSE 
60.1 ± 1.32 60.2 ± 2.13 60.7 ± 2.13 65.2 ± 1.73 63.4 ± 2.65 
P value (p)* NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D  
                     (One way ANOVA followed by Dunnett’s test) 
 
          Table -5.14: Food intake (gm/day) of Wistar albino rats group exposed to SC 
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 37 ± 5.37 38.5 ± 3.22 39.5 ± 3.37 38.5 ± 3.37 37 ± 3.12 
LOW DOSE 43.7 ± 2.98 45.3 ± 1.22 45.1 ± 1.18 45.4 ± 2.12 45.6 ± 2.42 
MID DOSE 47.2 ± 3.75 47.2 ± 3.60 47.2 ± 4.25 47.4 ± 2.68 49.2 ± 2.44 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 220.6 ± 33.673  221.4 ± 40.114 221.7 ± 39.661 222.6 ± 39.73 222.7 ± 41.311 
LOW DOSE 180.2 ± 21.124 180.7 ± 33.64 181.4 ± 21.514 182 ± 21.66 182.42 ± 12.76 
MID DOSE 176.6 ± 10.64 176.3 ± 22.74 176.4 ± 38.12 178.1 ± 33.36 179.7 ± 23.12 
HIGH DOSE 187.4 ± 36.74 187.6 ± 32.72 187.6 ± 32.46 187 ± 22.78 186.92 ± 26.49 
P value (p)* NS NS NS NS NS 
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HIGH 
DOSE 
46.2 ± 2.34 46.2 ± 2.64 49.6 ± 2.66 48.2 ± 3.20 48.0 ± 3.62 
P value (p)* NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
                          (One way ANOVA followed by Dunnett’s test) 
 
   
Table – 5.15: Haematological parameters of Wistar albino rats group exposed to SC 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin 
       (g/dl) 
13.8±0.88 13.80±0.66 14.14±0.66 13.28±0.96 N.S 
Total WBC  
(×103   l) 
11.91±0.59 11.25±0.73 11.48±0.91 11.20±1.17 N.S 
Neutrophils(%) 33.65±0.06 32.23±0.14 35.41±1.36 35.20±2.20 N.S 
lymphocyte (%) 70.24±1.48 70.12±3.12 70.20±2.66 70.10±2.16 N.S 
Monocyte (%) 0.86±0.07 0.84±0.09 0.82±0.03 0.81±0.06 N.S 
Eosinophil (%) 0.54±0.09 0.56±0.02 0.56±0.06 0.57±0.04 N.S 
Platelets cells   
103/µl 
687.17±8.76 688.71±8.16 683.18±9.0 687.16±9.74 N.S 
Total RBC  
    (106/ µl) 
7.99±0.12 7.99±0.57 7.82±0.59 8.05±0.72 N.S 
PCV% 37.79±0.6 41.35±1.13 43±1.68 45.82±2.54 N.S 
MCHC g/Dl 33.6±2.23 35.09±1.29 36.98±1.22 34.03±1.24 N.S 
MCV fL (µm3) 49.07±3.64 50.20±1.22 51.20±1.24 52.24±1.44 N.S 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D  
   (One way ANOVA followed by Dunnett’s test) 
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Table – 5.16: Biochemical Parameters of Wistar albino rats group exposed to SC 
BIOCHEMICAL 
PARAMETERS 
CONTRO
L 
LOW 
DOSE MID DOSE 
HIGH 
DOSE 
P 
Value 
(p)* 
GLUCOSE (R) 
(mg/dl) 74.45±13.4 76.16±8.44 78.26±11.20 76.42±11.6 N.S 
T.CHOLESTEROL 
(mg/dl) 
115.26±1.8
3 
115.45±1.8
3 116.42±1.78 116.22±1.73 N.S 
TRIGLY(mg/dl) 46.35±1.48 46.32±1.48 44.58±1.30 45.66±1.33* N.S 
LDL 73.8±2.43 73.24±2.54 73±2.44 73.64±24.32 NS 
VLDL 15.2±2.44 15.42±4.64 15.44±6.64 15.64±34.36 NS 
HDL 26.66±6.88 26.86±2.24 26.68±4.66 26.78±21.22 NS 
Ratio 1(T.CHO/HDL) 
4.42±2.44 4.46±3.14 4.44±8.44 4.46±22.22 NS 
Ratio 2(LDL/HDL) 
 
2.83±24.22 2.84±2.22 2.86±2.20 2.66±46.02 NS 
Albumin (g/dL) 3.3±0.17 3.43±0.12 3.34±22.02 3.54±6.86 NS 
 NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D  
                                  (One way ANOVA followed by Dunnett’s test) 
 
         Table – 5.17: Renal function test of Wistar albino rats group exposed to SC 
PARAMETERS CONTROL LOW DOSE 
MID 
DOSE 
HIGH 
DOSE 
P Value 
(p)* 
UREA (mg/dl) 13.35±0.99 14.31±0.46 14.06±1.38 14.48±1.42 N.S 
CREATININE 
  (mg/dl) 
0.58±0.08 0.46±0.06 0.62±0.04 0.66±0.02 N.S 
BUN (mg/dL) 15.12±0.10 15.10±0.60 16±0.44 16.10±2.12 NS 
URIC ACID 
(mg/dl) 
5.37±0.35 5.11±0.43 5.7±1.25* 5.48±0.23 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D  
                       (One way ANOVA followed by Dunnett’s test) 
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         Table – 5.18: Liver Function Test of Wistar albino rats group exposed to SC 
PARAMETERS CONTROL 
LOW 
DOSE 
MID DOSE HIGH DOSE 
P 
Value   
(p)*  
    T.BILIRUBIN 
         (mg/dl) 
0.50±0.07 0.55±0.06 0.59±0.08 0.56±0.05 N.S 
SGOT/AST(U/L) 114.95±1.39 116.35±0.51 117.01±1.53 116.55±1.03 N.S 
SGPT/ALT(U/L) 71.23±1.28 75.91±1.59 75.34±1.48 74.32±0.68 N.S 
ALP(U/L) 146.25±8.77 141±16.17 148.16±24.07* 149.33±14.65* N.S 
T.PROTEIN(g/dL) 6.32±0.38 7.48±0.34 7.016±0.23 6.53±0.46 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D  
                        (One way ANOVA followed by Dunnett’s test) 
 
HISTOPATHOLOGY 
CONTROL GROUP 
         Kidney         Liver        Spleen                       
         
 
TEST GROUP (HIGH DOSE) 
                 Kidney          Liver        Spleen      
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PHARMACOLOGICAL STUDY: 
 
SAMPLE: SAMUTHARA CHOORANAM 
                     
        Table – 5.19: Immunomodulator activity of SC 
Sample Concentration(µg/ml) OD at 540nm Concentration(µg) 
Control 0.1185 586.575 
25 0.1158 573.21 
50 0.0849 420.255 
100 0.0723 357.885 
     
 
                                             Chart – 1: Immunomodulatory result of SC 
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Standard – Nitrate level 
                   Table –5.20: Standard nitrate level for Immunomodulatory activity 
Concentration(µg) OD(540 nm) 
100 0.021 
200 0.42 
300 0.06 
400 0.08 
500 0.17 
Result and Inference: 
While the concentration level is decreased, nitrate level increased. Hence 25µg/ml 
of SC has rich level of nitrate and thus proven to be an Immunomodulator. 
 
SELECTION OF CASE: 
        Table – 5.21: Selection of cases 
S.NO    SELECTION OF CASES   NO OF PATIENTS 
 
PERCENTAGE(%) 
1. INTERNAL                20              33.3 
2. EXTERNAL & OTTRADAM               20              33.3 
3. 
INTERNAL , EXTERNAL & 
OTTRADAM               20              33.3 
 
                                Chart - 2: Selection of cases 
                                                 
 
34%
33%
33%
SELECTION OF CASES
INTERNAL
EXTERNAL&OTTRADAM
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OTTRADAM
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Inference: 
 Among 60 cases, 20 cases(34%) were treated with internal drug alone, 20 
cases(33%) were treated with external drug & ottradam and 20 cases(33%) were treated 
with internal, external drug & ottradam. 
 
GENDER DISTRIBUTION: 
                    Table -5.22: Gender distribution 
S.NO GENDER DISTRIBUTION NO OF PATIENTS PERCENTAGE(%) 
1. MALE 8 13 
2. FEMALE 52 87 
  
                      Chart - 3: Gender distribution 
                    
 
Inference: 
 Among 60 cases, 8 cases(13%) were male and 52 cases(87%) were female. 
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AGE DISTRIBUTION: 
                  Table -5.23: Age distribution 
S.NO   AGE DISTRIBUTION   NO OF CASES 
   
PERCENTAGE(%) 
1.           18 – 20           0               0 
2.           21 – 30          5             8.3 
3.           31 – 40         17            28.3 
4.           41 – 50         16            26.6 
5.           51 – 60         22            36.6 
   
 
                 Chart - 4: Age distribution 
          
 
Inference: 
 Among 60 cases, high age incidence is between 51-60(36.6%) and 31-40(28.3%). 
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FAMILY HISTORY: 
     Table –5.24: Family history 
S.NO FAMILY HISTORY NO OF CASES PERCENTAGE(%) 
1. PRESENT            5            8 
2. ABSENT           55            92 
 
        
   Chart - 5: Family history 
                       
 
 
Inference: 
 Among 60 cases, only 5 cases(8%) had positive family history of Rheumatoid 
arthritis. 
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OCCUPATIONAL STATUS: 
                   Table -5.25: Occupational status 
S.NO 
OCCUPATIONAL 
STATUS NO OF CASES PERCENTAGE(%) 
1. ENGINEER 1 1.6 
2. TEACHER 3 5 
3. DRIVER 1 1.6 
4. EMPLOYEE 11 18.3 
5. BUSINESS 2 3.3 
6. LABOR 4 6.6 
7. TAILOR 2 3.3 
8. HOME MAKER 34 56.6 
9. AGRICULTURE 2 3.3 
    
              Chart - 6: Occupational status 
              
 
Inference: 
 Among 60 cases, 34 cases(56.6%) were Home maker and 11 cases(18.3%) were 
Employee.  
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SOCIO – ECONOMIC STATUS: 
            
     Table – 5.26: Socio – Economic Status 
S.NO SOCIO – ECONOMIC STATUS NO OF CASES PERCENTAGE(%) 
1.                POOR          30             50 
2.          MODERATE          21             35 
3.                HIGH           9             15 
 
 
            Chart - 7: Socio – Economic Status                                                          
 
 
 
Inference: 
 Among 60 cases, 30 cases(50%) were poor, 21 cases(35%) were moderate and 9 
cases(15%) were from high class.  
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DIET: 
             Table – 5.27: Diet 
S.NO            DIET NO OF CASES PERCENTAGE(%) 
1. VEGETARIAN           12             20 
2. 
NON 
VEGETARIAN           48             80 
 
 
                             Chart - 8: Diet                                  
                      
                                                                                                                                             
 
Inference: 
 Among 60 cases, 48 cases(80%) were non-vegetarian and 12 cases(20%) were 
vegetarian. 
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DURATION OF ILLNESS: 
        Table – 5.28: Duration of illness 
S.NO 
DURATION OF 
ILLNESS NO OF CASES PERCENTAGE(%) 
1. UPTO 6 MONTHS          11          18.3 
2. 6 MONTH – 1 YEAR           7          11.6 
3. 1 – 2 YEAR           9           15 
4. 2 – 3 YEAR          15           25 
5. 3 – 4 YEAR           6           10 
6. 4 – 6 YEAR          10          16.6 
7. 6 – 10 YEAR           2           3.3 
 
 
             Chart - 9: Duration of illness 
                   
 
Inference:  
 Among 60 cases,15 cases(25%) had 2-3 years of illness, 11 cases(18.3%) had 6 
months of illness, 10 cases(16.6) had 4-6 years of illness, 9 cases(15%) had 1-2 years of 
illness, 7 cases(11.6%) had 6 month-1 year of illness, 6 cases(10%) had 3-4 years of illness 
and 2 cases(3.3%) had 6-10 years of chronic illness. 
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MODE OF ONSET: 
Acute onset: upto 6 months 
Sub-acute: 6 months – 3 years 
Chronic: 4 – 10 years 
        Table – 5.29: Mode of Onset 
S.NO MODE OF ONSET NO OF CASES PERCENTAGE(%) 
1. ACUTE           11            18 
2. SUB ACUTE           31            52 
3. CHRONIC           18            30 
 
        Chart - 10: Mode of Onset 
                      
 
 
Inference: 
 Among 60 cases, 11 cases(18%) were suffering from acute illness, 31 cases(52%) 
were suffering from sub-acute illness, 18 cases(30%) were suffering from chronic illness. 
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CLINICAL FEATURES: 
       Table – 5.30: Clinical Features 
S.NO CLINICAL FEATURES NO OF CASES PERCENTAGE(%) 
1. PAIN         60           100 
2. SWELLING         48            80 
3. TENDERNESS         26          43.3 
4. MORNING STIFFNESS         47          78.3 
5. LOW GRADE FEVER         15            25 
6. POLYARTHRALGIA         57            95 
7. RESTRICTED MOVEMENTS         28          46.6 
8. LOSS OF APPETIDE         26          43.3 
    
  Chart -11: Clinical features 
               
 
Inference 
Among 60 cases, 60 cases(100%) had pain, 48 cases(80%) had swelling, 47 cases(78.3%) 
had morning stiffness, 57 cases(95%) had polyarthralgia, 26 cases(43.3%) had tenderness, 
28 cases (46.6%) had restriction of movements, 26 cases(43.3%) had loss of appetide, 15 
cases(25%) had low grade fever. 
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INVOLVEMENT OF JOINTS: 
              
      Table -5.31: Involvement of Joints 
S.NO INVOLVEMENT OF JOINTS 
NO OF 
CASES PERCENTAGE(%)   
1. CERVICAL VERTEBRAE          2             3.3 
2. 
METACARPO PHALANGEAL 
JOINT(MCP)         50            83.3 
3. 
PROXIMAL 
INTERPHALANGEAL JOINT(PIP)         48             80 
4. WRIST JOINT         39             65 
5. ELBOW JOINT         15             25 
6. SHOULDER JOINT         17            28.3 
7. 
METATARSAL PHALANGEAL 
JOINT(MTP)         20            33.3 
8. KNEE JOINT         28            46.6 
9. ANKLE JOINT         26            43.3 
10. HIP JOINT          7            11.6 
11. LUMBOSACRAL JOINT          4             6.6 
                                   
                                 Chart - 12: Involvement of Joint         
         
 
Inference: 
Among 60 cases, high involvement of joints were MCP and PIP joints, 50 
cases(83.3%) and 48 cases(80%) respectively. 
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RESULTS AFTER TREATMENT: 
IMPROVEMENT OF GROUP I SUBJECTS: 
Improvement in subjects treated with internal trial drug “SAMUTHARA 
CHOORANAM” in group I subjects 
                                           Table –5.32: Improvement of group I subjects 
S.NO CLINICAL 
FEATURES 
    BEFORE TREATMENT       AFTER TREATMENT 
SUBJECTS PERCENTAGE SUBJECTS PERCENTAGE 
          
1. PAIN AND 
SWELLING OF 
PIP JOINT 
16 80% 2 10% 
2. MORNING 
STIFFNESS > 1 hr 
18 90% 4 20% 
3. TENDERNESS 10 50% 1 5% 
4. LOW GRADE 
FEVER 
4 20% 2 10% 
5. ARTHRITIS OF 
MORE THAN 3 
JOINTS 
19 95% 2 10% 
6. RESTRICTION OF 
MOVEMENTS 
10 50% 2 10% 
7. LOSS OF 
APPETITE 
8 40% 3 15% 
   
                                   Chart – 13: Improvement of group I subject                
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Inference: 
Among 20 cases, 16 cases(80%) had pain and swelling of PIP joints, 18 cases(90%) 
had morning stiffness > 1hr, 10 cases(50%) had tenderness, 4 cases(20%) had low grade 
fever, 19 cases(95%) had arthritis of more than 3 joints, 10 cases(50%) had restriction of 
movements, 8 cases(40%) had loss of appetite before treatment. But after treatment only 2 
cases(10%) had pain and swelling of PIP joints, 4 cases(20%) had morning stiffness > 1hr, 
1 cases(5%) had tenderness, 2 cases(10%) had low grade fever, 2 cases(10%) had arthritis 
of more than 3 joints, 2 cases(10%) had restriction of movements, 3 cases(15%) had loss 
of appetite. 
 
IMPROVEMENT OF GROUP II SUBJECTS: 
Improvement in subjects treated with external trial drug “VADHA NOIKU 
VELIPRAYOGHA THAILAM & OTTRADAM” in group II subjects. 
                             
                        Table – 5.33: Improvement of group II subjects 
S.
N
O 
CLINICAL 
FEATURES 
    BEFORE TREATMENT       AFTER TREATMENT 
SUBJECTS PERCENTAGE 
         
SUBJECTS PERCENTAGE 
          
1. PAIN AND 
SWELLING OF PIP 
JOINT 
14 70% 3 15% 
2. MORNING 
STIFFNESS > 1 hr 
14 70% 3 15% 
3. TENDERNESS 7 35% 1 5% 
4. LOW GRADE FEVER 4 20% 2 10% 
5. ARTHRITIS OF MORE 
THAN 3 JOINTS 
19 95% 3 15% 
6. RESTRICTION OF 
MOVEMENTS 
10 50% 3 15% 
7. LOSS OF APPETITE 8 40% 3 15% 
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                               Chart – 14: Improvement of group II subjects 
    
 
Inference: 
Among 20 cases, 14 cases(70%) had pain and swelling of PIP joints, 14 cases(70%) 
had morning stiffness > 1hr, 7 cases(35%) had tenderness, 4 cases(20%) had low grade 
fever, 19 cases(95%) had arthritis of more than 3 joints, 10 cases(50%) had restriction of 
movements, 8 cases(40%) had loss of appetite before treatment. But after treatment only 3 
cases(15%) had pain and swelling of PIP joints, 3 cases(15%) had morning stiffness > 1hr, 
1 cases(5%) had tenderness, 2 cases(10%) had low grade fever, 3 cases(15%) had arthritis 
of more than 3 joints, 3 cases(15%) had restriction of movements, 3 cases(15%) had loss 
of appetite. 
 
IMPROVEMENT OF GROUP III SUBJECTS: 
Improvement in subjects treated with internal and external trial drug 
“SAMUTHARA CHOORANAM” and “VADHA NOIKU VELIPRAYOGHA 
THAILAM’ respectively & “OTTRADAM” in group III subjects. 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
70% 70%
35%
20%
95%
50%
40%
15% 15%
5%
10%
15% 15% 15%
Improvement of group II subjects
BEFORE TREATMENT AFTER TREATMENT
                                                                        RESULTS AND OBSERVATIONS/2018 
159 
 
                             Table –5.34: Improvement of group III subjects 
S.NO CLINICAL 
FEATURES 
    BEFORE TREATMENT       AFTER TREATMENT 
SUBJECTS PERCENTAGE 
         
SUBJECTS PERCENTAGE 
          
 
 
1. 
PAIN AND 
SWELLING OF 
PIP JOINT 
18 90% 2 10% 
2. MORNING 
STIFFNESS > 1 hr 
15 75% 1 5% 
3. TENDERNESS 9 45% 1 5% 
4. LOW GRADE 
FEVER 
7 35% 1 5% 
5. ARTHRITIS OF 
MORE THAN 3 
JOINTS 
19 95% 2 10% 
6. RESTRICTION OF 
MOVEMENTS 
8 40% 2 10% 
7. LOSS OF 
APPETITE 
10 50% 2 10% 
 
         Chart – 15: Improvement of group III subjects   
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Inference: 
Among 20 cases, 18 cases(90%) had pain and swelling of PIP joints, 15 cases(75%) 
had morning stiffness > 1hr, 9 cases(45%) had tenderness, 7 cases(35%) had low grade 
fever, 19 cases(95%) had arthritis of more than 3 joints, 8 cases(40%) had restriction of 
movements, 10 cases(50%) had loss of appetite before treatment. But after treatment only 
2 cases(10%) had pain and swelling of PIP joints, 1 cases(5%) had morning stiffness > 1hr, 
1 cases(5%) had tenderness, 1 cases(5%) had low grade fever, 2 cases(10%) had arthritis 
of more than 3 joints, 2 cases(10%) had restriction of movements, 2 cases(10%) had loss 
of appetite. 
 
REDUCTION OF PAIN: 
SEVERE PAIN: PAIN SCORE 7 – 10 
 MODERATE PAIN: PAIN SCORE 4 – 6 
 MILD PAIN: PAIN SCORE 1 – 3 
 NO PAIN: PAIN SCORE 0 
                                             
 
                                              Table – 5.35: Reduction of pain 
S.NO REDUCTION 
OF PAIN 
    BEFORE TREATMENT       AFTER TREATMENT 
SUBJECTS PERCENTAGE 
        (%) 
SUBJECTS PERCENTAGE 
         (%) 
1. SEVERE 26 43.4% 7 12% 
2. MODERATE 22 36.6% 6 10% 
3. MILD 12 20% 32 53% 
4. NO PAIN 0 0 15 25% 
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          Chart – 16: Reduction of pain  
              
Inference: 
Among 60 cases, 26 cases(43.4%) had severe pain, 22 cases(36.6%) had moderate 
pain and 12 cases(20%) had mild pain before treatment. But after treatment only 7 
cases(12%) had severe pain, 6 cases(10%) had moderate pain, 32 cases(53%) had mild 
pain and 15 cases(25%) had no pain.  
 
FUNCTIONAL ABILITY GRADATION: 
 GRADE I – FIT FOR ALL ACTIVITIES 
 GRADE II – MILD RESTRICTION 
 GRADE III – MODERATE RESTRICTION 
 GRADE IV – CONFINED TO CHAIR OR BED RIDDEN 
                                          
              Table – 5.36: Functional ability gradation 
S.NO GRADE     BEFORE TREATMENT       AFTER TREATMENT 
SUBJECTS PERCENTAGE 
        (%) 
SUBJECTS PERCENTAGE 
        (%)      
1. GRADE I 12 20% 44 73% 
2. GRADE II  22 37% 14 24% 
3. GRADE III 24 40% 2 3% 
4. GRADE IV 2 3% 0 0 
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                                       Chart – 17: Functional ability gradation 
          
 
Inference: 
Among 60 cases, 12 cases(20%) was fit for all activities, 22 cases(37%) had mild 
restriction in movements, 24 cases(40%) had moderate restriction in movements and 2 
cases(3%) had confined to chair on before treatment. 
But after treatment, 44 cases(73%) became fit for all activities, 14 cases(24%) had 
mild restriction in movements, 2 cases(3%) had moderate restriction in movements and no 
one was confined to chair. 
 
OVERALL RESULT: 
 
IMPROVEMENT OF RA: 
                                          Table – 5.37: Improvement of RA 
S.NO IMPROVEMENT NO OF 
PATIENTS 
PERCENTAGE(%) 
1. GOOD 47 78% 
2. MODERATE 6 10% 
3. MILD 7 12% 
4. NO IMPROVEMENT 0 0 
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                                               Chart – 18: Improvement of RA 
             
 
Inference: 
Among 60 cases, 47 cases(78%) had good improvement, 6 cases(10%) had 
moderate improvement and 7 cases(12%) had mild improvement. 
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GROUP I SUBJECTS: BLOOD INVESTIGATIONS 
S. 
N 
O 
OP. 
NO     NAME 
   TC (Cells/ 
        Cu.mm)                                      DC (%)       ESR (mm/ Hr) 
    Hb 
 (gm%) 
BT AT 
     N       B       E      M      L    ½ hr    1 hr 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1. 653 AAMINA 7700 8000 58 59 0 0 7 5 0 0 35 36 8 7 16 13 11.2 12.5 
2. 3786 SELVAMANI 8000 8700 48 55 0 1 8 7 0 2 44 35 4 4 10 13 11.1 12.3 
3. 5791 JOTHI 7500 7700 57 57 0 0 6 4 2 3 35 36 12 11 30 26 13.3 14 
4. 6197 PONMALAR 9610 9700 51 65 0 0 3 3 2 1 44 31 25 23 51 48 9.2 10.1 
5. 6055 MAALA 6200 6420 47 58 1 1 8 5 3 2 41 34 20 18 45 40 9.1 10.3 
6. 6577 VIJAYA 10400 10000 57 66 0 0 7 7 0 2 36 25 36 38 59 56 12.5 14 
7. 6988 SUSHILA 9250 9500 67 65 0 1 3 3 4 3 26 28 16 15 37 35 12.6 13 
8. 1360 SHANMUGAM 8200 8400 70 68 0 1 5 3 0 2 25 26 21 15 44 30 15.1 15.5 
9. 9097 SUGUNA 8700 9100 56 56 1 1 6 7 6 1 31 35 45 40 83 76 9.5 10 
10. 450 
PREM 
KUMAR 8600 9000 68 59 0 0 7 4 0 2 25 35 10 9 22 18 15 16 
11. 2240 SAIGEETHA 10500 9000 64 58 0 0 8 6 0 2 28 34 18 15 38 30 12.1 13 
12. 2683 MANJULA 7800 8000 67 65 1 0 6 3 2 1 24 31 14 12 29 25 10.3 11.5 
13. 2685 VIMALA SRI 8300 8500 54 59 1 0 7 4 2 1 36 36 22 21 46 44 9.6 10.2 
14. 4069 AMUDHA 7900 8250 56 60 1 0 5 4 2 0 36 36 15 15 32 30 10.9 11.5 
15. 4511 SUGANYA 8600 9000 71 67 0 1 6 5 0 1 23 26 5 5 18 15 11.8 13 
16. 6512 
SHANMUGA 
   SUNDARAM 8700 9200 75 71 0 0 8 6 0 1 17 22 18 14 42 37 11.4 13 
17. 7866 VALLI 9400 9500 66 65 1 0 5 5 2 0 26 30 10 9 21 18 11.3 12 
18. 9354 SHANTHI 9622 9800 51 59 0 0 2 1 2 0 45 40 25 23 42 38 10.4 11 
19 495 SUNDAR 8400 8600 61 67 0 0 6 4 0 0 33 29 10 8 24 16 10.2 11 
20. 1086 DURGA DEVI 5600 6300 54 58 0 0 7 4 0 0 39 38 6 6 15 12 11.8 12.4 
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GROUP II SUBJECTS: BLOOD INVESTIGATIONS 
S. 
N 
O 
OP. 
NO      NAME 
    TC (Cells/ 
       Cu.mm)                                      DC (%)       ESR (mm/ Hr) 
    Hb 
 (gm%) 
BT AT 
     N       B       E      M      L    ½ hr     1 hr 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1. 656 MALLIKA 9200 7000 51 63 0 0 3 4 1 0 45 33 26 25 43 40 10.3 10.5 
2. 793 TAMIL SELVI 8100 8100 55 59 0 1 6 5 3 3 36 32 17 16 23 24 12 11.5 
3. 983 R.SUSHEELA 7700 8200 49 60 1 0 6 5 4 0 40 35 9 10 17 19 12 11 
4. 1346 KAVERI 8200 7800 53 61 0 0 5 6 3 0 39 33 12 12 25 24 10 11.5 
5. 4717 
PONN 
AZHAGU 11000 10500 67 66 0 1 7 7 0 1 26 25 12 11 24 22 10.6 11 
6. 4411 MEGALAI 9200 9100 63 59 1 0 7 8 2 0 27 33 7 9 16 18 11 10.5 
7. 8324 KANCHANA 8500 8600 50 56 1 0 5 4 4 0 40 40 12 11 27 26 10.4 11 
8. 9239 HEMALATHA 9700 9500 53 55 0 1 3 3 1 1 43 40 16 16 35 34 10.2 10.4 
9. 9704 GOKILA 8700 8550 53 57 0 0 4 2 0 0 43 41 18 15 29 30 9.3 10 
10. 1731 JEEVA 8100 8000 70 65 0 0 5 5 0 0 25 30 14 13 29 26 11.2 12 
11. 5249 NIRMALA 9300 9100 65 65 1 0 5 5 3 1 26 29 14 13 33 30 10.3 11 
12. 3466 VENKATESAN 8200 8300 58 60 1 0 5 4 1 0 35 36 20 18 35 35 11.6 11 
13. 6129 SARASWATHI 9400 9440 65 64 0 0 7 6 1 0 27 30 25 25 43 40 10.4 11 
14. 8044 P.VIJAYA 8300 8300 50 56 0 0 5 4 2 2 43 38 10 10 35 30 10.8 12.4 
15. 8243 LILLY 3800 4000 79 73 0 0 2 2 0 0 19 25 10 9 22 22 10.4 11.2 
16. 8689 YUVARANI 6900 7100 57 64 1 0 6 5 1 1 35 30 15 13 34 28 10.5 11.5 
17. 9208 EZHILRANI 6400 6200 68 68 0 0 5 5 2 1 25 26 30 29 60 54 12.7 13 
18. 2134 SAVITHRI 7300 7200 64 60 2 0 5 4 2 1 27 35 16 15 31 30 9.6 10.5 
19 7648 RADHA 8400 9000 54 59 1 0 7 5 2 1 36 35 22 20 45 43 10.5 11.4 
20. 7986 K.SHANTHI 8200 7900 53 60 1 0 8 6 1 0 37 34 9 10 26 24 11.3 12 
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GROUP III SUBJECTS: BLOOD INVESTIGATIONS 
S. 
N 
O 
OP. 
NO      NAME 
     TC (Cells/ 
         Cu.mm)                                      DC (%)       ESR (mm/ Hr) 
    Hb 
 (gm%) 
BT AT 
     N       B       E      M      L     ½ hr    1 hr 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1. 5446 JAGADAMBAL 7000 7200 47 62 1 1 7 4 3 2 42 31 11 9 28 26 10 11.4 
2. 5718 PRIYANKA 8500 8400 61 61 0 0 6 5 0 2 33 32 5 4 12 12 12.4 13 
3. 8134 VASANTHI 15200 14300 71 64 0 0 5 4 0 1 24 31 12 10 40 35 10.2 11.3 
4. 3976 PARVATHY 8200 8600 65 63 1 1 3 3 4 2 27 31 6 5 13 10 11 12.5 
5. 976 KAVITHA 7200 8000 47 55 1 0 7 5 4 2 41 38 12 10 36 25 9.7 10.5 
6. 2315 ABIRAMI 8200 8500 64 60 2 1 3 2 4 1 27 36 7 6 24 20 10.5 11.2 
7. 3408 THILAGA 9600 10000 66 67 0 0 6 4 2 1 26 28 19 15 37 30 11.1 11.8 
8. 5295 BANUMATHY 10400 10100 69 68 0 0 6 3 0 0 25 29 24 20 47 40 11.4 12 
9. 5941 VIJAYARANI 8000 8800 49 55 1 0 6 4 0 0 44 41 15 11 30 23 10.7 11.5 
10. 6680 SIVANESAN 10300 10500 70 67 0 1 2 2 8 4 20 26 17 15 45 32 12.9 13.5 
11. 7437 JEYANTHI 9800 10000 71 70 0 0 2 2 5 3 22 25 9 9 24 25 11.5 13 
12. 25 SARANYA 7200 7600 56 60 1 0 5 4 2 1 36 35 19 16 36 32 11.3 12 
13. 315 KRISHNAVENI 8900 9300 70 71 1 0 6 4 1 0 22 25 24 20 47 40 10.8 11.4 
14. 1167 KODIARASI 6100 6800 58 63 0 1 4 3 3 1 35 32 30 22 61 46 11.2 12 
15. 3629 SELVI 7500 8000 63 67 2 1 6 5 1 0 28 27 21 18 34 36 10.2 11 
16. 7633 SIVAKUMAR 7500 8800 58 63 0 0 6 4 0 0 36 33 7 6 23 20 11.6 12 
17. 3361 SUNDARI 11700 12000 62 65 0 0 6 5 0 0 32 30 21 19 43 38 8.5 9.5 
18. 3288 SALIKA BANU 8900 8600 70 69 0 0 5 3 0 0 25 28 21 20 43 40 9.8 10.3 
19 6300 MOHAN BABU 9800 9600 55 61 0 0 8 5 0 0 37 34 5 5 13 12 14.8 15 
20. 6363 ROSIE 7500 8200 59 62 0 0 7 6 0 0 34 32 36 33 74 60 12.2 13 
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GROUP I SUBJECTS: BLOOD INVESTIGATIONS 
S. 
N 
O 
OP. 
NO NAME 
  BLOOD SUGAR 
PLT (103 
     ×mm3) 
S. CHOLESTEROL 
           (mg/dl) 
S. URIC 
ACID 
(mg/dl) 
BLEEDING 
    TIME 
( in mins & secs) 
CLOTTING 
   TIME 
(in mins & secs) 
    FBS    PPBS 
BT AT     BT     AT BT AT    BT    AT BT AT BT AT BT AT 
1. 653 AAMINA 77 80 126 130 236 305 170 181 2.2 2.3 2 & 30 2 & 35 4 & 15 4 & 30 
2. 3786 SELVAMANI 82 86 125 132 234 266 189 192 3.5 3.4 2 & 15 2 & 15 5 & 30 5 & 15 
3. 5791 JOTHI 76 81 120 126 319 330 152 147 2.2 2.0 3 & 30 3 & 45 6 & 15 6 & 30 
4. 6197 PONMALAR 102 100 141 135 280 310 160 151 2.7 2.5 1 & 45 1 & 50 4 & 15 4 & 15 
5. 6055 MAALA 81 78 161 150 241 275 146 158 2.6 2.4 2 & 45 2 & 30 5 & 15 5 & 10 
6. 6577 VIJAYA 96 90 137 130 234 260 186 183 2.3 3.0 3 & 15 3 & 30 5 & 45 5 & 30 
7. 6988 SUSHILA 94 85 135 126 221 239 179 166 4.8 4.4 2 & 15 2 & 20 4 & 35 4 & 35 
8. 1360 SHANMUGAM 98 100 143 145 296 306 231 224 4.1 4.0 3 & 30  3 & 20 5 & 15 5 & 10 
9. 9097 SUGUNA 77 80 138 140 429 419 179 184 3.5 3.5 2 & 45 2 & 40 4 & 30 4 & 45 
10. 450 PREM KUMAR 85 90 129 130 313 316 216 215 3.4 3.4 3 & 15 3 & 30 5 & 30 5 & 30 
11. 2240 SAIGEETHA 107 110 207 212 293 310 185 191 2.9 3.0 2 & 10 2 & 10 4 & 30 4 & 10 
12. 2683 MANJULA 84 90 143 145 243 251 174 180 4.8 4.9 3 & 15 3 & 20 5 & 30 5 & 15 
13. 2685 VIMALA SRI 79 85 128 133 194 215 169 164 2.6 2.5 2 & 30 2 & 15 4 & 15 4 & 15 
14. 4069 AMUDHA 88 85 137 130 296 303 173 170 2.4 2.3 2 & 45 2 & 30 4 & 30 4 & 20 
15. 4511 SUGANYA 96 100 145 145 322 353 176 171 5.8 5.5 3 & 10 2 & 45 5 & 15 4 & 45 
16. 6512 
SHANMUGA 
   SUNDARAM 101 110 152 150 242 290 187 184 4.1 4.0 3 & 15 3 & 15 5 & 45 5 & 40 
17. 7866 VALLI 89 84 131 120 214 247 193 190 3.5 3.4 2 & 20 2 & 15 4 & 10 4 & 10 
18. 9354 SHANTHI 95 90 134 138 247 294 193 205 3.8 3.7 2 & 10 2 & 15 4 & 15 4 & 15 
19. 495 SUNDAR 83 80 125 126 212 260 200 205 2.4 2.2 2 & 30 2 & 15 4 & 45 4 & 30 
20. 1086 DURGA DEVI 77 70 148 145 264 308 185 190 4.2 4.4 2 & 15 2 & 30   4 & 45 4 & 40 
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GROUP II SUBJECTS: BLOOD INVESTIGATIONS 
S. 
N 
O 
OP. 
NO NAME 
  BLOOD SUGAR 
PLT (103 
     ×mm3) 
S. CHOLESTEROL 
           (mg/dl) 
S. URIC 
ACID 
(mg/dl) 
BLEEDING 
    TIME 
( in mins & secs) 
CLOTTING 
     TIME 
(in mins & secs) 
    FBS    PPBS 
BT AT      BT     AT BT AT    BT    AT BT AT BT AT BT AT 
1. 656 MALLIKA 103 98 151 143 246 240 163 170 2.7 2.5 2 & 30 2 & 30 4 & 15 4 & 10 
2. 793 TAMIL SELVI 83 80 148 135 302 310 187 190 3.7 4.0 2 & 15 2 & 10 5 & 30 5 & 10 
3. 983 R.SUSHEELA 98 78 165 143 256 290 133 130 2.5 2.3 2 & 45 2 & 30 4 & 30 4 & 15 
4. 1346 KAVERI 100 95 154 148 248 256 145 151 3.0 3.0 2 & 15 2 & 45 4 & 45 4 & 45 
5. 4717 PONN AZHAGU 95 100 130 140 341 330 189 188 4.4 4.3 2 & 30 2 & 15 4 & 15 4 & 15 
6. 4411 MEGALAI 87 85 141 135 310 351 184 190 3.9 4.0 2 & 15 2 & 30 4 & 30 4 & 45 
7. 8324 KANCHANA 78 70 127 110 206 200 163 165 2.2 2.0 2 & 30 2 & 15 4 & 15 4 & 30 
8. 9239 HEMALATHA 86 75 130 115 217 215 154 153 2.8 2.5 2 & 15 2 & 30 4 & 35  4 & 30 
9. 9704 GOKILA 87 85 128 126 194 196 163 174 2.5 2.5 3 & 15 2 & 45 5 & 30 4 & 45 
10. 1731 JEEVA 104 98 155 153 244 250 179 170 3.5 3.1 2 & 20 2 & 30 4 & 15  4 & 30 
11. 5249 NIRMALA 79 85 123 141 193 255 184 182 5.4 5.4 2 & 10 2 & 10 4 & 15 3 & 45 
12. 3466 VENKATESAN 85 80 145 145 254 240 169 170 4.3 4.2 3 & 10 2 & 45 5 & 15 4 & 30 
13. 6129 SARASWATHI 76 86 126 140 278 280 167 170 3.7 3.6 3 & 15 3 & 15 5 & 10 4 & 45 
14. 8044 P.VIJAYA 98 85 141 140 315 325 185 181 4.6 4.5 3 & 30 3 & 15 6 & 15 5 & 45 
15. 8243 LILLY 102 105 128 132 145 145 270 266 2.6 2.6 2 & 45 2 & 40 5 & 15  5 & 45 
16. 8689 YUVARANI 89 90 139 140 269 280 168 170 2.3 2.1 2 & 30 2 & 30 5 & 45 4 & 50 
17. 9208 EZHILRANI 82 90 148 151 368 370 174 169 3.8 3.2 2 & 25 2 & 20 4 & 30 4 & 20 
18. 2134 SAVITHRI 100 97 140 128 310 305 171 175 3.7 3.5 2 & 20 2 & 15 4 & 45 4 & 30 
19. 7648 RADHA 80 80 125 130 320 300 183 182 2.6 2.2 3 & 15 3 & 15 4 & 45 4 & 30 
20. 7986 K.SHANTHI 93 95 110 126 336 340 187 183 4.3 4.1 2 & 30 2 & 35 4 & 15 4 & 20 
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GROUP III SUBJECTS: BLOOD INVESTIGATIONS 
S. 
N 
O 
OP. 
NO NAME 
  BLOOD SUGAR 
PLT (103 
     ×mm3) 
S. CHOLESTEROL 
           (mg/dl) 
S. URIC 
ACID 
(mg/dl) 
BLEEDING 
    TIME 
( in mins & secs) 
CLOTTING 
   TIME 
(in mins & secs) 
    FBS    PPBS 
BT AT     BT     AT BT AT    BT    AT BT AT BT AT BT AT 
1. 5446 JAGADAMBAL 92 100 140 148 250 260 147 155 3.1 3.3 3 & 15 3 & 30 5 & 15 5 & 30 
2. 5718 PRIYANKA 100 103 146 145 242 284 170 177 3.6 4.0 2 & 30 2 & 15 4 & 30 4 & 30 
3. 8134 VASANTHI 106 98 147 140 302 320 171 163 3.4 3.0 2 & 30 2 & 40 4 & 15 4 & 30 
4. 3976 PARVATHY 75 80 125 136 253 294 160 168 3.5 3.5 2 & 10 2 & 10 4 & 15 4 & 10 
5. 976 KAVITHA 74 80 136 140 173 210 179 182 3.4 3.2 2 & 40 2 & 35 4 & 30 4 & 15 
6. 2315 ABIRAMI 96 100 125 136 185 230 175 171 2.8 2.5 2 & 30  2 & 15 4 & 30 4 & 15 
7. 3408 THILAGA 72 81 130 141 187 261 174 178 3.6 3.6 2 & 15 2 & 15 4 & 45 4 & 45 
8. 5295 BANUMATHY 92 88 140 138 279 300 195 200 2.5 2.0 2 & 40 2 & 30 4 & 15 3 & 45 
9. 5941 VIJAYARANI 84 85 129 135 257 293 176 181 2.8 2.3 2 & 35 2 & 15 4 & 30 4 & 15 
10. 6680 SIVANESAN 71 79 130 141 400 450 191 195 5.6 5.2 1 & 50 2 & 10 4 & 10 4 & 30 
11. 7437 JEYANTHI 87 96 153 150 366 360 193 205 2.2 2.0 2 & 20 2 & 30 4 & 30 4 & 45 
12. 25 SARANYA 94 95 130 145 298 310 164 168 2.7 2.6 2 & 40 2 & 45 4 & 45 4 & 50 
13. 315 KRISHNAVENI 81 89 128 138 287 322 155 162 5.9 6.0 2 & 30 2 & 45 6 & 15 5 & 45 
14. 1167 KODIARASI 97 91 135 130 220 261 166 169 4.2 4.2 3 & 10 2 & 45 5 & 45 5 & 30 
15. 3629 SELVI 78 82 129 138 264 275 176 178 2.5 2.5 2 & 45 2 & 35 5 & 30 5 & 15 
16. 7633 SIVAKUMAR 91 100 142 146 268 307 157 160 2.2 2.2 2 & 15 2 & 15 4 & 30 4 & 35 
17. 3361 SUNDARI 102 110 200 180 251 278 165 171 3.8 3.6 2 & 45 2 & 30 4 & 45 4 & 30 
18. 3288 SALIKA BANU 78 83 137 135 341 360 179 175 4.3 4.2 3 & 30 3 & 10 5 & 30 5 & 15 
19. 6300 MOHAN BABU 90 98 102 120 364 350 176 172 3.5 3.2 3 & 15 2 & 45 5 & 30 5 & 15 
20. 6363 ROSIE 62 75 103 118 279 291 155 160 4.8 4.5 2 & 45 2 & 15 4 & 15 4 & 20 
 
   
 
170 
 
GROUP I SUBJECTS: RENAL FUNCTION TEST 
S.NO OP.NO          NAME 
               S. UREA      
                (mg/dl) 
                       S. CREATININE 
                               (mg/dl) 
BT AT    BT   AT 
1. 653 AAMINA 24 22 0.5 0.4 
2. 3786 SELVAMANI 22 21 0.8 0.6 
3. 5791 JOTHI 18 18 1 0.8 
4. 6197 PONMALAR 21 19 0.6 0.5 
5. 6055 MAALA 22 19 0.5 0.5 
6. 6577 VIJAYA 20 21 0.5 0.4 
7. 6988 SUSHILA 14 12 0.6 0.4 
8. 1360 SHANMUGAM 15 15 0.6 0.5 
9. 9097 SUGUNA 20 20 0.5 0.4 
10. 450 PREM KUMAR 18 18 0.7 0.7 
11. 2240 SAIGEETHA 25 23 0.6 0.5 
12. 2683 MANJULA 21 21 0.5 0.4 
13. 2685 VIMALA SRI 24 22 0.7 0.5 
14. 4069 AMUDHA 21 21 0.4 0.3 
15. 4511 SUGANYA 27 25 0.5 0.4 
16. 6512 
SHANMUGA 
   SUNDARAM 20 19 0.4 0.4 
17. 7866 VALLI 14 15 0.5 0.5 
18. 9354 SHANTHI 20 20 0.6 0.5 
19. 495 SUNDAR 21 19 0.7 0.6 
20. 1086 DURGA DEVI 18 17 0.4 0.4 
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GROUP II SUBJECTS: RENAL FUNCTION TEST 
S.NO OP.NO           NAME 
              S. UREA      
               (mg/dl) 
                      S. CREATININE 
                                (mg/dl) 
BT AT BT AT 
1. 656 MALLIKA 19 19 0.4 0.5 
2. 793 TAMIL SELVI 25 23 0.6 0.5 
3. 983 R.SUSHEELA 39 34 1.2 0.8 
4. 1346 KAVERI 21 20 0.3 0.4 
5. 4717 PONN AZHAGU 22 21 0.4 0.4 
6. 4411 MEGALAI 21 20 0.6 0.5 
7. 8324 KANCHANA 18 18 0.7 0.6 
8. 9239 HEMALATHA 19 18 0.6 0.5 
9. 9704 GOKILA 24 22 0.5 0.5 
10. 1731 JEEVA 20 19 0.5 0.5 
11. 5249 NIRMALA 22 20 0.5 0.4 
12. 3466 VENKATESAN 25 22 0.8 0.6 
13. 6129 SARASWATHI 27 23 0.6 0.5 
14. 8044 P.VIJAYA 19 20 0.9 0.8 
15. 8243 LILLY 25 23 0.7 0.7 
16. 8689 YUVARANI 23 23 0.4 0.4 
17. 9208 EZHILRANI 22 21 0.6 0.6 
18. 2134 SAVITHRI 22 20 0.6 0.5 
19. 7648 RADHA 22 21 0.5 0.4 
20. 7986 K.SHANTHI 18 17 0.4 0.3 
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GROUP III SUBJECTS: RENAL FUNCTION TEST 
S.NO OP.NO       NAME 
               S. UREA      
               (mg/dl) 
                         S. CREATININE 
                                (mg/dl) 
BT AT BT AT 
1. 5446 JAGADAMBAL 22 21 0.7 0.6 
2. 5718 PRIYANKA 20 20 0.4 0.4 
3. 8134 VASANTHI 25 22 0.6 0.5 
4. 3976 PARVATHY 23 22 0.4 0.4 
5. 976 KAVITHA 19 20 0.5 0.4 
6. 2315 ABIRAMI 17 17 0.6 0.4 
7. 3408 THILAGA 33 29 0.7 0.5 
8. 5295 BANUMATHY 24 23 0.6 0.4 
9. 5941 VIJAYARANI 14 14 0.3 0.4 
10. 6680 SIVANESAN 24 20 0.8 0.7 
11. 7437 JEYANTHI 19 19 0.5 0.4 
12. 25 SARANYA 21 18 0.5 0.5 
13. 315 KRISHNAVENI 20 19 0.4 0.4 
14. 1167 KODIARASI 15 16 0.3 0.3 
15. 3629 SELVI 18 17 0.4 0.4 
16. 7633 SIVAKUMAR 21 19 0.6 0.5 
17. 3361 SUNDARI 20 19 0.4 0.4 
18. 3288 SALIKA BANU 21 20 0.5 0.4 
19. 6300 MOHAN BABU 22 19 0.4 0.5 
20. 6363 ROSIE 22 21 0.3 0.3 
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GROUP I SUBJECTS: LIVER FUNCTION TEST 
S.NO OP.NO          NAME 
   T. BILIRUBIN  
         (mg/dl) 
 ALKALINE PHOSPHATASE 
                          (U/L) 
  SGOT 
   (U/L) 
 SGPT 
  (U/L) 
BT AT           BT        AT BT AT BT AT 
1. 653 AAMINA 0.3 0.4 148 147 16 17 13 12 
2. 3786 SELVAMANI 0.2 0.2 163 160 23 22 19 19 
3. 5791 JOTHI 0.5 0.4 189 187 22 20 20 19 
4. 6197 PONMALAR 0.3 0.3 91 90 21 20 30 26 
5. 6055 MAALA 0.2 0.2 123 123 25 23 21 20 
6. 6577 VIJAYA 0.7 0.5 154 152 22 21 18 16 
7. 6988 SUSHILA 0.4 0.3 94 92 18 18 27 24 
8. 1360 SHANMUGAM 0.7 0.6 93 90 18 15 29 25 
9. 9097 SUGUNA 0.7 0.8 156 158 24 23 20 21 
10. 450 PREM KUMAR 0.4 0.3 139 135 37 36 31 31 
11. 2240 SAIGEETHA 0.8 0.7 149 150 23 22 18 16 
12. 2683 MANJULA 0.4 0.4 210 200 31 28 25 22 
13. 2685 VIMALA SRI 0.5 0.5 194 190 25 21 20 18 
14. 4069 AMUDHA 0.6 0.5 98 98 19 18 17 16 
15. 4511 SUGANYA 0.6 0.4 178 170 36 32 42 38 
16. 6512 
SHANMUGA 
   SUNDARAM 0.7 0.7 210 198 30 24 35 20 
17. 7866 VALLI 0.4 0.3 164 158 24 20 23 21 
18. 9354 SHANTHI 0.4 0.4 120 119 24 23 30 27 
19. 495 SUNDAR 0.8 0.6 210 195 31 27 35 31 
20. 1086 DURGA DEVI 0.5 0.5 160 158 28.2 28 26.2 24 
 
   
 
174 
 
GROUP II SUBJECTS: LIVER FUNCTION TEST 
S.NO OP.NO           NAME 
   T. BILIRUBIN  
          (mg/dl) 
    ALKALINE PHOSPHATASE 
                          (U/L) 
    SGOT 
     (U/L) 
    SGPT 
     (U/L) 
BT AT           BT        AT BT AT BT AT 
1. 656 MALLIKA 0.3 0.3 133 131 33 33 21 20 
2. 793 TAMIL SELVI 0.4 0.3 139 135 37 36 31 31 
3. 983 R.SUSHEELA 0.2 0.2 204 202 31 30 33 31 
4. 1346 KAVERI 0.4 0.3 173 173 22 20 17 18 
5. 4717 PONN AZHAGU 0.7 0.5 194 189 36 33 30 26 
6. 4411 MEGALAI 0.5 0.6 196 200 23 25 20 22 
7. 8324 KANCHANA 0.8 0.6 147 143 19 19 22 20 
8. 9239 HEMALATHA 0.6 0.5 105 104 13 14 19 16 
9. 9704 GOKILA 0.7 0.5 158 148 20 15 22 19 
10. 1731 JEEVA 0.7 0.6 159 154 24 22 27 25 
11. 5249 NIRMALA 0.4 0.5 188 188 25 26 20 22 
12. 3466 VENKATESAN 0.6 0.4 167 162 28 25 22 19 
13. 6129 SARASWATHI 0.5 0.6 110 106 19 19 23 23 
14. 8044 P.VIJAYA 0.5 0.3 190 183 23 20 19 15 
15. 8243 LILLY 0.7 0.5 215 212 35 34 30 28 
16. 8689 YUVARANI 0.3 0.4 68 65 22 21 16 15 
17. 9208 EZHILRANI 0.4 0.3 155 152 21 19 17 15 
18. 2134 SAVITHRI 0.4 0.3 196 193 23 21 20 19 
19. 7648 RADHA 0.5 0.4 168 168 27 25 24 24 
20. 7986 K.SHANTHI 0.4 0.4 195 194 17 15 19 16 
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GROUP III SUBJECTS: LIVER FUNCTION TEST 
S.NO OP.NO NAME 
T. BILIRUBIN  
      (mg/dl) 
ALKALINE PHOSPHATASE 
                    (U/L) 
  SGOT 
   (U/L) 
 SGPT 
  (U/L) 
BT AT           BT        AT BT AT BT AT 
1. 5446 JAGADAMBAL 0.6 0.6 210 212 31 30 25 25 
2. 5718 PRIYANKA 0.4 0.4 192 193 25.7 25 20.6 20 
3. 8134 VASANTHI 0.3 0.4 90 90 13 14 17 16 
4. 3976 PARVATHY 0.3 0.3 163 164 24 24 21 19 
5. 976 KAVITHA 0.6 0.4 175 172 26 25 23 23 
6. 2315 ABIRAMI 0.5 0.5 133 134 34 33 22 20 
7. 3408 THILAGA 0.3 0.3 153 149 19 20 24 22 
8. 5295 BANUMATHY 0.5 0.4 154 150 20 19 23 20 
9. 5941 VIJAYARANI 0.4 0.4 98 100 13 14 18 15 
10. 6680 SIVANESAN 0.3 0.4 125 124 15 14 9 9 
11. 7437 JEYANTHI 0.2 0.2 138 137 24 22 28 24 
12. 25 SARANYA 0.3 0.3 183 184 25 22 23 22 
13. 315 KRISHNAVENI 0.5 0.5 178 179 13.7 13 11 11 
14. 1167 KODIARASI 0.6 0.5 165 163 15 15 19 18 
15. 3629 SELVI 0.3 0.3 147 145 25 24 21 20 
16. 7633 SIVAKUMAR 0.3 0.4 188 183 31 27 34 30 
17. 3361 SUNDARI 0.7 0.5 176 171 30 28 26 23 
18. 3288 SALIKA BANU 0.6 0.6 195 188 21 16 19 13 
19. 6300 MOHAN BABU 0.5 0.5 187 185 25 24 20 20 
20. 6363 ROSIE 0.6 0.4 191 185 33 30 35 27 
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GROUP I SUBJECTS: URINE ANALYSIS 
S.NO OP.NO           NAME 
    SUGAR    ALBUMIN 
                      DEPOSITS 
                       (Pus cells) 
BT AT BT AT BT AT 
1. 653 AAMINA NIL NIL NIL NIL 1 - 4 cells 1 – 2 cells  
2. 3786 SELVAMANI NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
3. 5791 JOTHI NIL NIL NIL NIL 10 – 12 cells 5 – 10 cells 
4. 6197 PONMALAR NIL NIL NIL NIL 2 – 3 cells 1 – 2 cells 
5. 6055 MAALA NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
6. 6577 VIJAYA NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
7. 6988 SUSHILA NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
8. 1360 SHANMUGAM NIL NIL NIL NIL 1 – 3 cells 1 – 4 cells 
9. 9097 SUGUNA NIL NIL NIL NIL 2 – 4 cells 1 – 3 cells 
10. 450 PREM KUMAR NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
11. 2240 SAIGEETHA NIL NIL NIL NIL 4 – 6 cells 2 – 5 cells  
12. 2683 MANJULA NIL NIL NIL NIL 2 – 4 cells 2 – 3 cells 
13. 2685 VIMALA SRI NIL NIL NIL NIL 2 – 6 cells 2 – 4 cells 
14. 4069 AMUDHA NIL NIL NIL NIL 1 – 4 cells 1 – 3 cells 
15. 4511 SUGANYA NIL NIL NIL NIL 0 – 1 cells 1 – 2 cells 
16. 6512 
SHANMUGA 
   SUNDARAM NIL NIL NIL NIL 2 – 3 cells 0 – 1 cells 
17. 7866 VALLI NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
18. 9354 SHANTHI NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
19. 495 SUNDAR NIL NIL NIL NIL 2 – 6 cells 2 – 4 cells 
20. 1086 DURGA DEVI NIL NIL NIL NIL 1 – 4 cells 0 – 2 cells 
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GROUP II SUBJECTS: URINE ANALYSIS 
S.NO OP.NO             NAME 
     SUGAR   ALBUMIN 
                    DEPOSITS 
                    (Pus cells) 
BT AT BT AT BT AT 
1. 656 MALLIKA NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
2. 793 TAMIL SELVI NIL NIL NIL NIL 1 – 4 cells 2 – 4 cells 
3. 983 R.SUSHEELA NIL NIL NIL NIL 1 – 3 cells 2 – 3 cells 
4. 1346 KAVERI NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
5. 4717 PONN AZHAGU NIL NIL NIL NIL 2 – 5 cells 2 – 4 cells 
6. 4411 MEGALAI NIL NIL NIL NIL 0 – 3 cells 0 – 2 cells 
7. 8324 KANCHANA NIL NIL NIL NIL 1 – 4 cells 0 – 1 cells 
8. 9239 HEMALATHA NIL NIL NIL NIL 2 – 6 cells 1 – 3 cells 
9. 9704 GOKILA NIL NIL NIL NIL 2 – 4 cells 2 – 4 cells 
10. 1731 JEEVA NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
11. 5249 NIRMALA NIL NIL NIL NIL 1 – 3 cells 2 – 4 cells 
12. 3466 VENKATESAN NIL NIL NIL NIL 2 – 6 cells 1 – 3 cells 
13. 6129 SARASWATHI NIL NIL NIL NIL 1 – 4 cells 0 – 2 cells 
14. 8044 P.VIJAYA NIL NIL NIL NIL 1 – 3 cells 2 – 4 cells 
15. 8243 LILLY NIL NIL NIL NIL 4 – 7 cells 1 – 3 cells 
16. 8689 YUVARANI NIL NIL NIL NIL 1 – 4 cells 1 – 2 cells 
17. 9208 EZHILRANI NIL NIL NIL NIL 4 – 5 cells 1 – 3 cells 
18. 2134 SAVITHRI NIL NIL NIL NIL 2 – 6 cells 1 – 3 cells 
19. 7648 RADHA NIL NIL NIL NIL 1 – 2 cells 1 - 3 cells 
20. 7986 K.SHANTHI NIL NIL NIL NIL 2 – 4 cells 2 – 4 cells 
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GROUP III SUBJECTS: URINE ANALYSIS 
S.NO OP.NO            NAME 
      SUGAR     ALBUMIN 
                DEPOSITS 
                 (Pus cells) 
BT AT BT AT BT AT 
1. 5446 JAGADAMBAL NIL NIL NIL NIL 2 – 4 cells 2 – 3 cells 
2. 5718 PRIYANKA NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
3. 8134 VASANTHI NIL NIL NIL NIL 1 – 4 cells 1 – 3 cells 
4. 3976 PARVATHY NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
5. 976 KAVITHA NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
6. 2315 ABIRAMI NIL NIL NIL NIL 2 – 4 cells 1 – 3 cells 
7. 3408 THILAGA NIL NIL NIL NIL 4 – 6 cells 2 – 5 cells 
8. 5295 BANUMATHY NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
9. 5941 VIJAYARANI NIL NIL NIL NIL 1 – 3 cells 1 – 2 cells 
10. 6680 SIVANESAN NIL NIL NIL NIL 2 – 4 cells 1 – 3 cells 
11. 7437 JEYANTHI NIL NIL NIL NIL 2 – 4 cells 2 – 4 cells 
12. 25 SARANYA NIL NIL NIL NIL 2 – 4 cells 0 – 2 cells 
13. 315 KRISHNAVENI NIL NIL NIL NIL 1 – 4 cells 1 – 2 cells 
14. 1167 KODIARASI NIL NIL NIL NIL 2 – 4 cells 1 – 4 cells 
15. 3629 SELVI NIL NIL NIL NIL 1 – 2 cells 1 – 2 cells 
16. 7633 SIVAKUMAR NIL NIL NIL NIL 1 – 2 cells 1 – 3 cells 
17. 3361 SUNDARI NIL NIL NIL NIL 2 - 3 cells 1 – 2 cells 
18. 3288 SALIKA BANU NIL NIL NIL NIL 1 – 3 cells 1 – 3 cells 
19. 6300 MOHAN BABU NIL NIL NIL NIL 1 - 2 cells 2 – 3 cells 
20. 6363 ROSIE NIL NIL NIL NIL 0 cells 0 – 2 cells 
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GROUP I SUBJECTS: SPECIAL INVESTIGATIONS 
S.NO OP.NO             NAME 
                  CRP                    ANTI-CCP 
BT AT BT AT 
1. 653 AAMINA 3.9 2.8 9.9 6.5 
2. 3786 SELVAMANI 10.2 8 188.7 183 
3. 5791 JOTHI 2.9 1.5 170.6 168 
4. 6197 PONMALAR 15 9 200.5 188 
5. 6055 MAALA 4.4 2 98.3 94 
6. 6577 VIJAYA 26 25 205 203 
7. 6988 SUSHILA 35 30 210 203 
8. 1360 SHANMUGAM 16 8 200 188 
9. 9097 SUGUNA 5.4 6 220 216 
10. 450 PREM KUMAR 15 13 482 478 
11. 2240 SAIGEETHA 7.3 4 160 150 
12. 2683 MANJULA 8.2 4 43 38 
13. 2685 VIMALA SRI 13.6 9.3 84 77 
14. 4069 AMUDHA 20 15 36 30 
15. 4511 SUGANYA 5.3 5 150 142 
16. 6512 
SHANMUGA 
   SUNDARAM 19 17 45 39 
17. 7866 VALLI 9.6 9 68 63 
18. 9354 SHANTHI 5.8 5.5 15 8 
19. 495 SUNDAR 9 7.5 12 8 
20. 1086 DURGA DEVI 7.8 5 30 28 
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GROUP II SUBJECTS: SPECIAL INVESTIGATIONS 
S.NO OP.NO              NAME 
               CRP                     ANTI-CCP 
BT AT BT AT 
1. 656 MALLIKA 7.8 7.3 310 309 
2. 793 TAMIL SELVI 43 40 80.3 75 
3. 983 R.SUSHEELA 39 38 110 109 
4. 1346 KAVERI 9.1 9 85 81 
5. 4717 PONN AZHAGU 12 12 153 146 
6. 4411 MEGALAI 15 14 37 36 
7. 8324 KANCHANA 29 25 74 69 
8. 9239 HEMALATHA 5.6 5 22 18 
9. 9704 GOKILA 6.3 4.3 26 21 
10. 1731 JEEVA 15 10 48 44 
11. 5249 NIRMALA 96 90 110 108 
12. 3466 VENKATESAN 48 40 54 48 
13. 6129 SARASWATHI 40 36 67 60.3 
14. 8044 P.VIJAYA 11 10 48 44 
15. 8243 LILLY 40.7 37 135 128 
16. 8689 YUVARANI 2.5 2.5 6.2 5 
17. 9208 EZHILRANI 48 43 8 4.6 
18. 2134 SAVITHRI 12 8 65 60 
19. 7648 RADHA 18 15 58 52 
20. 7986 K.SHANTHI 9 5 34 28 
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GROUP III SUBJECTS: SPECIAL INVESTIGATIONS 
S.NO OP.NO            NAME 
               CRP                   ANTI-CCP 
BT AT BT AT 
1. 5446 JAGADAMBAL 31 26 200 184 
2. 5718 PRIYANKA 180 178 162.3 155 
3. 8134 VASANTHI 30 21 193.8 189 
4. 3976 PARVATHY 10.1 7 124 112 
5. 976 KAVITHA 24 21 20 9 
6. 2315 ABIRAMI 100 98 123 117 
7. 3408 THILAGA 35 30 96 88 
8. 5295 BANUMATHY 55 43 69 61 
9. 5941 VIJAYARANI 8 4 18 11 
10. 6680 SIVANESAN 3.7 3 220 214 
11. 7437 JEYANTHI 51 49 100 98 
12. 25 SARANYA 66 63 140 139 
13. 315 KRISHNAVENI 7.6 5 33.9 30 
14. 1167 KODIARASI 54 46 130 122 
15. 3629 SELVI 26 15 76 71 
16. 7633 SIVAKUMAR 25 15 110 103 
17. 3361 SUNDARI 36 28 124 116 
18. 3288 SALIKA BANU 79 70 188 179 
19. 6300 MOHAN BABU 12 5 45 35 
20. 6363 ROSIE 15 6 24 15 
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STATISTICAL ANALYSIS - CLINICAL PROGNOSIS 
IMPROVEMENT OF GROUP I SUBJECTS:  
          Improvement in subjects treated with internal trial drug “SAMUTHARA 
CHOORANAM” in group I subjects 
The most popular non parametric statistical tool, namely, McNemar Test analysis 
has been employed to analyses the effectiveness with the help of a hypothesis. 
                                  
                                IMPROVEMENT OF GROUP I SUBJECTS  
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. PAIN AND SWELLING OF 
PIP JOINT 
16(80) 2(10)** 
2. MORNING STIFFNESS > 1 hr 18(90) 4(20)** 
3. TENDERNESS 10(50) 1(5)** 
4. LOW GRADE FEVER 4(20) 2(10)* 
5. ARTHRITIS OF MORE THAN 
3 JOINTS 
19(95) 2(10)** 
6. RESTRICTION OF 
MOVEMENTS 
10(50) 2(10)** 
7. LOSS OF APPETITE 8(40) 3(15)* 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
 
Inference:  
Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of Uthiravadha 
Suronitham (Rheumatoid Arthritis). Hence it is concluded that the treatment was effective 
and significant. 
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IMPROVEMENT IN GROUP II SUBJECTS:  
          Improvement in subjects treated with external trial drug “VADHA NOIKU 
VELIPRAYOGHA THAILAM & OTTRADAM” in group II subjects 
The most popular non parametric statistical tool, namely, McNemar Test analysis 
has been employed to analyses the effectiveness with the help of a hypothesis. 
 
                                   IMPROVEMENT OF GROUP II SUBJECTS 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. PAIN AND SWELLING OF 
PIP JOINT 
14(70) 3(15)** 
2. MORNING STIFFNESS > 1 hr 14(70) 3(15)** 
3. TENDERNESS 7(35) 1(5)* 
4. LOW GRADE FEVER 4(20) 2(10)* 
5. ARTHRITIS OF MORE THAN 
3 JOINTS 
19(95) 3(15)** 
6. RESTRICTION OF 
MOVEMENTS 
10(50) 3(15)* 
7. LOSS OF APPETITE 8(40) 3(15)* 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of Uthiravadha 
Suronitham (Rheumatoid Arthritis). Hence it is concluded that the treatment was effective 
and significant. 
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 IMPROVEMENT IN GROUP III SUBJECTS:  
Improvement in subjects treated with internal and external trial drug 
“SAMUTHARA CHOORANAM” and “VADHA NOIKU VELIPRAYOGHA 
THAILAM’ respectively & “OTTRADAM” in group III subjects.  
The most popular non parametric statistical tool, namely, McNemar Test analysis 
has been employed to analyses the effectiveness with the help of a hypothesis. 
 
                              IMPROVEMENT OF GROUP III SUBJECTS 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. PAIN AND SWELLING OF 
PIP JOINT 
18(90) 2(10)** 
2. MORNING STIFFNESS > 1 
hr 
15(75) 1(5)** 
3. TENDERNESS 9(45) 1(5)** 
4. LOW GRADE FEVER 7(35) 1(5)* 
5. ARTHRITIS OF MORE 
THAN 3 JOINTS 
19(95) 2(10)** 
6. RESTRICTION OF 
MOVEMENTS 
8(40) 2(10)* 
7. LOSS OF APPETITE 10(40) 2(10)* 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of Uthiravadha 
Suronitham (Rheumatoid Arthritis). Hence it is concluded that the treatment was effective 
and significant. 
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Group I Subjects :Liver Function Test 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P 
value 
2 SGPT 24.96±7.37 22.3±6.18 <0.05 
3 SGOT 24.86±5.76 22.90±5.14 <0.001 
4 Alkaline Phosphatase 152.15±39.59 148.5±36.73 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
Group II Subjects :Liver Function Test 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 22.6±5.01 21.2±5.05 <0.05 
3 SGOT 24.90±6.60 23.60±6.63 <0.05 
4 Alkaline Phosphatase 163.00±37.75 160.10±38.23 <0.001 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
 
Group III Subjects :Liver Function Test 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
2 SGPT 21.93±6.23 19.85±5.19 <0.001 
3 SGOT 23.17±6.77 21.95±6.11 <0.05 
4 Alkaline Phosphatase 162.05±32.39 160.40±31.64 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
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GROUP I SUBJECTS :RFT 
 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 20.25±3.44 19.35±3.01 <0.05 
2 Creatinine 0.58±0.14 0.48±0.11 <0.001 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant.  
 
GROUP II SUBJECTS :RFT 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 22.65±4.60 21.20±3.50 <0.001  
2 Creatinine 0.59±0.20 0.52±0.13 <0.05  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP III SUBJECTS :RFT 
 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 21.00±4.01 19.75±3.05 <0.05  
2 Creatinine 0.49±0.14 0.44±0.09 <0.05  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
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GROUP I SUBJECTS: BLOOD INVESTIGATION 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.42±1.69 12.31±1.70 <0.001 
2 ESR1hr 35.20±17.44 31.00±16.51 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
 
GROUP II SUBJECTS: BLOOD INVESTIGATION 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 10.75±0.84 11.22±0.72 <0.05 
2 ESR1 hr 31.60±10.45 29.95±8.95 <0.05  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP III SUBJECTS:BLOOD INVESTIGATION 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.09±1.34 11.89±1.23 <0.001  
2 ESR1 hr 35.50±15.72 30.10±12.46 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
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GROUP I SUBJECTS: SPECIAL INVESTIGATIONS 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 CRP 11.97±8.20 9.33±7.47 <0.001  
2 Anti CCP 131.40±112.95 125.52±112.63 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP II SUBJECTS: SPECIAL INVESTIGATIONS 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 CRP 25.35±22.85 22.55±21.45 <0.001  
2 Anti CCP 76.52±67.80 72.29±68.11 <0.001 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP III SUBJECTS: SPECIAL INVESTIGATIONS 
S.No. Investigations Before Treatment 
Mean±SD 
n= 20 
After Treatment 
Mean±SD 
n= 20 
P value 
1 CRP 42.42±41.30 36.65±41.99 <0.001  
2 Anti CCP 109.85±62.83 102.40±62.78 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
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         6. DISCUSSION 
 Rheumatoid arthritis(RA) is a chronic inflammatory syndrome with a strong 
autoimmune component(autoantigens) are neither tissue nor organ-specific, but comprise 
a broad collection of post-translational modified proteins, such as citrullinated proteins. 
Both innate and adaptive mechanisms will closely interplay to promote chronic 
inflammation in peripheral joints (PIP, MCP, MTP & Wrist joints) more often and very 
rarely after the larger joints. 
 The disease Rheumatoid arthritis signs and symptoms were correlates with the 
symptoms of Uthiravadha Suronitham mentioned in the siddha literature Yugi Vaithiya 
Chindhamani. 
 The drugs in the SAMUTHARA CHOORANAM and VADHA NOIKU 
VELIPRAYOGHA THAILAM possesses anti-vadha and anti-spasmodic actions as 
indicated in the siddha literature Gunapadam-Mooligai & Thadhu Seeva Vagupu were 
selected as Internal and External medicines respectively for the clinical evaluation on 
Uthiravadha Suronitham (Rheumatoid arthritis). 
 After getting proper Authentication from the Head of the Department of Medicinal 
Botany & Gunapadam (Pharmacology) and after conducting the proper analysis of 
Toxicological & Pharmacological study for the Internal trial medicine (Samuthara 
Chooranam), the medicine was administered to the patients. 
 60 patients were admitted for the trial in the outpatient ward (Room No:4). Out of 
which 20 patients was treated with Internal medicine alone (Group I), 20 patients was 
treated with External medicine with Ottradam(Group II), 20 patients was treated with 
Internal, External medicine & Ottradam(Group III) and guided by the Head of the 
Department of Sirappu Maruthuvam, GSMC, Chennai-106. 
 Progress of the patients was followed and documented regularly. Various criteria 
like Distribution of Gender, Age, Diet, Occupational & Socio-Economic status were 
assessed. Clinical manifestation and assessment of the enhancement in the prognosis of the 
disease(RA) with the trial drugs along with ottradam were taken into account for evaluating 
the Efficacy of the trial drugs. 
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GENDER: 
 13.3% of Patients were in the gender of male 
 86.7% of Patients were in the gender of female 
AGE: 
 8.3% of Patients were in the age group of 21-30 
 28.3% of Patients were in the age group of 31-40 
 26.6% of Patients were in the age group of 41-50 
 36.6% of Patients were in the age group of 51-60 
OCCUPATIONAL STATUS: 
 56.6% of Patients was Homemakers were affected 
 18.3% of Patients was Employees were affected 
6.6% of Patients was Labours were affected  
Mostly Homemakers and Employees were affected 
SOCIO-ECONOMIC STATUS: 
 50% of Patients were affected in the socio-economic status of lower income group 
because of the low nutrition, poor hygiene and poor immunity.  
DIET: 
 80% of Patients were Non-vegetarian and only 20% of Patients were Vegetarian. 
DURATION OF ILLNESS: 
 25% of Patients had illness for 2-3 years 
 18.3% of Patients had illness upto 6 months 
 16.6% of Patients had illness for 4-6 years 
 15% of Patients had illness for 1-2 years 
 11.6% of Patients had illness for 6 months – 1 year 
10% of Patients had illness for 3-4years 
3.3% of Patients had illness for 6-10 years 
MODE OF ONSET: 
 51.6% of Patients were in the Sub-acute stage of the disease (6 month – 3 years) 
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CLINICAL FEATURES: 
 80% of Patients merely have all the above said clinical features of the presenting 
illness. 
CLINICAL PROGRESS WITH INTERNAL MEDICINE: 
 80% of Patients got relief from Pain, Morning stiffness, Inflammation and 
Restriction of movements. 
 About 70-75% of Patients had the progress in their clinical features when treated 
with providing Internal medicine alone. 
CLINICAL PROGRESS WITH EXTERNAL MEDICINE AND OTTRADAM: 
 75% of Patients got relief from Pain, Morning stiffness, Inflammation and 
Restriction of movements. 
 About 65-70% of Patients had the progress in their clinical features when treated 
with providing External medicine and Ottradam. 
CLINICAL PROGRESS WITH INTERNAL, EXTERNAL MEDICINE AND 
OTTRADAM: 
  80% of Patients got relief from Pain, Morning stiffness, Inflammation and 
Restriction of movements. 
 About 70-75% of Patients had the progress in their clinical features when treated 
with providing Internal medicine, External medicine and Ottradam. 
 
RESULTS: 
 
GROUP I SUBJECTS (INTERNAL MEDICINE): 
Among 20 cases, 16 cases(80%) had pain and swelling of PIP joints, 18 cases(90%) 
had morning stiffness > 1hr, 10 cases(50%) had tenderness, 4 cases(20%) had low grade 
fever, 19 cases(95%) had arthritis of more than 3 joints, 10 cases(50%) had restriction of 
movements, 8 cases(40%) had loss of appetite before treatment. But after treatment only 2 
cases(10%) had pain and swelling of PIP joints, 4 cases(20%) had morning stiffness > 1hr, 
1 cases(5%) had tenderness, 2 cases(10%) had low grade fever, 2 cases(10%) had arthritis 
of more than 3 joints, 2 cases(10%) had restriction of movements, 3 cases(15%) had loss 
of appetite. 
                                                                                                              DISCUSSION/2018 
192 
 
GROUP II SUBJECTS (EXTERNAL MEDICINE AND OTTRADAM): 
Among 20 cases, 14 cases(70%) had pain and swelling of PIP joints, 14 cases(70%) 
had morning stiffness > 1hr, 7 cases(35%) had tenderness, 4 cases(20%) had low grade 
fever, 19 cases(95%) had arthritis of more than 3 joints, 10 cases(50%) had restriction of 
movements, 8 cases(40%) had loss of appetite before treatment. But after treatment only 3 
cases(15%) had pain and swelling of PIP joints, 3 cases(15%) had morning stiffness > 1hr, 
1 cases(5%) had tenderness, 2 cases(10%) had low grade fever, 3 cases(15%) had arthritis 
of more than 3 joints, 3 cases(15%) had restriction of movements, 3 cases(15%) had loss 
of appetite. 
 
GROUP III SUBJECTS (INTERNAL, EXTERNAL MEDICINE AND 
OTTRADAM): 
Among 20 cases, 18 cases(90%) had pain and swelling of PIP joints, 15 cases(75%) 
had morning stiffness > 1hr, 9 cases(45%) had tenderness, 7 cases(35%) had low grade 
fever, 19 cases(95%) had arthritis of more than 3 joints, 8 cases(40%) had restriction of 
movements, 10 cases(50%) had loss of appetite before treatment. But after treatment only 
2 cases(10%) had pain and swelling of PIP joints, 1 cases(5%) had morning stiffness > 1hr, 
1 cases(5%) had tenderness, 1 cases(5%) had low grade fever, 2 cases(10%) had arthritis 
of more than 3 joints, 2 cases(10%) had restriction of movements, 2 cases(10%) had loss 
of appetite. 
 
OVERALL RESULTS: 
Among 60 cases, 47 cases(78%) had good improvement, 6 cases(10%) had 
moderate improvement and 7 cases(12%) had mild improvement. 
 
GRADING OF RESULTS: 
 There is certainly marked improvement noted in the grading of the result before 
and after treatment. 
 
 
                                                                                                              DISCUSSION/2018 
193 
 
STATISTICAL REPORT: 
Inference: 
 Since the p value is significant in all clinical features, so there is significant 
reducing of clinical features among the patients for the treatment of Uthiravadha 
Suronitham (Rheumatoid arthritis). Hence it is concluded that the treatment was 
effective and significant. 
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          7. SUMMARY  
 The primary purpose of the study is to analyse my trial drugs in the disease 
Uthiravadha Suronitham (Rheumatoid Arthritis). 
 Many literature reviews in both siddha and modern textbooks has been collected 
for the disease Uthiravadha Suronitham and Rheumatoid Arthritis respectively. Literature 
reviews has also been collected from siddha and modern textbooks as well as from various 
articles for the ingredients in the trial drugs. 
 The trial drugs Internal and External medicine along with Ottradam has been 
approved by Institutional Ethics Committee(IEC No: GSMC-CH-ME-5/011/2016). 
 After getting proper permission from the Institutional Animal Ethics 
Committee(IAEC No: XLVIII/23/CLBMCP/2016), Acute and Sub-acute Toxicity for 
the trial drug SAMUTHARA CHOORANAM was carried out in Wistar albino rats. 
 Standardization and Quality Evaluation(NRS/AS/0084) for the trial drug 
SAMUTHARA CHOORANAM was carried out in several methods which includes 
Organaoleptic characters, Qualitative and Quantitative Analysis, TLC & HPTLC 
evaluation, Heavy Metal Analysis, Phytochemical analysis and Sterility Test. 
 Pharmacological study (Immunomodulator activity) for the trial drug 
SAMUTHARA CHOORANAM was done in-vitro method by using RAW 264.7 Cell line. 
 The patients with raised CRP, Anti-CCP, along with the clinical symptoms 
mentioned in inclusion criteria were included in my clinical trial. 
 Before conducting the clinical trial, the details about the trial drug and my study 
was informed to the patients in their vernacular language and their signature were obtained 
in the consent forms. Separate Proforma was maintained for each and every patient. 
  After completing all above studies and procedures, the clinical study was conducted 
in 60 patients. Out of which 20 were treated with Internal medicine (Group I), 20 patients 
were treated with External medicine with Ottradam(Group II) and 20 patients were treated 
with Internal and External medicine with Ottradam therapy(Group III) 
 The trial drugs SAMUTHARA CHOORANAM at the dose of 2 grams (twice 
daily) and VADHA NOIKU VELIPRAYOGHA THAILAM of 50ml (per week) with 
OTTRADAM were administered to the above said group patients for 48 days. 
  SUMMARY/2018 
195 
 
 The Efficacy of the trial drugs were assessed by Reduction in Inflammation of 
joints, Morning stiffness, CRP and Anti-CCP. 
 The Safety of the trial drugs were assessed by comparing the safety parameters LFT 
& RFT before and after treatment. 
 Hence the Statistical Analysis helps to evaluate the EFFICACY and SAFETY of 
the trial drug SAMUTHARA CHOORANAM(Internal), VADHA NOIKU 
VELIPRAYOGHA THAILAM(External) with OTTRADAM(Therapy) in 
Uthiravadha Suronitham (Rheumatoid Arthritis).  
 
 
  
 
   CONCLUSION 
   CONCLUSION/2018 
196 
 
8. CONCLUSION 
As expressed before, various studies have conducted to evaluate whether the trial 
drug Samuthara chooranam(Internal) along with Vadha Noiku Veliprayogha 
Thailam(External) and Ottradam(Therapy) is Efficacy and Safety for the disease 
Uthiravadha suronitham (Rheumatoid Arthritis). 
 
Heavy Metal Analytical study clearly shows that the metal mercury was absent and 
the metal arsenic seems very low trace when compared to the allowed recommended limit 
in the sample Samuthara chooranam. Thus the drug Samuthara chooranam is 
recommended for the clinical trial. 
 
Phytochemical study indicates the presence of rich Flavanoids, Glycosides, 
Steroids, Phenol, Tanin, Saponins and Sugar. This analysis clearly proves that the 
ingredients of Samuthara chooranam has Antioxidant and Immunomodulator activity 
which helps to reduce the inflammation in RA. 
 
Acute oral toxic study and Repeated dose 28-day oral toxic study was done in 
Wistar Albino Rats for the sample Samuthara chooranam and hence no other significant 
changes were observed in their behavior, body weight, water intake, food intake, LFT, 
RFT. It proves that the trial drug Samuthara chooranam is safe for animal models. 
 
In Pharmacological study, 25µg/ml concentration of Samuthara chooranam has 
rich level of nitrate(573.21µg) and thus proven to be a potent IMMUNOMODULATOR 
drug. 
 
Overall clinical study with the trial drugs (Internal, External medicine with 
Therapy) for 48days reveals that 78% cases have Good improvement, 10% cases have 
Moderate improvement and 12% cases have mild improvement in patients with 
Uthiravadha suronitham(RA).    
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This study proves that the trial medicines are more Effective in reducing the signs 
and symptoms of Uthiravadha suronitham(RA) such as Inflammation of joints (PIP, MCP, 
Wrist, Ankle), Morning stiffness, Tenderness, Loss of appetite and Restriction of 
movements. 
   
There is no significant changes in LFT and RFT before and after the treatment. No 
Adverse reactions has noted in the clinical study. Hence it proves that the trial medicine 
Samuthara chooranam along with External oil and therapy is safe for human trial. 
 
Finally from all above studies and results, I conclude that my clinical study with 
siddha trial medicine Herbal – Mineral formulation drug “SAMUTHARA 
CHOORANAM” (INTERNAL) a potent Immunomodulator, along with “VADHA 
NOIKU VELIPRAYOGHA THAILAM” (EXTERNAL) and “OTTRADAM” 
(THERAPY) has been proven to be much EFFICACY and SAFETY for treating the 
disease UTHIRAVADHA SURONITHAM (RHEUMATOID ARTHRITIS). 
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Project ID NRS/AS/0084/01/2018 
Name and Address of the Researcher DR.A.B.Kavinaya 
Govt Siddha Medical College, Chennai  
Tamil Nadu, India 
Parameter Requested by the Customer for Analysis Heavy Metal analysis by AAS 
Sample Received Post  
Sample –ID SC 
Description of the Sample Solid 
Method of Analysis 
Instrument 
Extraction Solvent 
 
Model: AA 240 Series 
HCl  
Analysis Type Third Party Analysis  
Date of Analysis 07/02/2018 
Result of Analysis Test Report Attached 
 
 
 
 
 
 
              Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis  
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
HEAVY METAL ANALYSIS BY AAS 
Standard: Hg and As- Sigma 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique for detecting 
metals and metalloids in environmental samples. The total heavy metal content of the sample SC 
was performed by Atomic Absorption Spectrometry (AAS) Model AA 240 Series. In order to 
determination the heavy metals such as mercury and arsenic concentrations in the test sample SC 
Sample Digestion 
Test sample SC digested with 1mol/L HCl for determination of arsenic and mercury.  
Standard reparation 
 As & Hg- 100 ppm sample in 1mol/L HCl 
Test Report of the Sample SC 
Name of the Heavy 
Metal 
Absorption Max 
Λ max 
Result Analysis Maximum Limit 
Mercury 253.7 nm BDL 1 ppm 
Arsenic 193.7 nm 0.268 ppm 3 ppm 
BDL- Below Detection Limit 
Report and Inference 
 Results of the present investigation has clearly shows that the sample SC has no traces of 
Mercury and further shows the presence of Arsenic at 0.268 ppm level and hence it was 
considered that the heavy metals mercury was absent in the sample SC. 
 The reported heavy metal arsenic seems very low (0.268 ppm) when compare to the 
allowed recommended limit of 3ppm. 
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Project ID NRS/AS/0084/01/2018 
Name and Address of the Researcher DR.A.B.Kavinaya 
Govt Siddha Medical College, Chennai  
Tamil Nadu, India 
Parameter Requested by the Customer for Analysis HPTLC Analysis 
Sample Received Post  
Sample –ID SC 
Description of the Sample Solid 
Method of Analysis 
Instrument 
TLC Plate 
Mobile Phase 
Extraction Solvent 
 
CAMAG TLC SCANNER III 
Aluminium Coated Silica Gel – Merck 
Toulene: Ethyl Acetate: Acetic Acid (1.5:1:0.5) 
Acetone 
Analysis Type Third Party Analysis  
Date of Analysis 30/01/2018 
Result of Analysis Test Report Attached 
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TLC Analysis at 254 nm                                                  TLC Analysis at 366 nm 
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HPTLC finger printing of Sample SC 
 
Peak Table 
 
REPORT 
HPTLC finger printing analysis of the sample SC reveals the presence of three prominent peaks 
corresponds to presence of three versatile phytocomponents present with in it. Rf value of the peaks 
ranges from 0.04 to 0.74.  Further the peak 1 occupies the major percentage of area of 48.29 % which 
denotes the abundant existence of such compound. Followed by this peak 3 and 2 occupies the percentage 
area of 31.43 and 20.28 %. 
 
 
 
               Noble Research Solutions     
We Trust in Quality and Ethics 
 
 
 
Services offered: Standardization and Characterization of AYUSH formulations 
In-vitro and In-silico Evaluations/ Instrumental analysis/Histopathological Analysis    
Blood & Serum Estimations 
Thesis Writing/ Research Article Preparation and Publication Services 
E-mail: nobleresearchsolutions@gmail.com 
Contact: 9710437419, Admin: 044 - 42691289 
Project ID NRS/AS/0083/01/2018 
Name and Address of the Researcher Dr.A.B.Kavinaya 
Department of Special Medicine 
Govt Siddha Medical College, Chennai  
Tamil Nadu, India 
Parameter Requested by the Customer for 
Analysis 
Physicochemical Analysis 
Sample Received Post  
Sample –ID Samuthata Chooranam 
SC 
Description of the Sample Solid 
Method of Analysis PLIM- Protocol – ASU Formulations 
Analysis Type Physicochemical Analysis  
Date of Analysis 02/03/2018 
Result of Analysis Test and Analytical Reports Attached As 
Annexures 
Test Report 
S.NO TEST OBSERVATION 
1 ALKALOIDS    - 
2 FLAVANOIDS    + 
3 GLYCOSIDES    + 
4 STEROIDS    + 
5 TRITERPENOIDS    - 
6 COUMARIN    - 
7 PHENOL    + 
8 TANIN    + 
9 PROTEIN    - 
10 SAPONINS    + 
11 SUGAR    + 
12 ANTHOCYANIN    - 
13 BETACYANIN    - 
Note: +-> Indicates Presence and - -> Indicates Absence of the 
Phytocomponents. 
         GOVERNMENT SIDDHA MEDICAL COLLEGE 
     ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                           CHENNAI – 600 106 
 POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON UTHIRAVADHA 
SURONITHAM (RHEUMATOID ARTHRITIS) WITH SIDDHA HERBAL-
MINERAL FORMULATION  DRUG   “SAMUTHARA CHOORANAM”(INT), 
“VADHA NOIKU VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
 
FORM l - SCREENING AND SELECTION PROFORMA 
 
1. OP NO:  ................................................................. 
2. NAME:  ………………………………………….  
3. AGE&GENDER: ………….....  4.OCCUPATION:……………………………  
5.INCOME:   ………………… 
6. ADDRESS:    ……………………………………    
…………………………………… 
…………………………………… 
7. CONTACT NO:    ……………………………………              
 
 
INCLUSION CRITERIA 
 Age: 18-60 Years        YES/NO 
 Sex: Both male & female      YES/NO 
 Low grade fever       YES/NO 
 Pain,swelling & tenderness in interphalangeal joints   YES/NO 
 Pain and swelling in other joints     YES/NO 
 Redness of joint       YES/NO 
 Morning stiffness       YES/NO 
 Anti CCP  +ve        YES/NO 
 CRP +ve                                                                                              YES/NO 
 RA factor +ve /-ve       YES/NO 
 Arthritis of 3 or more joints      YES/NO 
 Patient willing to sign the consent form.    YES/NO 
 
EXCLUSION CRITERIA 
KNOWN CASES OF 
 Rheumatic fever 
 Psoriatic arthropathica  
 Gouty arthritis 
 Systemic lupus erythematosus(SLE) 
 Progressive systemic sclerosis(PSS) 
 History of long term intake of steroids 
 Renal failure 
 Carries spine 
 Ankylosing spondylitis  
 Tumours  
 Osteomyelitis  
 HIV 
 Pregnancy and lactation 
 
ADMITTED TO TRIAL: 
                          YES                        NO                 
 
      If yes,             OPD                  
 
 
 
Date:        
Station: 
 
 
 
Signature of the Guide    Signature of the Investigator  
   GOVERNMENT SIDDHA MEDICAL COLLEGE 
   ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                    CHENNAI – 600 106 
      POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON UTHIRAVADHA 
SURONITHAM (RHEUMATOID ARTHRITIS) WITH SIDDHA HERBAL-
MINERAL FORMULATION  DRUG   “SAMUTHARA CHOORANAM”(INT), 
“VADHA NOIKU VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
       
FORM lI -HISTORY TAKING PROFORMA 
 
1. SERIAL NO OF THE CASE: …….   2.OP/IP NO:……………….  
3. NAME: ………………………………………… 4. AGE & GENDER ………… 
6. OCCUPATION: …………………… 7. INCOME:…………………    
8.COMPLAINTS & DURATION:   
 
 
 
 
 
9. CHIEF COMPLAINTS WITH DURATION 
         Present        Absent        
 Low grade fever 
 Pain in the joints 
 Tenderness & Swelling of joints 
I. MCP 
II. PIP 
III. Wrist 
IV. Ankle 
V. Knee 
 Morning stiffness 
 Restriction of joint movements 
 Loss of appetite  
 Subcutaneous nodules 
 Ulnar deviation 
 Deformities 
 
HISTORY OF PRESENT ILLNESS 
 
1. Onset of disease  :         Acute    Insidious 
 
2. Duration of disease  : 
3. Treatment given so far : Ayurvedic medicine  Modern Medicine 
 
    Unani    Homeopathy 
                                                                                                                                                   
8.PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES, SPECIFY 
DURATION/QUANTI
TY 
Smoking    
Tobacco Chewing    
Alcoholism    
Narcotic drugs    
9. HISTORY OF PREVIOUS ILLNESS/PELVIC SURGERY 
 
 
10. DIETARY HABIT:     
             1.Vegetarian              
             2.Non-vegetarian 
 
11. FAMILY HISTORY: 
               Whether this problem runs in family? 
                                         1. Yes                               2.No         
If yes, mention the relationship of affected person(s) --------------------- 
History of previous investigations if any ------------------------------ 
 
 
Date:                  
Station: 
 
 
Signature of the Guide    Signature of the Investigator  
                     GOVERNMENT SIDDHA MEDICAL COLLEGE 
  ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                CHENNAI – 600 106 
         POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM  
 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON UTHIRAVADHA 
SURONITHAM (RHEUMATOID ARTHRITIS) WITH  SIDDHA  HERBAL-
MINERAL FORMULATION  DRUG   “SAMUTHARA CHOORANAM”(INT), 
“VADHA NOIKU VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
                              
                               FORM III   
           CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1. SI NO:..........  2. OP NO: -------------   3. NAME:...................................................  
4.  RELIGION: H / C / M / O                                  
5. AGE/GENDER:...................     6. OCCUPATION: ……………………………… 
7. SOCIAL STATUS:…………………. 8.CONTACT NUM:………………………         
 
SIDDHA SYSTEM OF EXAMINATION 
 
1. THEGI (BODY CONSTITUTION): 
1. Vatha udal 
2. Pitha udal 
3. Kaba udal 
4. Thontha udal 
 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji  
2. Mullai 
3. Marutham 
4. Neithal 
5. Paalai   
 
 
3. KAALAM: 
1. Kaar kaalam    (Aavani-Puratasi) 
2. Koothir kaalam     (Ippasi-Kaarthigai) 
3. Munpani kaalam     (Maargazhi-Tai) 
4. Pinpani kaalam       (Maasi-Panguni) 
5. Ilavenil kaalam        (Chithirai-Vaigasi)       
6. Muthuvenil kaalam    (Aani-Aadi) 
 
4. GUNAM: 
1. Sathuvam 
2. Rasatham 
3. Thamasam 
 
5. PORI PULANGAL (SENSORY ORGANS):                  
   Normal     Affected   
1. Mei              .................................................................. 
2. Vaai(Naaku)             ................................................................... 
3. Kan                                  .................................................................. 
4. Mookku                          .................................................................. 
5. Sevi                                      .................................................................. 
 
6. KANMENDRIYAM (MOTOR ORGANS) :         
  Normal    Affected  
1. Vaai                                    .................................................................. 
2. Kaal                                  .................................................................. 
3. Kai                                     .................................................................. 
4. Eruvaai                                 .................................................................. 
5. Karuvaai                               .................................................................. 
 
7. KOSANGAL (SHEATH):          
 Normal    Affected  
1. Annamaya kosam  .      ....                 ..................................................... 
2. Pranamaya kosam                                    ...................................................... 
3. Manomaya kosam    ...................................................... 
4. Vignanamaya kosam     ....   ...................................................... 
5. Anandhamaya kosam     ...   ...................................................... 
8. UYIR THATHUKKAL (THREE HUMOURS): 
8a.VALI:              Normal   Affected 
1. Praanan                          ………………………………………… 
2. Abaanan                                ................................................................ 
3. Viyaanan                                .................................................................. 
4. Uthaanan                                 .................................................................. 
5. Samaanan                                 .................................................................. 
6. Naagan                                     .................................................................. 
7. Koorman                                  .................................................................. 
8. Kirukaran                                 .................................................................. 
9. Devathathan                              .................................................................. 
10. Dhananjayan   ………………………………………….. 
8b. AZHAL:                Normal    Affected 
1. Analam                                   ………………………………………… 
2. Ranjagam                              ................................................................ 
3. Saathagam                              ................................................................ 
4. Aalosagam                               ................................................................. 
5. Praasagam                                ................................................................. 
 
8c.IYAM:              Normal    Affected 
1. Avalambagam                         .................................................................. 
2. Kilethagam                              .................................................................. 
3. Pothagam                                 .................................................................. 
4. Tharpagam                               .................................................................. 
5. Santhigam                                .................................................................. 
 
9. EN VAGAI THERVU (EIGHT FOLDS OF EXAMINATION): 
1.Naadi  :                ………………………................. 
2.Parisam :                ………………………................. 
3.Naa          :                ............……………….................. 
4.Niram      :                .....……………………................. 
5.Mozhi :                .....……………………................. 
6.Vizhi        :                ...................................................... 
7.Malam     :                ..................................................... 
8. Moothiram :               …………………………………. 
     8a.Neerkuri: 
Niram      :       1.Whitish                                2. Yellowish     
  3.Straw coloured                                 4. Crystal clear 
Edai: 1.Present                        2.Absent 
Manam :  1.Nil                     2.Reduced                    3. Increased 
Nurai:  1. Normal             2. Increased                  3. Decreased  
Enjal: 
      8b: Neerkuri (Oil –in urine sign): 
 Vatha Neer                              Pitha Neer                  Kaba Neer 
 
10. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS):       
     Normal      Affected   
 1. Saaram                                                 …………………………………. 
2. Senneer    ..          ………………………………… 
3. Oon                                                  ………………………………… 
4. Kozhuppu                                      ………………………………… 
5. Enbu                                          .................................................... 
6.Moolai                                                         ..................................................... 
7. Sukkilam / Suronitham         ..................................................... 
 
GENERAL EXAMINATION: 
1. Body weight [Kg]    :                      
2. Height [cm]                        :                        
3. Body Temperature [F]        :   
4. Blood Pressure (mmHg)  :      
5. Pulse Rate /min.   : 
6. Heart Rate / min.    : 
7. Respiratory Rate /min.  :    
            Yes              No   
8. Pallor  :   
9. Jaundice  :   
10. Clubbing  : 
11. Cyanosis  : 
12. Pedal Oedema  : 
13. Lymphadenopathy           :  
14. Jugular venous pulsation  :   
 
VITAL ORGAN EXAMINATION:                                                      
      Normal          Abnormal 
1. Heart  
2. Lungs  
3. Brain 
4. Liver 
5. Kidney 
6. Spleen 
7. Stomach   
 
SYSTEMIC EXAMINATION: 
     Normal          Abnormal 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
4. Central nervous system 
5. Genital urinary system     
6.  Endocrine system        
CLINICAL ASSESSMENT AND PROGRESS 
 
S.NO CLINICAL  
FEATURES 
BEFORE  
TREATMENT 
                 AFTER  TREATMENT                               
8th 
DAY 
16th 
DAY 
24th  
DAY 
32nd 
DAY 
40th 
DAY 
48th 
DAY 
1. Pain in the 
joints 
       
2. Morning 
stiffness 
       
3. Swelling and 
Tenderness of 
joints 
a. PIP 
       
b. MCP        
c. Wrist        
d. Ankle        
e. Knee        
4. Fever        
5. Loss of appetite        
6. Anaemia        
7. Restriction of 
joint 
       
8. Subcutaneous 
nodules 
       
9. Ulnar deviation        
10. Deformities        
   
0 – nil 
+ - mild 
++ - moderate 
+++ - severe 
 
 
PAIN ASSESMENT:  
              VISUAL ANALOGUE SCALE; 
 
 
 
 
 
Date :      
Station: 
 
 
Signature of the Guide   Signature of the Investigator 
 
 
                       
 
 
 
 
 
 
 
 
 
 
             
     GOVERNMENT SIDDHA MEDICAL COLLEGE 
 ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
             CHENNAI – 600 106 
        POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON UTHIRAVADHA 
SURONITHAM (RHEUMATOID ARTHRITIS) WITH SIDDHA HERBAL-
MINERAL FORMULATION  DRUG   “SAMUTHARA CHOORANAM”(INT), 
“VADHA NOIKU VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
                    
              FORM IV: LABORATORY INVESTIGATIONS PROFORMA 
 
1. SERIAL NO OF THE CASE: …………………  2.OP NO:………………….. 
3. NAME: ……………………………………..   4.AGE & GENDER: .................   
 
A) BLOOD INVESTIGATIONS:                        
BLOOD INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb ( gm/dL)   
ESR (mm) ½ hr.   
  
1 hr.   
T.WBC (Cells / Cu.mm)   
Differential 
Count (%) 
Polymorphs   
  
Lymphocytes   
  
Monocytes   
  
Eosinophils   
  
Basophils   
 
BLOOD INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Blood glucose 
(mg/dl) 
Fasting   
  
PP   
Serum Uric acid (mg/dl)   
Bleeding time    
Clotting time   
Renal Function 
Test 
  
Blood urea(mg/dl)   
Serum creatinine(mg/dl)   
Liver function 
test 
Alkaline phosphatase(U/L)  
SGOT(U/L) 
SGPT(U/L) 
  
Specific 
Investigation 
CRP (mg/dl) 
Anti CCP (U/ml) 
  
 
B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
 Sugar   
Deposits   
 
Date:          
Station: 
 
 
Signature of the Guide          Signature of the Investigator 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
           CHENNAI – 600 106 
      POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON UTHIRAVADHA 
SURONITHAM (RHEUMATOID ARTHRITIS) WITH SIDDHA  HERBAL-
MINERAL FORMULATION  DRUG   “SAMUTHARA CHOORANAM”(INT), 
“VADHA NOIKU VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
        FORM V: INFORMED CONSENT FORM 
             “I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it and any question I have asked has 
been answered to my satisfaction.  
            I consent voluntarily to participate as a participant in this study and 
understand that I have the right to withdraw from the study at any time without in 
any way it affecting my further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date:                                                                                              
 
Signature of the Participant                                                Signature of the Investigator                                                                                                                   
In case of Illiterate Participant 
      “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
Date: 
 
Signature of a witness  
         (Selected by the participant bearing no connection with the 
           Survey team)                      Left thumb Impression                                                                      
Date:                       of the Participant 
Station: 
             Signature of the Investigator 
Signature of the Participant      
 
                  Signature of the Guide 
அரசு சித்த மருத்துவக் கல்லூரி, சென்னன-106 
அறிஞர் அண்ணா மருத்துவமனண, சென்னன 
       உதிரவாத சுரராணிதம் ரநாய்க்கான சித்தமருந்தின் “ொமுதர சூரணம்,  
                  வாத ரநாய்க்கு சவளிப்பிரரயாக னதலம் மற்றும் ஒற்றடம்) 
     பரிகரிப்புத் திறனணக் கண்டரியும் மருத்துவ ஆய்விற்கான தகவல் படிவம்                           
 
ஒப்புதல் படிவம் ஆய்வாளரால் சான்றளிக்கப்பட்டது 
நான் இந்த ஆய்வை குறித்த அவனத்து விபரங்கவையும் நநாயாைிக்கு புரியும் 
ைவகயில் எடுத்துவரத்நதன் என உறுதியைிக்கிநேன். 
 
நததி:        வகயயப்பம் 
இடம்:        யபயர:் 
 
ந ாயாளியின் ஒப்புதல் படிவம் 
என்னிடம் இந்த மருத்துை ஆய்வின் காரணத்வதயும், மருந்தின் தன்வம 
மே்றும் மருத்துை ைழிமுவே பே்றியும், யதாடரந்்து எனது உடல் இயக்கத்வத 
கண்காணிக்கவும், அதவன பாதுகாக்கவும் பயன்படும் மருத்துை ஆய்வுக்கூட 
பரிந ாதவனகை் பே்றி திருப்தி அைிக்கும் ைவகயில் ஆய்வு மருத்துைரால் விைக்கிக் 
கூேப்பட்டது. 
நான் இந்த மருத்துை ஆய்வின் நபாது, காரணம் எதுவும் கூோமல், எப்யபாழுது 
நைண்டுமானாலும் இந்த ஆய்விலிருந்து என்வன விடுவித்து யகாை்ளும் உரிவமவய 
யதரிந்திருக்கின்நேன். நான் என்னுவடய சுதந்திரமாக நதரவ்ு ய ய்யும் உரிவமவயக் 
யகாண்டு உதிரைாத சுநராணிதம் நநாய்க்கான  ாமுதர சூரணம் மருந்தின் 
பரிகரிப்புத் திேவணக் கண்டரியும் மருத்துை ஆய்விே்கு என்வன உட்படுதத் ஒப்புதல் 
அைிக்கிநேன். 
 
 
நததி:        வகயயப்பம் 
இடம்:        யபயர:் 
  
 
நததி:                     ாட்சிக்காரர ் வகயயப்பம் 
இடம்:       யபயர:் 
உேவுமுவே: 
 
 
 
துவேத்தவலைர ்வகயயப்பம்    ஆராய் ச்ியாைர ்வகயயப்பம் 
 
   
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
                         GOVERNMENT SIDDHA MEDICAL COLLEGE, 
   ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                CHENNAI – 600 106 
 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON UTHIRAVADHA 
SURONITHAM (RHEUMATOID ARTHRITIS) WITH  SIDDHA  HERBAL-
MINERAL FORMULATION  DRUG   “SAMUTHARA CHOORANAM”(INT), 
“VADHA NOIKU VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
 
FORM VI - WITHDRAWAL FORM 
 
SI NO:                                                                       OP  NO:                                               
NAME:                                                                     AGE / GENDER :                
 
DATE OF TRIAL COMMENCEMENT: 
 
DATE OF WITHDRAWAL FROM TRIAL: 
 
REASONS FOR WITHDRAWAL: 
• Long absence at reporting :                                    Yes/ No 
• Irregular treatment:                                                Yes/ No 
• Shift of locality :                                                    Yes/No 
• Increase in severity of symptoms:                         Yes/No 
• Development of severe adverse drug reactions:    Yes/No 
 
Date:          
Station: 
 
 
Signature of the Guide        Signature of the Investigator
               
 
 
 
                      GOVERNMENT SIDDHA MEDICAL COLLEGE 
       ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                        CHENNAI – 600 106 
   POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON UTHIRAVADHA 
SURONITHAM (RHEUMATOID ARTHRITIS) WITH  SIDDHA  HERBAL-
MINERAL FORMULATION  DRUG   “SAMUTHARA CHOORANAM”(INT), 
“VADHA NOIKU VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
 
FORM VII – PATIENT INFORMATION SHEET 
 
Name of Investigator: Dr.A.B.KAVINAYA 
 
Name of the college: Govt. Siddha Medical College 
                                    Arumbakkam 
                             Chennai-106. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
         
I, A. B. KAVINAYA studying M.D (Siddha) at Govt. Siddha Medical College, 
Chennai, is doing a clinical trial on “Uthiravadha suronitham(Rheumatoid 
arthritis)”. It is becoming a most common disease, occurring throughout the world. 
In this regard, I am in need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained. There will be no risk of disclosing your identity 
and no physical, psychological or professional risk is involved by taking part in this 
study. Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study. 
           
 You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
            If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal 
medicine “SAMUTHARA CHOORANAM” (Internal medicine) Two gram bid with 
Ghee for 48 days.  
   
The information I am collecting in this study will remain between you and the 
Co- investigator (myself). I will ask you few questions through a questionnaire. I will 
not write your name on this form. I will use a code instead. 
 
The questionnaire will take approximately 20 minutes of your time. 
 
If you wish to find out more about this study before taking part, you can ask 
me all the questions you want or contact A.B.KAVINAYA, PG Scholar cum co-
investigator of this study, attached to Govt. Siddha Medical College, Chennai-106. 
You can also contact the Member-secretary of Ethics committee, Govt. Siddha 
Medical College, Chennai.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
அரசு சித்த மருத்துவக் கல்லூரி, சென்னன-106 
அறிஞர் அண்ணா மருத்துவமனண, சென்னன 
        உதிரவாத சுரராணிதம்  ரநாய்க்கான சித்த மருந்தின் “ொமுதர சூரணம்,  
                      வாத ரநாய்க்கு சவளிப்பிரரயாக னதலம் மற்றும் ஒற்றடம்”                                                                                       
    பரிகரிப்புத் திறனணக் கண்டரியும் மருத்துவ ஆய்விற்கான தகவல் படிவம்                           
 
ஆராய்சச்ியாளர் பபயர:் ஆ.பூ.கவி யா 
 
 ிறுவனத்தின் பபயர:் அரசு சித்த மருத்துவக் கல்லூரி,  
   அரும்பாக்கம்     
    சென்னன-106 
 
அரசு சித்த மருத்துவக் கல்லூரியில் பட்ட ரமற்படிப்பு பயின்று வரும் நான் 
மருத்துவர் ஆ.பூ.கவிநயா, உதிரவாத சுரராணிதம் என்னும் ரநாயில் மருத்துவ 
ஆராய்ெெ்ய்ில் ஈடுபட்டுள்ரளன். 
இந்த ஆராய்ெச்ி ெம்பந்தமான சில ரகள்விகனளக் ரகட்கவும், ரதனவயான 
பரிரொதனனக்கு தங்கனள உட்படுத்தவும் உள்ரளன். 
இந்த ஆராய்ெச்ிக்கு தாங்கள் விருப்பத்தின் ரபரில் உட்படும் பட்ெத்தில் 
உள்மருந்தாக “ொமுதர சூரணம்” 2 கிராம் சநய்யில் இருரவனள(கானல, மானல) 
உணவுக்கு பின் 48 நாட்கள் உட்சகாள்ள ரவண்டும். சவளிமருந்தாக “வாத 
ரநாய்க்கு சவளிப்பிரரயாக னதலம்” 48 நாட்கள்  ரநாய் உள்ள இடங்களில் 
சவளிரய தடவி ஒற்றடம் செய்ய ரவண்டும். சவளி ரநாயாளரக்ள் 7 நாட்களுக்கு 
ஒருமுனற மருத்துவமனனக்கு வர ரவண்டும். 
இந்த ஆராய்ெச்ியில் தங்கனள அனுமதித்த பிறகு உங்களுக்கு விருப்பம் 
இல்னலசயனில் எப்ரபாது ரவண்டுமானாலும் ஆராய்ெச்ியில் இருந்து விலகிக் 
சகாள்ள உரினம உள்ளது. 
இந்த ஆராய்ெச்ி ெம்மந்தமாக ரநாயின் தன்னம பற்றியும் மற்ற 
விபரங்களுக்கும் ஆராய்ெச்ியாளரான மருத்துவர் ஆ.பூ.கவிநயா(பட்ட 
ரமற்படிப்பாளர் சிறப்பு மருத்துவ துனற) அவரக்னள எந்த ரநரத்திலும் சதாடர்பு 
சகாள்ளலாம். னகரபசி எண்:7502469757 
ரமலும் இந்த ஆராய்ெச்ிக்கு தக்க அனுமதி ொன்று(IEC) சபறப்பட்டு 
உள்ளது.     
ரமலும் உணவு முனறயில் மருத்துவரால் கூறப்படும் பத்தியம் காக்குமாறு 
அறிவுறுத்தபடுகிறது. 
இது ெம்பந்தமான தங்களது அனனத்து விபரங்களும் ரகசியமாக 
னவக்கப்படும் என உறுதி அளிக்கிரறன். 
இதில் பயணப்படி முதலிய எந்த உதவித் சதானகயும் வழங்கப்பட 
மாட்டாது. 
இந்த ஆராய்ெச்ியின் ரபாது உடலுக்கு ரவறு பாதிப்பு ஏற்படும் பட்ெத்தில் 
அறிஞர் அண்ணா சித்த மருத்துவமனனயில் தக்க சிகிென்ெ அளிக்கப்படும்.    
இந்த மருந்து சிறப்பாக உதிரவாத சுரராணிதம் ரநாய்க்காக 
அங்கீகரிக்கப்பட்ட சித்த மருத்துவ நூலில் கூறப்பட்டுள்ளது. ஏற்கனரவ 
உபரயாகத்தில் உள்ள இதுரபான்ற மருந்து இதுவனர ரநாயாளிகளிடம் எந்தவித 
பக்கவினளவுகனள ஏற்படுத்தவில்னல. 
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             FORM VIII: DIETARY ADVICE FORM  
ரெரக்்க கூடிய உணவுகள்: 
 காய்கள்: கத்திரி பிஞ்சு, முருங்னக பிஞ்சு, அவனர பிஞ்சு ஆகியனவ 
ரெரக்்க ரவண்டும். 
 கீனரகள்: கரிொனல, சபான்னாங்கன்னி,ம ணத்தக்காளி, முருங்னககீனர, 
பெனலக்கீனர, சிறுகீனர, கறிநவப்பிலல ஆகியலவ நசரக்்க நவண்டும். 
 பழங்கள்: மாதுலள, ஆப்பில், வாலழ, நபரசீல்ச, அத்தி, திராசல்ச, 
பகாய்யா, ஆரஞ்சு, எலிமிசல்ச,  ாவல், தக்காளி ஆகியலவ நசரக்்க 
நவண்டும். 
 தானியங்கள்: நகாதுலம, ஓட்ஸ், நசாயாபீன்ஸ், பட்டாணி, 
பகாண்லடகடலல, எள், பாதாம் ஆகியலவ நசரக்்க நவண்டும். 
 அலசவம்: பவள்ளாட்டுக்கறி, ஈரல், எலும்புமஜ்லஜ ஆகியலவ நசரக்்க 
நவண்டும். 
 
நசரக்்க கூடாதலவகள்: 
 ம ்தப்பபாருள் 
 ஊருலளக் கிழங்கு 
 அகத்திக்கீலர 
 புளிப்பு 
 புலகயிலல 
 மது அரு ்துதல் 
                 GOVERNMENT SIDDHA MEDICAL COLLEGE 
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AN OPEN COMPARATIVE CLINICAL EVALUATION ON 
UTHIRAVADHA SURONITHAM (RHEUMATOID ARTHRITIS) WITH  
SIDDHA  HERBAL-MINERAL FORMULATION  DRUG   
“SAMUTHARA CHOORANAM”(INT), “VADHA NOIKU 
VELIPRAYOGHA THAILAM” (EXT) AND OTTRADAM” 
 
                  FORM IX: ADVERSE REACTION FORM 
 
SERIAL NO: 
OP NO: 
NAME: 
AGE/GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURENCE OF THE ADVERSE REACTION: 
TIME 
DESCRIPTION OF ADVERSE REACTION: 
 
 
Date: 
Station: 
 
 
 
    Signature of the Guide          Signature of the Investigator 
            
 
 
 
 
 
  
 
 
 
       
 
